

Connecting via Winsock to STN

Welcome to STN International! Enter x:X

LOGINID:ssptacrs1614

PASSWORD:

TERMINAL (ENTER 1, 2, 3, OR ?):2

* * * * * Welcome to STN International * * * * *

NEWS	1		Web Page for STN Seminar Schedule - N. America
NEWS	2	JUL 28	CA/Caplus patent coverage enhanced
NEWS	3	JUL 28	EPFULL enhanced with additional legal status information from the epoline Register
NEWS	4	JUL 28	IFICDB, IFIPAT, and IFIUDB reloaded with enhancements
NEWS	5	JUL 28	STN Viewer performance improved
NEWS	6	AUG 01	INPADOCDB and INPAFAMDB coverage enhanced
NEWS	7	AUG 13	CA/Caplus enhanced with printed Chemical Abstracts page images from 1967-1998
NEWS	8	AUG 15	CAOLD to be discontinued on December 31, 2008
NEWS	9	AUG 15	Caplus currency for Korean patents enhanced
NEWS	10	AUG 27	CAS definition of basic patents expanded to ensure comprehensive access to substance and sequence information
NEWS	11	SEP 18	Support for STN Express, Versions 6.01 and earlier, to be discontinued
NEWS	12	SEP 25	CA/Caplus current-awareness alert options enhanced to accommodate supplemental CAS indexing of exemplified prophetic substances
NEWS	13	SEP 26	WPIDS, WPINDEX, and WPIX coverage of Chinese and Korean patents enhanced
NEWS	14	SEP 29	IFICLS enhanced with new super search field
NEWS	15	SEP 29	EMBASE and EMBAL enhanced with new search and display fields
NEWS	16	SEP 30	CAS patent coverage enhanced to include exemplified prophetic substances identified in new Japanese-language patents
NEWS	17	OCT 07	EPFULL enhanced with full implementation of EPC2000
NEWS	18	OCT 07	Multiple databases enhanced for more flexible patent number searching
NEWS	19	OCT 22	Current-awareness alert (SDI) setup and editing enhanced
NEWS	20	OCT 22	WPIDS, WPINDEX, and WPIX enhanced with Canadian PCT Applications
NEWS	21	OCT 24	CHEMLIST enhanced with intermediate list of pre-registered REACH substances
NEWS EXPRESS	JUNE 27 08	CURRENT WINDOWS VERSION IS V8.3, AND CURRENT DISCOVER FILE IS DATED 23 JUNE 2008.	
NEWS HOURS		STN Operating Hours Plus Help Desk Availability	
NEWS LOGIN		Welcome Banner and News Items	
NEWS IPC8		For general information regarding STN implementation of IPC 8	

Enter NEWS followed by the item number or name to see news on that specific topic.

All use of STN is subject to the provisions of the STN Customer agreement. Please note that this agreement limits use to scientific research. Use for software development or design or implementation of commercial gateways or other similar uses is prohibited and may result in loss of user privileges and other penalties.

***** STN Columbus *****

FILE 'HOME' ENTERED AT 12:29:01 ON 17 NOV 2008

=> file registry

COST IN U.S. DOLLARS

SINCE FILE

TOTAL

ENTRY

SESSION

FULL ESTIMATED COST

0.21

0.21

FILE 'REGISTRY' ENTERED AT 12:29:17 ON 17 NOV 2008

USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.

PLEASE SEE "HELP USAGETERMS" FOR DETAILS.

COPYRIGHT (C) 2008 American Chemical Society (ACS)

Property values tagged with IC are from the ZIC/VINITI data file provided by InfoChem.

STRUCTURE FILE UPDATES: 16 NOV 2008 HIGHEST RN 1072892-84-2

DICTIONARY FILE UPDATES: 16 NOV 2008 HIGHEST RN 1072892-84-2

New CAS Information Use Policies, enter HELP USAGETERMS for details.

TSCA INFORMATION NOW CURRENT THROUGH July 5, 2008.


Please note that search-term pricing does apply when conducting SmartSELECT searches.

REGISTRY includes numerically searchable data for experimental and predicted properties as well as tags indicating availability of experimental property data in the original document. For information on property searching in REGISTRY, refer to:

<http://www.cas.org/support/stngen/stndoc/properties.html>

=>

Uploading C:\Program Files\STNEXP\Queries\10582124.str



chain nodes :

7 8 9 10 11 12 13 20 21

ring nodes :

1 2 3 4 5 6 14 15 16 17 18 19

```

chain bonds :
1-8  5-7  8-9  8-20  9-10  10-11  11-12  12-13  12-21  13-15
ring bonds :
1-2  1-6  2-3  3-4  4-5  5-6  14-15  14-19  15-16  16-17  17-18  18-19
exact/norm bonds :
5-7  8-9  9-10  10-11  12-21  13-15  14-15  14-19  15-16  16-17  17-18  18-19
exact bonds :
1-8  8-20  11-12  12-13
normalized bonds :
1-2  1-6  2-3  3-4  4-5  5-6

```

```

Match level :
1:Atom 2:Atom 3:Atom 4:Atom 5:Atom 6:Atom 7:CLASS 8:CLASS 9:CLASS 10:CLASS
11:CLASS 12:CLASS 13:CLASS 14:Atom 15:Atom 16:Atom 17:Atom 18:Atom 19:Atom
20:CLASS 21:CLASS


```

L1 STRUCTURE UPLOADED

=> d l1

L1 HAS NO ANSWERS

L1 STR



Structure attributes must be viewed using STN Express query preparation.

=> s l1 fam ful

FULL SEARCH INITIATED 12:29:35 FILE 'REGISTRY'

FULL SCREEN SEARCH COMPLETED - 66 TO ITERATE

100.0% PROCESSED 66 ITERATIONS

0 ANSWERS

SEARCH TIME: 00.00.01

L2 0 SEA FAM FUL L1

=> s l1 sss ful

FULL SEARCH INITIATED 12:29:40 FILE 'REGISTRY'

FULL SCREEN SEARCH COMPLETED - 118 TO ITERATE

100.0% PROCESSED 118 ITERATIONS

0 ANSWERS

SEARCH TIME: 00.00.01

L3 0 SEA SSS FUL L1

=> logoff

ALL L# QUERIES AND ANSWER SETS ARE DELETED AT LOGOFF

LOGOFF? (Y)/N/HOLD:y

COST IN U.S. DOLLARS

SINCE FILE

TOTAL

ENTRY

SESSION

FULL ESTIMATED COST

248.01

248.22

STN INTERNATIONAL LOGOFF AT 12:29:50 ON 17 NOV 2008

Connecting via Winsock to STN

Welcome to STN International! Enter x:X

LOGINID:ssptacrs1614

PASSWORD:

TERMINAL (ENTER 1, 2, 3, OR ?):2

***** Welcome to STN International *****

NEWS 1 Web Page for STN Seminar Schedule - N. America
NEWS 2 JUL 28 CA/CAPlus patent coverage enhanced
NEWS 3 JUL 28 EPFULL enhanced with additional legal status
information from the epoline Register
NEWS 4 JUL 28 IFICDB, IFIPAT, and IFIUDB reloaded with enhancements
NEWS 5 JUL 28 STN Viewer performance improved
NEWS 6 AUG 01 INPADOCDB and INPAFAMDB coverage enhanced
NEWS 7 AUG 13 CA/CAPlus enhanced with printed Chemical Abstracts
page images from 1967-1998
NEWS 8 AUG 15 CAOLD to be discontinued on December 31, 2008
NEWS 9 AUG 15 CAPlus currency for Korean patents enhanced
NEWS 10 AUG 27 CAS definition of basic patents expanded to ensure
comprehensive access to substance and sequence
information
NEWS 11 SEP 18 Support for STN Express, Versions 6.01 and earlier,
to be discontinued
NEWS 12 SEP 25 CA/CAPlus current-awareness alert options enhanced
to accommodate supplemental CAS indexing of
exemplified prophetic substances
NEWS 13 SEP 26 WPIDS, WPINDEX, and WPIX coverage of Chinese and
and Korean patents enhanced
NEWS 14 SEP 29 IFICLS enhanced with new super search field
NEWS 15 SEP 29 EMBASE and EMBAL enhanced with new search and
display fields
NEWS 16 SEP 30 CAS patent coverage enhanced to include exemplified
prophetic substances identified in new Japanese-
language patents
NEWS 17 OCT 07 EPFULL enhanced with full implementation of EPC2000
NEWS 18 OCT 07 Multiple databases enhanced for more flexible patent
number searching
NEWS 19 OCT 22 Current-awareness alert (SDI) setup and editing
enhanced
NEWS 20 OCT 22 WPIDS, WPINDEX, and WPIX enhanced with Canadian PCT
Applications

NEWS 21 OCT 24 CHEMLIST enhanced with intermediate list of
pre-registered REACH substances

NEWS EXPRESS JUNE 27 08 CURRENT WINDOWS VERSION IS V8.3,
AND CURRENT DISCOVER FILE IS DATED 23 JUNE 2008.

NEWS HOURS STN Operating Hours Plus Help Desk Availability
NEWS LOGIN Welcome Banner and News Items
NEWS IPC8 For general information regarding STN implementation of IPC 8

Enter NEWS followed by the item number or name to see news on that
specific topic.

All use of STN is subject to the provisions of the STN Customer
agreement. Please note that this agreement limits use to scientific
research. Use for software development or design or implementation
of commercial gateways or other similar uses is prohibited and may
result in loss of user privileges and other penalties.

* * * * * STN Columbus * * * * *

FILE 'HOME' ENTERED AT 13:03:06 ON 17 NOV 2008

=> file registry

COST IN U.S. DOLLARS	SINCE FILE ENTRY	TOTAL SESSION
FULL ESTIMATED COST	0.21	0.21

FILE 'REGISTRY' ENTERED AT 13:03:15 ON 17 NOV 2008

USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.
COPYRIGHT (C) 2008 American Chemical Society (ACS)

Property values tagged with IC are from the ZIC/VINITI data file
provided by InfoChem.

STRUCTURE FILE UPDATES: 16 NOV 2008 HIGHEST RN 1072892-84-2
DICTIONARY FILE UPDATES: 16 NOV 2008 HIGHEST RN 1072892-84-2

New CAS Information Use Policies, enter HELP USAGETERMS for details.


TSCA INFORMATION NOW CURRENT THROUGH July 5, 2008.

Please note that search-term pricing does apply when
conducting SmartSELECT searches.

REGISTRY includes numerically searchable data for experimental and
predicted properties as well as tags indicating availability of
experimental property data in the original document. For information
on property searching in REGISTRY, refer to:

<http://www.cas.org/support/stngen/stdnoc/properties.html>

=>
Uploading C:\Program Files\STNEXP\Queries\10582124a.str



```

chain nodes :
7 8 9 10 11 12 19 20
ring nodes :
1 2 3 4 5 6 13 14 15 16 17 18
chain bonds :
1-7 7-8 7-19 8-9 9-10 10-11 11-12 11-20 12-14
ring bonds :
1-2 1-6 2-3 3-4 4-5 5-6 13-14 13-18 14-15 15-16 16-17 17-18
exact/norm bonds :
7-8 8-9 9-10 11-20 12-14 13-14 13-18 14-15 15-16 16-17 17-18
exact bonds :
1-7 7-19 10-11 11-12
normalized bonds :
1-2 1-6 2-3 3-4 4-5 5-6

```

Match level :

```

1:Atom 2:Atom 3:Atom 4:Atom 5:Atom 6:Atom 7:CLASS 8:CLASS 9:CLASS 10:CLASS
11:CLASS 12:CLASS 13:Atom 14:Atom 15:Atom 16:Atom 17:Atom 18:Atom 19:CLASS
20:CLASS


```

L1 STRUCTURE UPLOADED

=> d l1

L1 HAS NO ANSWERS

L1 STR



Structure attributes must be viewed using STN Express query preparation.

```
=> s l1 sss ful
FULL SEARCH INITIATED 13:03:31 FILE 'REGISTRY'
FULL SCREEN SEARCH COMPLETED -      118 TO ITERATE

100.0% PROCESSED      118 ITERATIONS      31 ANSWERS
SEARCH TIME: 00.00.01

L2      31 SEA SSS FUL L1

=> file caplus
COST IN U.S. DOLLARS      SINCE FILE      TOTAL
                        ENTRY      SESSION
FULL ESTIMATED COST      178.36      178.57

FILE 'CAPLUS' ENTERED AT 13:03:35 ON 17 NOV 2008
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.
COPYRIGHT (C) 2008 AMERICAN CHEMICAL SOCIETY (ACS)
```

Copyright of the articles to which records in this database refer is held by the publishers listed in the PUBLISHER (PB) field (available for records published or updated in Chemical Abstracts after December 26, 1996), unless otherwise indicated in the original publications. The CA Lexicon is the copyrighted intellectual property of the American Chemical Society and is provided to assist you in searching databases on STN. Any dissemination, distribution, copying, or storing of this information, without the prior written consent of CAS, is strictly prohibited.

FILE COVERS 1907 - 17 Nov 2008 VOL 149 ISS 21
FILE LAST UPDATED: 16 Nov 2008 (20081116/ED)

Caplus now includes complete International Patent Classification (IPC) reclassification data for the third quarter of 2008.

Effective October 17, 2005, revised CAS Information Use Policies apply. They are available for your review at:

<http://www.cas.org/legal/infopolicy.html>

```
=> s l2
L3      75 L2

=> s l3 and (amyotroph? or als)
      7910 AMYOTROPH?
      6582 ALS
L4      8 L3 AND (AMYOTROPH? OR ALS)

=> d l4 ibib abs 1-8

L4 ANSWER 1 OF 8 CAPLUS COPYRIGHT 2008 ACS on STN
ACCESSION NUMBER:      2008:918262 CAPLUS
DOCUMENT NUMBER:      149:258394
TITLE:      Arimoclomol at dosages up to 300 Mg/day is well
      tolerated and safe in amyotrophic lateral
      sclerosis
AUTHOR(S):      Cudkowicz, Merit E.; Shefner, Jeremy M.; Simpson,
```

Elizabeth; Grasso, Daniela; Yu, Hong; Zhang, Hui;
Shui, Amy; Schoenfeld, David; Brown, Robert H.;
Wieland, Scott; Barber, Jack R.
CORPORATE SOURCE: NORTHEAST ALS CONSORTIUM, Neurology Clinical Trials
Unit, Massachusetts General Hospital, Charlestown, MA,
02129, USA
SOURCE: Muscle & Nerve (2008), 38(1), 837-844
CODEN: MUNED; ISSN: 0148-639X
PUBLISHER: John Wiley & Sons, Inc.
DOCUMENT TYPE: Journal
LANGUAGE: English
AB Arimoclomol is an investigational drug for amyotrophic lateral
sclerosis (ALS) that amplifies heat shock protein gene
expression during cell stress. The objectives of the present study were
to assess the safety, tolerability, and pharmacokinetics of arimoclomol in
ALS. Eighty-four participants with ALS received
arimoclomol at one of three oral doses (25, 50, or 100 mg three times
daily) or placebo. The primary outcome measure was safety and
tolerability. A subset of 44 participants provided serum and
cerebrospinal fluid (CSF) samples for pharmacokinetic anal. Participants
who completed 12 wk of treatment could enroll in a 6-mo open-label study.
Arimoclomol at doses up to 300 mg/day was well tolerated and safe.
Arimoclomol resulted in dose-linear pharmacol. exposures and the half-life
did not change with continued treatment. Arimoclomol CSF levels increased
with dose. Arimoclomol was shown to be safe, and it crosses the
blood-brain barrier. Serum pharmacokinetic profiles support dosing of
three times per day. An efficacy study in ALS is planned.
REFERENCE COUNT: 27 THERE ARE 27 CITED REFERENCES AVAILABLE FOR THIS
RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L4 ANSWER 2 OF 8 CAPLUS COPYRIGHT 2008 ACS on STN
ACCESSION NUMBER: 2008:411857 CAPLUS
DOCUMENT NUMBER: 148:410753
TITLE: Composition comprising hydroxyamine compound for
treating diseases associated with neurodegeneration
INVENTOR(S): Barber, Jack R.
PATENT ASSIGNEE(S): Cytrx Corporation, USA
SOURCE: PCT Int. Appl., 119pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2008039514	A1	20080403	WO 2007-US20853	20070926
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BH, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LT, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RS, RU, SC, SD, SE, SG, SK, SL, SM, SV, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW				
RW: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, LV, MC, MT, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GO, GW, ML, MR, NE, SN, TD, TG, BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
US 20080227813	A1	20080918	US 2007-904534	20070926
PRIORITY APPLN. INFO.:			US 2006-847606P	P 20060926
			US 2006-852791P	P 20061018

OTHER SOURCE(S): MARPAT 148:410753

AB The present invention relates to methods for treating diseases, conditions or disorders using hydroxyamine compds., and in particular, N-[2-hydroxy-3-(1-piperidinyl)-propoxyl-pyridine-1-oxide-3-carboximidoyl chloride, alone or in combination with one or more other therapeutic agents, for the treatment of conditions, disorders or diseases associated with neurodegeneration in the central nervous system. The present invention also relates to pharmaceutical compns. comprising hydroxyamine compds., an addnl. therapeutic agent and a pharmaceutically acceptable carrier and methods for treating diseases using them. Thus, capsule was prepared containing N-[2-hydroxy-3-(1-piperidinyl)-propoxyl-pyridine-1-oxide-3-carboximidoyl chloride 25 mg, MC cellulose 252 mg, and talc 3 mg.

REFERENCE COUNT: 7 THERE ARE 7 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L4 ANSWER 3 OF 8 CAPLUS COPYRIGHT 2008 ACS on STN

ACCESSION NUMBER: 2008:223578 CAPLUS

DOCUMENT NUMBER: 148:269430

TITLE: Methods and compositions for the treatment of neurodegenerative disorders such as Huntington's disease

INVENTOR(S): Jin, Xiaowei; Wilson, Amy Beth; Staunton, Jane; MacDonald, Douglas

PATENT ASSIGNEE(S): Combinatorx, Incorporated, USA; Chdi, Inc.

SOURCE: PCT Int. Appl., 127pp.

CODEN: PIXXD2

DOCUMENT TYPE: Patent

LANGUAGE: English

FAMILY ACC. NUM. COUNT: 1

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2008021210	A2	20080221	WO 2007-US17751	20070810
WO 2008021210	A3	20081030		
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BH, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LT, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RS, RU, SC, SD, SE, SG, SK, SL, SM, SV, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW				
RW: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, LV, MC, MT, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG, BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AP, EA, EP, OA				

US 20080044390 A1 20080221 US 2007-891552 20070810

PRIORITY APPLN. INFO.: US 2006-837448P P 20060811
US 2007-898479P P 20070131
US 2007-925777P P 20070423
US 2007-958832P P 20070709

AB The present invention features compns., kits, and methods for treating, preventing, and ameliorating neurodegenerative disorders, e.g., Huntington's disease (HD). Screening methods for identifying candidate compds. that treat, prevent, or ameliorate neurodegenerative disorders, e.g., HD, are provided. Thus, N-terminal fragment of Htt has been shown to form protein aggregates in the nucleus, cytoplasm and processes of neurons in human HD patients and in HD animal models, as well as in many cellular models. Because of their similarities to neurons, rat pheochromocytoma PC12 cells have provided a useful model for studying neuronal cell biol.; in addition, PC12 cells are readily transfected,

selected and cloned. In order to perform screening according to a method of the present invention, PC12 cells were obtained that stably incorporated a plasmid that inducibly expresses a toxic expanded polyglutamine (103 glutamine) form of exon 1 of Htt, fused to the marker EGFP. Using the engineered PC12/HttN90Q103 cell line, a high throughput assay to screen small mols. for their ability to prevent mutant Htt exon 1-induced cell death was developed and optimized.

L4 ANSWER 4 OF 8 CAPLUS COPYRIGHT 2008 ACS on STN

ACCESSION NUMBER: 2007:1424894 CAPLUS
DOCUMENT NUMBER: 148:492092
TITLE: Heat shock proteins and protection of the nervous system
AUTHOR(S): Brown, Ian R.
CORPORATE SOURCE: Center for the Neurobiology of Stress, University of Toronto at Scarborough, Toronto, ON, Can.
SOURCE: Annals of the New York Academy of Sciences (2007), 1113(Stress Responses in Biology and Medicine), 147-158
CODEN: ANYAA9; ISSN: 0077-8923
PUBLISHER: Blackwell Publishing, Inc.
DOCUMENT TYPE: Journal; General Review
LANGUAGE: English

AB A review. Manipulation of the cellular stress response offers strategies to protect brain cells from damage induced by ischemia and neurodegenerative diseases. Overexpression of Hsp70 reduced ischemic injury in the mammalian brain. Investigation of the domains within Hsp70 that confers ischemic neuroprotection revealed the importance of the carboxyl-terminal domain. Arimoclomol, a coinducer of heat shock proteins, delayed progression of amyotrophic lateral sclerosis (ALS) in a mouse model in which motor neurons in the spinal cord and motor cortex degenerate. Celastrol, a promising candidate as an agent to counter neurodegenerative diseases, induced expression of a set of Hsps in differentiated neurons grown in tissue culture. Heat shock "preconditioning" protected the nervous system at the functional level of the synapse and selective overexpression of Hsp70 enhanced the level of synaptic protection. Following hyperthermia, constitutively expressed Hsc70 increased in synapse-rich areas of the brain where it associates with Hsp40 to form a complex that can refold denatured proteins. Stress tolerance in neurons is not solely dependent on their own Hsps but can be supplemented by Hsps from adjacent glial cells. Hence, application of exogenous Hsps at neural injury sites is an effective strategy to maintain neuronal viability.

REFERENCE COUNT: 72 THERE ARE 72 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L4 ANSWER 5 OF 8 CAPLUS COPYRIGHT 2008 ACS on STN

ACCESSION NUMBER: 2007:576156 CAPLUS
DOCUMENT NUMBER: 146:514797
TITLE: Use of (2-hydroxy-3-(1-piperidinyl)-propoxy)-pyridine carboximidoyl chloride for treatment of selected neurological diseases
INVENTOR(S): Karpati, Gyoergy; Molnar, Maria Judit
PATENT ASSIGNEE(S): Hung.
SOURCE: Hung. Pat. Appl., 9pp.
CODEN: HUXXCX
DOCUMENT TYPE: Patent
LANGUAGE: Hungarian
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
------------	------	------	-----------------	------

-----	-----	-----	-----
HU 9904451	A2	20021128	HU 1999-4451
PRIORITY APPLN. INFO.:			19991201
			HU 1999-4451
			19991201

AB The subject of the invention is the new therapeutic application of [2-hydroxy-3-(1-piperidinyl)-propoxy] pyridine-carboxyimidoyl chloride-maleate to treat sporadic amyotrophic lateral sclerosis, Friedreich disease, mitochondrial diseases accompanied by the damage of oxidative phosphorylation (OXPHOS) and in the case of inclusion testes myositis, in the presymptomatic and symptomatic phase, to prevent the harmful effects of primary etiol. factors and to alleviate the progression and clin. symptoms of the disease. According to the invention, the pharmaceutically acceptable derivative of the [2-hydroxy-3-(1-piperidinyl)propoxy]-pyridine carboxy imidoyl-chloride-maleate is used together with a pharmaceutically acceptable adjuvant, diluter or carrier in the neurol. clin. pictures defined above.

L4 ANSWER 6 OF 8 CAPLUS COPYRIGHT 2008 ACS on STN

ACCESSION NUMBER: 2006:598700 CAPLUS
DOCUMENT NUMBER: 145:499471
TITLE: Neuroprotective agents for clinical trials in ALS
AUTHOR(S): Traynor, B. J.; Bruijn, L.; Conwit, R.; Beal, F.; O'Neill, G.; Fagan, S. C.; Cudkowicz, M. E.
CORPORATE SOURCE: Neurology Clinical Trials Unit, Department of Neurology, Massachusetts General Hospital, Boston, MA, USA
SOURCE: Neurology (2006), 67(1), 20-27
CODEN: NEURAI; ISSN: 0028-3878
PUBLISHER: Lippincott Williams & Wilkins
DOCUMENT TYPE: Journal; General Review
LANGUAGE: English

AB A review. Background: Riluzole is currently the only Food and Drug Administration-approved treatment for ALS, but its effect on survival is modest. Objective: To identify potential neuroprotective agents for testing in phase III clin. trials and to outline which data need to be collected for each drug. Methods: The authors identified 113 compds. by inviting input from academic clinicians and researchers and via literature review to identify agents that have been tested in ALS animal models and in patients with ALS. The list was initially narrowed to 24 agents based on an evaluation of scientific rationale, toxicity, and efficacy in previous animal and human studies. These 24 drugs underwent more detailed pharmacol. evaluation. Results: Twenty drugs were selected as suitable for further development as treatments for patients with ALS. Talampanel and tamoxifen have completed early phase II trials and have demonstrated preliminary efficacy. Other agents (ceftriaxone, minocycline, ONO-2506, and IGF-1 polypeptide) are already in phase III trials involving large nos. of patients with ALS. Remaining agents (AEOL 10150, arimoclomol, celastrol, coenzyme Q10, copaxone, IGF-1-viral delivery, memantine, NAALADase inhibitors, nimesulide, scriptaid, sodium phenylbutyrate, thalidomide, trehalose) require addnl. preclin. animal data, human toxicity and pharmacokinetic data including CNS penetration prior to proceeding to large scale phase III human testing. Further development of riluzole analogs should be considered. Conclusions: Several potential neuroprotective compds., representing a wide range of mechanisms, are available and merit further investigation in ALS.

REFERENCE COUNT: 86 THERE ARE 86 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L4 ANSWER 7 OF 8 CAPLUS COPYRIGHT 2008 ACS on STN

ACCESSION NUMBER: 2005:409316 CAPLUS
DOCUMENT NUMBER: 142:441894

TITLE: Use of a hydroximic acid halide derivative in the treatment of neurodegenerative diseases
 INVENTOR(S): Greensmith, Linda; Burnstock, Geoffrey; Urbanics, Rudolf
 PATENT ASSIGNEE(S): Biorex Kutato es Fejlesztő Rt., Hung.
 SOURCE: PCT Int. Appl., 24 pp.
 CODEN: PIXXD2
 DOCUMENT TYPE: Patent
 LANGUAGE: English
 FAMILY ACC. NUM. COUNT: 1
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2005041965	A1	20050512	WO 2004-HU98	20041025
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
RW: BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
AU 2004285343	A1	20050512	AU 2004-285343	20041025
CA 2544332	A1	20050512	CA 2004-2544332	20041025
EP 1696922	A1	20060906	EP 2004-791657	20041025
EP 1696922	B1	20080924		
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, PL, SK, HR				
BR 2004015625	A	20061212	BR 2004-15625	20041025
JN 1901913	A	20070124	CN 2004-80039619	20041025
JP 2007509920	T	20070419	JP 2006-537449	20041025
AT 409038	T	20081015	AT 2004-791657	20041025
MX 2006PA04814	A	20061211	MX 2006-PA4814	20060428
NO 2006002401	A	20060727	NO 2006-2401	20060526
IN 2006KN01464	A	20070504	IN 2006-KN1464	20060530
US 20080039497	A1	20080214	US 2007-582124	20070510
PRIORITY APPLN. INFO.:			HU 2003-3584	A 20031030
			WO 2004-HU98	W 20041025

AB The invention relates to the use of a chemical substance selected from the group consisting of N-[2-hydroxy-3-(1-piperidinyl)-propoxyl]-pyridine-1-oxide-3-carboximidoyl chloride, the optically active enantiomers and the mixts. of enantiomers thereof and pharmaceutically acceptable salts of the racemic and optically active compds. in the preparation of a pharmaceutical composition for the treatment or prevention of neurodegenerative diseases.

REFERENCE COUNT: 8 THERE ARE 8 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L4 ANSWER 8 OF 8 CAPLUS COPYRIGHT 2008 ACS on STN
 ACCESSION NUMBER: 2004:263763 CAPLUS
 DOCUMENT NUMBER: 140:399884
 TITLE: Treatment with arimocloamol, a coinducer of heat shock proteins, delays disease progression in ALS mice
 AUTHOR(S): Kieran, Dairin; Kalmar, Bernadett; Dick, James R. T.; Riddoch-Contreras, Joanna; Burnstock, Geoffrey; Greensmith, Linda
 CORPORATE SOURCE: The National Hospital for Neurology and Neurosurgery, Institute of Neurology, Sobell Department of Motor

Neuroscience and Movement Disorders, The Graham Watts
Laboratory, University College London, London, WC1N
3BG, UK

SOURCE: Nature Medicine (New York, NY, United States) (2004),
10(4), 402-405

CODEN: NAMEFI; ISSN: 1078-8956

PUBLISHER: Nature Publishing Group

DOCUMENT TYPE: Journal

LANGUAGE: English

AB Amyotrophic lateral sclerosis (ALS) is a fatal
neurodegenerative condition in which motoneurons of the spinal cord and
motor cortex die, resulting in progressive paralysis. This condition has
no cure and results in eventual death, usually within 1-5 yr of diagnosis.
Although the specific etiol. of ALS is unknown, 20% of familial
cases of the disease carry mutations in the gene encoding Cu/Zn superoxide
dismutase-1 (SOD1). Transgenic mice overexpressing human mutant SOD1 have
a phenotype and pathol. that are very similar to that seen in human
ALS patients. Here we show that treatment with arimoclomol, a
coinducer of heat shock proteins (HSPs), significantly delays disease
progression in mice expressing a SOD1 mutant in which glycine is
substituted with alanine at position 93 (SOD1G93A). Arimoclomol-treated
SOD1G93A mice show marked improvement in hind limb muscle function and
motoneuron survival in the later stages of the disease, resulting in a 22%
increase in lifespan. Pharmacol. activation of the heat shock response
may therefore be a successful therapeutic approach to treating ALS
, and possibly other neurodegenerative diseases.

REFERENCE COUNT: 20 THERE ARE 20 CITED REFERENCES AVAILABLE FOR THIS
RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

=> file registry

COST IN U.S. DOLLARS

SINCE FILE	TOTAL
ENTRY	SESSION

FULL ESTIMATED COST

36.64	215.21
-------	--------

DISCOUNT AMOUNTS (FOR QUALIFYING ACCOUNTS)

SINCE FILE	TOTAL
ENTRY	SESSION

CA SUBSCRIBER PRICE

-6.40	-6.40
-------	-------

FILE 'REGISTRY' ENTERED AT 13:15:05 ON 17 NOV 2008

USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.

PLEASE SEE "HELP USAGETERMS" FOR DETAILS.

COPYRIGHT (C) 2008 American Chemical Society (ACS)

Property values tagged with IC are from the ZIC/VINITI data file
provided by InfoChem.

STRUCTURE FILE UPDATES: 16 NOV 2008 HIGHEST RN 1072892-84-2

DICTIONARY FILE UPDATES: 16 NOV 2008 HIGHEST RN 1072892-84-2

New CAS Information Use Policies, enter HELP USAGETERMS for details.

TSCA INFORMATION NOW CURRENT THROUGH July 5, 2008.

Please note that search-term pricing does apply when
conducting SmartSELECT searches.

REGISTRY includes numerically searchable data for experimental and
predicted properties as well as tags indicating availability of
experimental property data in the original document. For information
on property searching in REGISTRY, refer to:

<http://www.cas.org/support/stngen/stdoc/properties.html>

=> e arimoclomol

E1	1	ARIMIDS/BI
E2	1	ARIMOCLOM/BI
E3	1 -->	ARIMOCLOMOL/BI
E4	2	ARIMOL/BI
E5	2	ARIMOSA/BI
E6	1	ARIMOTO/BI
E7	130	ARIN/BI
E8	17	ARINA/BI
E9	1	ARINAE/BI
E10	1	ARINAMINE/BI
E11	4	ARINATE/BI
E12	56	ARINE/BI

=> s e3

L5 1 ARIMOCLOMOL/BI

=> d 15

L5 ANSWER 1 OF 1 REGISTRY COPYRIGHT 2008 ACS on STN

RN 289893-25-0 REGISTRY

ED Entered STN: 21 Sep 2000

CN 3-Pyridinecarboximidoyl chloride, N-[(2R)-2-hydroxy-3-(1-piperidinyl)propoxy]-, 1-oxide (CA INDEX NAME)

OTHER NAMES:

CN Arimoclomol

FS STEREOSEARCH

MF C14 H20 Cl N3 O3


CI COM

SR CA

LC STN Files: ADISINSIGHT, CA, CAPLUS, CBNE, EMBASE, IMSRESEARCH, PROUSDDR, SYNTHLINE, TOXCENTER, USAN, USPAT2, USPATFULL

Absolute stereochemistry.

Double bond geometry unknown.



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

10 REFERENCES IN FILE CA (1907 TO DATE)

1 REFERENCES TO NON-SPECIFIC DERIVATIVES IN FILE CA

10 REFERENCES IN FILE CAPLUS (1907 TO DATE)

=> e brx

E1	6	BRWR1/BI
E2	1	BRWY/BI
E3	32 -->	BRX/BI
E4	6	BRX1/BI
E5	2	BRX1A/BI
E6	2	BRX1B/BI

E7	6	BRXE/BI
E8	2	BRXE10/BI
E9	2	BRXE11/BI
E10	2	BRXE12/BI
E11	2	BRXE13/BI
E12	2	BRXE14/BI

=> e brx220

E1	2	BRX1A/BI
E2	2	BRX1B/BI
E3	0 -->	BRX220/BI
E4	6	BRXE/BI
E5	2	BRXE10/BI
E6	2	BRXE11/BI
E7	2	BRXE12/BI
E8	2	BRXE13/BI
E9	2	BRXE14/BI
E10	2	BRXE15/BI
E11	2	BRXE16/BI
E12	3	BRXE2/BI

=> s e3

L6	0	BRX220/BI
----	---	-----------

=> e brx

E1	6	BRWR1/BI
E2	1	BRWY/BI
E3	32 -->	BRX/BI
E4	6	BRX1/BI
E5	2	BRX1A/BI
E6	2	BRX1B/BI
E7	6	BRXE/BI
E8	2	BRXE10/BI
E9	2	BRXE11/BI
E10	2	BRXE12/BI
E11	2	BRXE13/BI
E12	2	BRXE14/BI

=> s e3

L7	32	BRX/BI
----	----	--------

=> d l7 1-32

L7 ANSWER 1 OF 32 REGISTRY COPYRIGHT 2008 ACS on STN

RN 909311-85-9 REGISTRY

ED Entered STN: 02 Oct 2006

CN Glucagon-like peptide 1 [2-glycine,28-alanine,31-glycine] (human clone
WO2006/096515-SEQID-12) fusion protein with peptide (synthetic) fusion
protein with transferrin (human) (9CI) (CA INDEX NAME)

OTHER NAMES:

CN 20: PN: WO2006096515 SEQID: 12 claimed protein

CN BRX 0585

CN GLP 1Tf

FS PROTEIN SEQUENCE

MF Unspecified

CI MAN

SR CA

LC STN Files: CA, CAPLUS, TOXCENTER, USPATFULL

RELATED SEQUENCES AVAILABLE WITH SEQLINK

*** STRUCTURE DIAGRAM IS NOT AVAILABLE ***

*** USE 'SQD' OR 'SQIDE' FORMATS TO DISPLAY SEQUENCE ***
2 REFERENCES IN FILE CA (1907 TO DATE)
2 REFERENCES IN FILE CAPLUS (1907 TO DATE)

L7 ANSWER 2 OF 32 REGISTRY COPYRIGHT 2008 ACS on STN
RN 889930-43-2 REGISTRY
ED Entered STN: 28 Jun 2006
CN Protein (Arabidopsis thaliana strain ecotype-Uk-2 gene BRX (BREVIS
RADIX)) (9CI) (CA INDEX NAME)

OTHER NAMES:

CN GenBank ABG25053
CN GenBank ABG25053 (Translated from: GenBank AY702649)
FS PROTEIN SEQUENCE
MF Unspecified
CI MAN
SR GenBank
LC STN Files: CA, CAPLUS

*** STRUCTURE DIAGRAM IS NOT AVAILABLE ***
*** USE 'SQD' OR 'SQIDE' FORMATS TO DISPLAY SEQUENCE ***
1 REFERENCES IN FILE CA (1907 TO DATE)
1 REFERENCES IN FILE CAPLUS (1907 TO DATE)

L7 ANSWER 3 OF 32 REGISTRY COPYRIGHT 2008 ACS on STN
RN 889930-42-1 REGISTRY
ED Entered STN: 28 Jun 2006
CN DNA (Arabidopsis thaliana strain ecotype-Uk-2 gene BRX (BREVIS
RADIX) protein cDNA) (9CI) (CA INDEX NAME)

OTHER NAMES:

CN GenBank AY702649
FS NUCLEIC ACID SEQUENCE
MF Unspecified
CI MAN
SR GenBank
LC STN Files: CA, CAPLUS, GENBANK

*** STRUCTURE DIAGRAM IS NOT AVAILABLE ***
*** USE 'SQD' OR 'SQIDE' FORMATS TO DISPLAY SEQUENCE ***
1 REFERENCES IN FILE CA (1907 TO DATE)
1 REFERENCES IN FILE CAPLUS (1907 TO DATE)

L7 ANSWER 4 OF 32 REGISTRY COPYRIGHT 2008 ACS on STN
RN 889930-41-0 REGISTRY
ED Entered STN: 28 Jun 2006
CN Protein (Arabidopsis thaliana strain ecotype-Uk-1 gene BRX (BREVIS
RADIX) truncated isoform) (9CI) (CA INDEX NAME)

OTHER NAMES:

CN GenBank ABG25052
CN GenBank ABG25052 (Translated from: GenBank AY702648)
FS PROTEIN SEQUENCE
MF Unspecified
CI MAN
SR GenBank
LC STN Files: CA, CAPLUS

*** STRUCTURE DIAGRAM IS NOT AVAILABLE ***
*** USE 'SQD' OR 'SQIDE' FORMATS TO DISPLAY SEQUENCE ***
1 REFERENCES IN FILE CA (1907 TO DATE)
1 REFERENCES IN FILE CAPLUS (1907 TO DATE)


L7 ANSWER 5 OF 32 REGISTRY COPYRIGHT 2008 ACS on STN
RN 889930-40-9 REGISTRY

ED Entered STN: 28 Jun 2006
 CN DNA (Arabidopsis thaliana strain ecotype-Uk-1 gene BRX (BREVIS RADIX)
 protein truncated isoform cDNA plus 3'-flank) (9CI) (CA INDEX NAME)
 OTHER NAMES:
 CN GenBank AY702648
 FS NUCLEIC ACID SEQUENCE
 MF Unspecified
 CI MAN
 SR GenBank
 LC STN Files: CA, CAPLUS, GENBANK

*** STRUCTURE DIAGRAM IS NOT AVAILABLE ***
 *** USE 'SQD' OR 'SQIDE' FORMATS TO DISPLAY SEQUENCE ***
 1 REFERENCES IN FILE CA (1907 TO DATE)
 1 REFERENCES IN FILE CAPLUS (1907 TO DATE)

L7 ANSWER 6 OF 32 REGISTRY COPYRIGHT 2008 ACS on STN
 RN 850069-82-8 REGISTRY
 ED Entered STN: 09 May 2005
 CN Propanedioic acid, (6aS,11bR)-3-(acetyloxy)-7,11b-dihydrobenz[b]indeno[1,2-d]pyran-6a,9,10(6H)-triyl trimethyl ester (9CI) (CA INDEX NAME)
 OTHER NAMES:
 CN BRX 018
 FS STEREOSEARCH
 MF C30 H28 O15
 SR CA
 LC STN Files: CA, CAPLUS

Absolute stereochemistry.



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT
 1 REFERENCES IN FILE CA (1907 TO DATE)
 1 REFERENCES IN FILE CAPLUS (1907 TO DATE)

L7 ANSWER 7 OF 32 REGISTRY COPYRIGHT 2008 ACS on STN
 RN 688066-21-9 REGISTRY
 ED Entered STN: 01 Jun 2004
 CN Protein (Arabidopsis thaliana gene BRX) (9CI) (CA INDEX NAME)
 FS PROTEIN SEQUENCE
 MF Unspecified
 CI MAN
 SR CA
 LC STN Files: CA, CAPLUS

*** STRUCTURE DIAGRAM IS NOT AVAILABLE ***
 *** USE 'SQD' OR 'SQIDE' FORMATS TO DISPLAY SEQUENCE ***

1 REFERENCES IN FILE CA (1907 TO DATE)
1 REFERENCES IN FILE CAPLUS (1907 TO DATE)

L7 ANSWER 8 OF 32 REGISTRY COPYRIGHT 2008 ACS on STN
RN 502923-63-9 REGISTRY
ED Entered STN: 14 Apr 2003
CN Amplex BRX (9CI) (CA INDEX NAME)
ENTE An activator for pectinase mixture biopolishing agent (Color Center S.A., Spain)
MF Unspecified
CI MAN
SR CA
LC STN Files: CA, CAPLUS

*** STRUCTURE DIAGRAM IS NOT AVAILABLE ***
1 REFERENCES IN FILE CA (1907 TO DATE)
1 REFERENCES IN FILE CAPLUS (1907 TO DATE)


L7 ANSWER 9 OF 32 REGISTRY COPYRIGHT 2008 ACS on STN
RN 496816-64-9 REGISTRY
ED Entered STN: 03 Mar 2003
CN 3-Pyridinecarboximidoyl chloride, N-[(2R)-2-hydroxy-3-(1-piperidinyl)propoxy]-, [C(Z)]-, (2Z)-2-butenedioate (1:1) (9CI) (CA INDEX NAME)

OTHER NAMES:
CN BRX 51
FS STEREOSEARCH
MF C14 H20 Cl N3 O2 . C4 H4 O4
SR CA
LC STN Files: CA, CAPLUS

CM 1

CRN 496816-63-8
CMF C14 H20 Cl N3 O2


Absolute stereochemistry.
Double bond geometry as shown.



CM 2

CRN 110-16-7
CMF C4 H4 O4

Double bond geometry as shown.



1 REFERENCES IN FILE CA (1907 TO DATE)
1 REFERENCES IN FILE CAPLUS (1907 TO DATE)

L7 ANSWER 10 OF 32 REGISTRY COPYRIGHT 2008 ACS on STN
RN 496816-62-7 REGISTRY
ED Entered STN: 03 Mar 2003
CN 3-Pyridinecarboximidoyl chloride, N-[(2S)-2-hydroxy-3-(1-piperidinyl)propoxy]-, [C(Z)]-, (2Z)-2-butenedioate (1:1) (9CI) (CA INDEX NAME)


OTHER NAMES:

CN BRX 53
FS STEREOSEARCH
MF C14 H20 Cl N3 O2 . C4 H4 O4
SR CA
LC STN Files: CA, CAPLUS

CM 1

CRN 496816-61-6
CMF C14 H20 Cl N3 O2


Absolute stereochemistry. Rotation (-).
Double bond geometry as shown.



CM 2

CRN 110-16-7
CMF C4 H4 O4

Double bond geometry as shown.



1 REFERENCES IN FILE CA (1907 TO DATE)
1 REFERENCES IN FILE CAPLUS (1907 TO DATE)

L7 ANSWER 11 OF 32 REGISTRY COPYRIGHT 2008 ACS on STN
RN 412507-73-4 REGISTRY
ED Entered STN: 08 May 2002
CN DNA (mouse strain C57BL/6J clone UI-M-BH3-brx-a-05-0-UI EST (expressed sequence tag)) (CA INDEX NAME)

OTHER NAMES:

CN GenBank BM933144
FS NUCLEIC ACID SEQUENCE
MF Unspecified
CI MAN
SR GenBank
LC STN Files: CA, CAPLUS, GENBANK, TOXCENTER

*** STRUCTURE DIAGRAM IS NOT AVAILABLE ***
*** USE 'SQD' OR 'SQIDE' FORMATS TO DISPLAY SEQUENCE ***
1 REFERENCES IN FILE CA (1907 TO DATE)
1 REFERENCES IN FILE CAPLUS (1907 TO DATE)

L7 ANSWER 12 OF 32 REGISTRY COPYRIGHT 2008 ACS on STN
RN 392081-00-4 REGISTRY
ED Entered STN: 13 Feb 2002
CN DNA (human clone pDR2 gene BRX cDNA) (CA INDEX NAME)
OTHER NAMES:
CN 469: PN: WO2007132883 PAGE: 41 unclaimed DNA
CN GenBank AF126008
FS NUCLEIC ACID SEQUENCE
MF Unspecified
CI MAN
SR GenBank
LC STN Files: CA, CAPLUS, GENBANK, TOXCENTER

RELATED SEQUENCES AVAILABLE WITH SEQLINK

*** STRUCTURE DIAGRAM IS NOT AVAILABLE ***
*** USE 'SQD' OR 'SQIDE' FORMATS TO DISPLAY SEQUENCE ***
1 REFERENCES IN FILE CA (1907 TO DATE)
1 REFERENCES IN FILE CAPLUS (1907 TO DATE)

L7 ANSWER 13 OF 32 REGISTRY COPYRIGHT 2008 ACS on STN
RN 388566-72-1 REGISTRY
ED Entered STN: 31 Jan 2002
CN BRX-Q (9CI) (CA INDEX NAME)
ENTE An experimental acrylamido-based ion-exchanger for protein chromatography
(Bio-Rad Laboratories, Hercules, CA)
MF Unspecified
CI PMS, MAN
PCT Manual registration
SR CA
LC STN Files: CA, CAPLUS

*** STRUCTURE DIAGRAM IS NOT AVAILABLE ***
1 REFERENCES IN FILE CA (1907 TO DATE)
1 REFERENCES IN FILE CAPLUS (1907 TO DATE)

L7 ANSWER 14 OF 32 REGISTRY COPYRIGHT 2008 ACS on STN
RN 344670-25-3 REGISTRY
ED Entered STN: 05 Jul 2001
CN DNA (mouse strain C57BL/6J clone UI-M-BH3-brx-b-05-0-UI EST
(expressed sequence tag)) (CA INDEX NAME)
OTHER NAMES:
CN GenBank BI133445
FS NUCLEIC ACID SEQUENCE
MF Unspecified
CI MAN
SR GenBank
LC STN Files: CA, CAPLUS, GENBANK, TOXCENTER

*** STRUCTURE DIAGRAM IS NOT AVAILABLE ***
*** USE 'SQD' OR 'SQIDE' FORMATS TO DISPLAY SEQUENCE ***
1 REFERENCES IN FILE CA (1907 TO DATE)
1 REFERENCES IN FILE CAPLUS (1907 TO DATE)

L7 ANSWER 15 OF 32 REGISTRY COPYRIGHT 2008 ACS on STN
RN 326984-24-1 REGISTRY

ED Entered STN: 13 Mar 2001
CN DNA (Rattus norvegicus strain Sprague-Dawley clone
UI-R-CV1-brx-h-03-0-UI EST (expressed sequence tag)) (9CI) (CA INDEX
NAME)

OTHER NAMES:

CN 410: PN: US20050084872 TABLE: 9 claimed DNA
CN GenBank BG373361
FS NUCLEIC ACID SEQUENCE
MF Unspecified
CI MAN
SR GenBank
LC STN Files: CA, CAPLUS, GENBANK, TOXCENTER, USPATFULL

*** STRUCTURE DIAGRAM IS NOT AVAILABLE ***

*** USE 'SQD' OR 'SQIDE' FORMATS TO DISPLAY SEQUENCE ***
1 REFERENCES IN FILE CA (1907 TO DATE)
1 REFERENCES IN FILE CAPLUS (1907 TO DATE)

L7 ANSWER 16 OF 32 REGISTRY COPYRIGHT 2008 ACS on STN
RN 308063-34-5 REGISTRY *

* Use of this CAS Registry Number alone as a search term in other STN files may
result in incomplete search results. For additional information, enter HELP
RN* at an online arrow prompt (=>).

ED Entered STN: 12 Dec 2000

CN Rubber, butadiene, of cis-1,4-configuration (CA INDEX NAME)

OTHER NAMES:

CN Afdene Buna CB 11
CN Ameripol CB
CN Ameripol CB 200
CN Ameripol CB 220
CN Ameripol CB 221
CN B 27
CN B 27 (rubber)
CN B 37
CN B 37 (rubber)
CN BCP 820
CN BR 01
CN BR 10
CN BR 11
CN BR 1208
CN BR 1220
CN BR 1220N
CN BR 1220SG
CN BR 1241
CN BR 1280
CN BR 130B
CN BR 133P
CN BR 150
CN BR 150B
CN BR 150L
CN BR 153A
CN BR 18
CN BR 230
CN BR 31
CN BR 360L
CN BR 40
CN BR 51
CN BR 60
CN BR 700
CN BR 700 (rubber)
CN BR 701
CN BR 730

CN BR 9000
 CN BR 9002
 CN BR 9002L
 CN BR 9004
 CN BR 9053
 CN BRX 5000
 CN Bud 1207
 CN Bud 1254
 CN Budene 1207
 CN Budene 1208
 CN Budene 1254
 CN Budene 1280
 CN Budene 207
 CN Buna CB 10
 CN Nipol BRX 5000

ADDITIONAL NAMES NOT AVAILABLE IN THIS FORMAT - Use FCN, FIDE, or ALL for DISPLAY

MF Unspecified
 CI MAN, CTS
 SR CA


*** STRUCTURE DIAGRAM IS NOT AVAILABLE ***

L7 ANSWER 17 OF 32 REGISTRY COPYRIGHT 2008 ACS on STN
 RN 289893-26-1 REGISTRY
 ED Entered STN: 21 Sep 2000
 CN 3-Pyridinecarboximidoyl chloride, N-[(2R)-2-hydroxy-3-(1-piperidinyl)propoxy]-, 1-oxide, (2Z)-2-butenedioate (1:1) (CA INDEX NAME)
 OTHER CA INDEX NAMES:
 CN 3-Pyridinecarboximidoyl chloride, N-[(2R)-2-hydroxy-3-(1-piperidinyl)propoxy]-, 1-oxide, (2Z)-2-butenedioate (1:1) (salt) (9CI)
 OTHER NAMES:
 CN BRX 220
 FS STEREOSEARCH
 MF C14 H20 Cl N3 O3 . C4 H4 O4
 SR CA
 LC STN Files: BIOSIS, CA, CAPLUS, IMSDRUGNEWS, IMSRESEARCH, PROUSDDR, SYNTHLINE, TOXCENTER, USPAT2, USPATFULL

CM 1

CRN 289893-25-0
 CMF C14 H20 Cl N3 O3


Absolute stereochemistry.
 Double bond geometry unknown.



CM 2

CRN 110-16-7
 CMF C4 H4 O4

Double bond geometry as shown.



8 REFERENCES IN FILE CA (1907 TO DATE)
8 REFERENCES IN FILE CAPLUS (1907 TO DATE)

L7 ANSWER 18 OF 32 REGISTRY COPYRIGHT 2008 ACS on STN
RN 222187-17-9 REGISTRY
ED Entered STN: 07 May 1999
CN DNA (human clone 11.1/2.2 gene brx protein cDNA plus flanks) (9CI)
(CA INDEX NAME)
OTHER NAMES:
CN DNA (human clone 11.1/2.2 gene brx nuclear receptor-binding auxiliary
protein Brx cDNA plus flanks)
CN DNA (human clone 11.1/2.2 gene brx putative rho guanine nucleotide
exchange factor cDNA plus flanks)
FS NUCLEIC ACID SEQUENCE
MF Unspecified
CI MAN
SR CA
LC STN Files: CA, CAPLUS, TOXCENTER

*** STRUCTURE DIAGRAM IS NOT AVAILABLE ***
*** USE 'SQD' OR 'SQIDE' FORMATS TO DISPLAY SEQUENCE ***
1 REFERENCES IN FILE CA (1907 TO DATE)
1 REFERENCES IN FILE CAPLUS (1907 TO DATE)


L7 ANSWER 19 OF 32 REGISTRY COPYRIGHT 2008 ACS on STN
RN 222187-15-7 REGISTRY
ED Entered STN: 07 May 1999
CN Protein (human clone 11.1/2.2 gene brx reduced) (9CI) (CA INDEX
NAME)
OTHER NAMES:
CN Nuclear receptor-binding auxiliary protein Brx (human clone 11.1/2.2
gene brx reduced)
CN Putative Rho guanine nucleotide exchange factor (human clone 11.1/2.2
gene brx reduced)
FS PROTEIN SEQUENCE
MF Unspecified
CI MAN
SR CA
LC STN Files: CA, CAPLUS, TOXCENTER

RELATED SEQUENCES AVAILABLE WITH SEQLINK

*** STRUCTURE DIAGRAM IS NOT AVAILABLE ***
*** USE 'SQD' OR 'SQIDE' FORMATS TO DISPLAY SEQUENCE ***
1 REFERENCES IN FILE CA (1907 TO DATE)
1 REFERENCES IN FILE CAPLUS (1907 TO DATE)

L7 ANSWER 20 OF 32 REGISTRY COPYRIGHT 2008 ACS on STN
RN 215233-82-2 REGISTRY
ED Entered STN: 08 Dec 1998
CN Benzenecarboximidamide, N-[3-[(1,1-dimethylethyl)amino]-2-hydroxypropoxy]-
N'-phenyl-, monohydrochloride (9CI) (CA INDEX NAME)
OTHER NAMES:
CN BRX 156

MF C20 H27 N3 O2 . Cl H
 SR CA
 LC STN Files: BIOSIS, CA, CAPLUS, TOXCENTER, USPATFULL
 CRN (774166-55-1)



● HCl

3 REFERENCES IN FILE CA (1907 TO DATE)
 3 REFERENCES IN FILE CAPLUS (1907 TO DATE)


L7 ANSWER 21 OF 32 REGISTRY COPYRIGHT 2008 ACS on STN
 RN 210170-31-3 REGISTRY
 ED Entered STN: 20 Aug 1998
 CN Protein Brx (human) (9CI) (CA INDEX NAME)
 FS PROTEIN SEQUENCE
 MF Unspecified
 CI MAN
 SR CA
 LC STN Files: CA, CAPLUS

*** STRUCTURE DIAGRAM IS NOT AVAILABLE ***
 *** USE 'SQD' OR 'SQIDE' FORMATS TO DISPLAY SEQUENCE ***
 1 REFERENCES IN FILE CA (1907 TO DATE)
 1 REFERENCES IN FILE CAPLUS (1907 TO DATE)

L7 ANSWER 22 OF 32 REGISTRY COPYRIGHT 2008 ACS on STN
 RN 203805-20-3 REGISTRY
 ED Entered STN: 08 Apr 1998
 CN 2H-1,2,4-Oxadiazine, 5,6-dihydro-5-(1-piperidinylmethyl)-3-(3-pyridinyl)-
 (CA INDEX NAME)

OTHER NAMES:

CN BRX 005
 CN BRX 235
 DR 191159-87-2
 MF C14 H20 N4 O
 SR CA
 LC STN Files: BIOSIS, CA, CAPLUS, CHEMCATS, PROUSDDR, SYNTHLINE, TOXCENTER,
 USPAT2, USPATFULL



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

5 REFERENCES IN FILE CA (1907 TO DATE)
5 REFERENCES IN FILE CAPLUS (1907 TO DATE)

L7 ANSWER 23 OF 32 REGISTRY COPYRIGHT 2008 ACS on STN
RN 201556-27-6 REGISTRY
ED Entered STN: 19 Feb 1998
CN BRX 5 (primer) (9CI) (CA INDEX NAME)
OTHER NAMES:
CN BRX 5
ENTE A polyimide primer (Cytec)
MF Unspecified
CI PMS, MAN
PCT Manual registration
SR CA
LC STN Files: BIOSIS, CA, CAPLUS, TOXCENTER, USPATFULL

*** STRUCTURE DIAGRAM IS NOT AVAILABLE ***
4 REFERENCES IN FILE CA (1907 TO DATE)
4 REFERENCES IN FILE CAPLUS (1907 TO DATE)

L7 ANSWER 24 OF 32 REGISTRY COPYRIGHT 2008 ACS on STN
RN 181858-04-8 REGISTRY
ED Entered STN: 10 Oct 1996
CN RNA (measles virus strain Brx hemagglutinin gene
fragment-complementary) (9CI) (CA INDEX NAME)
OTHER NAMES:
CN GenBank Z80797
FS NUCLEIC ACID SEQUENCE
MF Unspecified
CI MAN
SR GenBank
LC STN Files: CA, CAPLUS, GENBANK

*** STRUCTURE DIAGRAM IS NOT AVAILABLE ***
*** USE 'SQD' OR 'SQIDE' FORMATS TO DISPLAY SEQUENCE ***
1 REFERENCES IN FILE CA (1907 TO DATE)
1 REFERENCES IN FILE CAPLUS (1907 TO DATE)

L7 ANSWER 25 OF 32 REGISTRY COPYRIGHT 2008 ACS on STN
RN 164479-36-1 REGISTRY
ED Entered STN: 07 Jul 1995
CN RNA (measles virus strain Brx nucleocapsid protein gene fragment)
(9CI) (CA INDEX NAME)
OTHER CA INDEX NAMES:
CN Ribonucleic acid (measles virus strain Brx nucleocapsid protein gene
fragment)
OTHER NAMES:
CN GenBank X84879
FS NUCLEIC ACID SEQUENCE
MF Unspecified
CI MAN
SR GenBank
LC STN Files: CA, CAPLUS, GENBANK

*** STRUCTURE DIAGRAM IS NOT AVAILABLE ***
*** USE 'SQD' OR 'SQIDE' FORMATS TO DISPLAY SEQUENCE ***
1 REFERENCES IN FILE CA (1907 TO DATE)
1 REFERENCES IN FILE CAPLUS (1907 TO DATE)

L7 ANSWER 26 OF 32 REGISTRY COPYRIGHT 2008 ACS on STN
RN 63394-00-3 REGISTRY *

* Use of this CAS Registry Number alone as a search term in other STN files may

result in incomplete search results. For additional information, enter HELP
RN* at an online arrow prompt (=>).

ED Entered STN: 16 Nov 1984

CN Rubber, butadiene (CA INDEX NAME)

OTHER NAMES:

CN 150L

CN 150L (rubber)

CN 60P

CN A 24

CN Alkadienes, rubber

CN Ameripol CB 441

CN Ameripol CB 880

CN Asadene

CN Asadene 35AS

CN Asadene 35NF

CN Asadene 55AS

CN Asadene 55NF

CN Asadene AS

CN Asadene NF 35A

CN Asadene NF 35AS

CN Asadene NF 50R

CN Asaprene 610AX

CN Asaprene 700A

CN Asaprene 720A

CN Asaprene 720AX

CN Asaprene 730AX

CN Asaprene 755A

CN Asaprene 756A

CN Asaprene 760A

CN Asaprene BR 730A

CN Austrapol 1220

CN Bayer 550

CN Bon RI 1

CN BR 02L

CN BR 02LL

CN BR 1200

CN BR 1202G

CN BR 1203

CN BR 1207

CN BR 1220L

CN BR 1220SU

CN BR 1250

CN BR 1441

CN BR 15HB

CN BR 200

CN BR 200 (rubber)

CN BR 23SH

CN BR 3505

CN BR 401

CN BR 401 (rubber)

CN BR 55F

CN BR 90

CN BR 900

CN BR 9001

CN BR 9073

CN BRX 3000

ADDITIONAL NAMES NOT AVAILABLE IN THIS FORMAT - Use FCN, FIDE, or ALL for
DISPLAY

DR 62361-95-9, 51426-11-0, 178234-67-8

MF Unspecified

CI PMS, MAN, CTS

PCT Manual registration

LC STN Files: ADISNEWS, AGRICOLA, BIOSIS, CA, CAPLUS, CHEMCATS, CHEMLIST,
CIN, CSCHEM, TOXCENTER

*** STRUCTURE DIAGRAM IS NOT AVAILABLE ***

L7 ANSWER 27 OF 32 REGISTRY COPYRIGHT 2008 ACS on STN

RN 3701-40-4 REGISTRY

ED Entered STN: 16 Nov 1984

CN 2,7-Naphthalenedisulfonic acid, 4-hydroxy-3-[2-[4'-(2-(2-hydroxy-1-naphthalenyl)diazenyl)-2,2'-dimethyl[1,1'-biphenyl]-4-yl]diazenyl]-, sodium salt (1:2) (CA INDEX NAME)

OTHER CA INDEX NAMES:

CN 2,7-Naphthalenedisulfonic acid, 4-hydroxy-3-[[4'-[(2-hydroxy-1-naphthalenyl)azo]-2,2'-dimethyl[1,1'-biphenyl]-4-yl]azo]-, disodium salt (9CI)

CN C.I. Acid Red 99 (7CI)

CN C.I. Acid Red 99, disodium salt (8CI)

OTHER NAMES:

CN Acid Leather Red 2BG

CN Acid Red 99

CN Acidine Red RD

CN Airedale Red RM

CN Benzyl Fast Red 2BG

CN Best Acid Milling Red FRS

CN Brilliant Milling Red

CN C.I. 23285

CN Calcocid Milling Red RC

CN Coomassie Red R

CN Dynacid Red RS

CN Elite Fast Red BG

CN Elite Fast Red R

CN Elite Fast Red RS

CN Kayanol Red RS

CN Levanol Brilliant Red BB

CN Milling Fast Red R

CN Milling Fast Red RS

CN Milling Fast Red RX

CN Milling Red PRX

CN Multicuer Red BRX

CN Naphthalene Leather Red R

CN Optanol Red R

CN Pharmanil Red RB

CN Polar Red GBD

CN Polar Red R

CN Shikiso Acid Red RS

CN Sulfonine Red RS

CN Suminol Milling Red GRS

CN Suminol Red RS

CN Supranol Fast Red RX

CN Takaoka Acid Red RS

CN Triacid Fast Red GRS

MF C34 H26 N4 O8 S2 . 2 Na


LC STN Files: CA, CAOLD, CAPLUS, CHEMCATS, CHEMLIST, RTECS*, TOXCENTER,
USPATFULL, USPATOLD

(*File contains numerically searchable property data)

Other Sources: DSL**, EINECS**, TSCA**

(**Enter CHEMLIST File for up-to-date regulatory information)

CRN (25317-42-4)




● 2 Na

21 REFERENCES IN FILE CA (1907 TO DATE)
 21 REFERENCES IN FILE CAPLUS (1907 TO DATE)
 2 REFERENCES IN FILE CAOLD (PRIOR TO 1967)

L7 ANSWER 28 OF 32 REGISTRY COPYRIGHT 2008 ACS on STN
 RN 2241-61-4 REGISTRY
 ED Entered STN: 16 Nov 1984
 CN Benz[b]indeno[1,2-d]pyran-3,6a,9,10(6H)-tetrol, 7,11b-dihydro-,
 tetraacetate, (6aS,11bR)- (9CI) (CA INDEX NAME)
 OTHER CA INDEX NAMES:
 CN Benz[b]indeno[1,2-d]pyran-3,6a,9,10(6H)-tetrol, 7,11b-dihydro-,
 tetraacetate (7CI)
 CN Benz[b]indeno[2,1-d]pyran-3,6a,9,10(6H)-tetrol, 7,10b-dihydro-,
 tetraacetate, (6aS-cis)-
 OTHER NAMES:
 CN BRX 019
 CN Tetraacetylbrasilin
 FS STEREOSEARCH
 MF C24 H22 O9
 LC STN Files: BEILSTEIN*, BIOSIS, CA, CAOLD, CAPLUS, CHEMCATS, MEDLINE,
 PROUSDDR, SYNTHLINE, TOXCENTER
 (*File contains numerically searchable property data)

Absolute stereochemistry. Rotation (+).




PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

5 REFERENCES IN FILE CA (1907 TO DATE)
 5 REFERENCES IN FILE CAPLUS (1907 TO DATE)
 2 REFERENCES IN FILE CAOLD (PRIOR TO 1967)

L7 ANSWER 29 OF 32 REGISTRY COPYRIGHT 2008 ACS on STN
 RN 1658-56-6 REGISTRY
 ED Entered STN: 16 Nov 1984
 CN 1-Naphthalenesulfonic acid, 4-[2-(2-hydroxy-1-naphthalenyl)diazenyl]-,
 sodium salt (1:1) (CA INDEX NAME)
 OTHER CA INDEX NAMES:
 CN 1-Naphthalenesulfonic acid, 4-[(2-hydroxy-1-naphthalenyl)azo]-, monosodium
 salt (9CI)
 CN C.I. Acid Red 88, monosodium salt (8CI)
 OTHER NAMES:
 CN 11391 Red
 CN 2-Naphthol Red J
 CN Acid Cardinal G
 CN Acid Fast Red A
 CN Acid Leather Red ROC
 CN Acid Red 88
 CN Acid Red A
 CN Acid Red A (Chinese)
 CN Acid Red AV
 CN Acid Red G
 CN Acid Rose AV
 CN Acid Scarlet G
 CN Airedale Red A
 CN Amacid Fast Red A
 CN Ambicid Fast Red E
 CN Anadurm Red A-ROC
 CN Anthrosin BRX
 CN Apollo Acid Roccelline
 CN Atul Acid Fast Red A
 CN Azo Acid Red GS
 CN Basacid Red 340
 CN Benzyl Red ROC
 CN Benzyl Red S
 CN Brasilan Red S
 CN Bucacid Fast Red A
 CN C.I. 15620
 CN C.I. Acid Red 88
 CN Calcocid Fast Red A
 CN Cavaleine Red A
 CN Colacid Red AV
 CN Colocid Fast Red A
 CN Conacid Red MM
 CN Daedo Acid Roccelline NS
 CN Dai-ei Roccelline
 CN Derma Fur Red R 150
 CN Diacid Red A
 CN Dinacid Fast Red A
 CN Dyacid Red J
 CN Dycosacid Red A
 CN Eniacid Fast Red A
 CN Eriosin Roccelline
 CN Eriosin Roccelline SS
 CN Ext D and C Red No. 8
 CN Fabracid Red S-A
 CN Fast Acid Red G
 CN Fast Red A
 CN Fast Red A (acid dye)
 CN Fast Red AE
 ADDITIONAL NAMES NOT AVAILABLE IN THIS FORMAT - Use FCN, FIDE, or ALL for
 DISPLAY
 DR 163442-07-7, 39309-87-0

MF C20 H14 N2 O4 S . Na
 CI COM
 LC STN Files: AGRICOLA, ANABSTR, BEILSTEIN*, BIOSIS, CA, CAOLD, CAPLUS,
 CASREACT, CHEMCATS, CHEMLIST, CSCHEM, DETHERM*, IFICDB, IFIPAT, IFIUDB,
 MEDLINE, MSDS-OHS, PIRA, PROMT, RTECS*, TOXCENTER, USPAT2, USPATFULL,
 USPATOLD
 (*File contains numerically searchable property data)
 Other Sources: DSL**, EINECS**, TSCA**
 (**Enter CHEMLIST File for up-to-date regulatory information)
 CRN (18268-54-7)



● Na

PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

429 REFERENCES IN FILE CA (1907 TO DATE)
 9 REFERENCES TO NON-SPECIFIC DERIVATIVES IN FILE CA
 429 REFERENCES IN FILE CAPLUS (1907 TO DATE)
 8 REFERENCES IN FILE CAOLD (PRIOR TO 1967)

L7 ANSWER 30 OF 32 REGISTRY COPYRIGHT 2008 ACS on STN
 RN 1326-85-8 REGISTRY
 ED Entered STN: 16 Nov 1984
 CN C.I. Sulphur Black 2 (8CI, 9CI) (CA INDEX NAME)
 OTHER NAMES:
 CN C.I. 53195
 CN C.I. Sulfur Black 2
 CN Calcogene Black 2R-CF
 CN Calcogene Black RB-CF
 CN Diresul Black 2R
 CN Diresul Black 3R
 CN Diresul Black EV-PL
 CN Eclipse Deep Black BG
 CN Fenoxyl Black 2R
 CN Katigen Deep Black RRND-CF
 CN Kayaku Sulphur Black BRX
 CN Mitsui Sulphur Black ABR
 CN Mitsui Sulphur Black BBRO
 CN Mitsui Sulphur Black BR
 CN Mitsui Sulphur Black R

CN Mitsui Sulphur Black RC
 CN Nissen Black BRX
 CN Sodyesul Black MCF
 CN Solfo Black 3R
 CN Solfo Black R
 CN Sulfanol Black 2R
 CN Sulfogene Carbon 4RCF
 CN Sulfogene Carbon MCF
 CN Sulfogene Carbon Supra CF Grains
 CN Sulfogene Carbon T
 CN Sulfogene Grey HLA grai
 CN Sulfur Black 2
 CN Sulfur Black 2RD
 CN Sulfur Black 4RD
 CN Sulfur Black DR
 CN Sulfur Black RND
 CN Sulphol Black BSP
 CN Sulphol Black BSP Paste
 CN Sulphol Black No. 44
 CN Sulphol Black PG
 CN Sulphol Black PXR Ex. Conc
 CN Sulphol Black PXR Paste
 CN Sulphol Black RS Grains
 CN Sulphol Liquid Black QR
 CN Sulphur Black 2
 CN Thionol Black R
 DEF This substance is identified in the COLOUR INDEX by Colour Index
 Constitution Number, C.I. 53195.
 MF Unspecified
 CI MAN
 LC STN Files: CA, CAPLUS, CHEMCATS, CHEMLIST, TOXCENTER, USPAT2, USPATFULL
 Other Sources: NDSL**, TSCA**
 (**Enter CHEMLIST File for up-to-date regulatory information)

*** STRUCTURE DIAGRAM IS NOT AVAILABLE ***
 11 REFERENCES IN FILE CA (1907 TO DATE)
 11 REFERENCES IN FILE CAPLUS (1907 TO DATE)

L7 ANSWER 31 OF 32 REGISTRY COPYRIGHT 2008 ACS on STN
 RN 1064-48-8 REGISTRY
 ED Entered STN: 16 Nov 1984
 CN 2,7-Naphthalenedisulfonic acid, 4-amino-5-hydroxy-3-[2-(4-nitrophenyl)diazenyl]-6-(2-phenyldiazenyl)-, sodium salt (1:2) (CA INDEX NAME)
 OTHER CA INDEX NAMES:
 CN 2,7-Naphthalenedisulfonic acid, 4-amino-5-hydroxy-3-[(4-nitrophenyl)azo]-6-(phenylazo)-, disodium salt (9CI)
 CN Amido Black 10B (6CI)
 OTHER NAMES:
 CN Acid Black 1
 CN Acid Black 10A
 CN Acid Black 10B
 CN Acid Black 10BA
 CN Acid Black 10BN
 CN Acid Black 10BX
 CN Acid Black 12B
 CN Acid Black 4BN
 CN Acid Black 4BNU
 CN Acid Black 8GB
 CN Acid Black Base M
 CN Acid Black BRX
 CN Acid Black BX

CN Acid Black H
 CN Acid Black JVS
 CN Acid Blue Black
 CN Acid Blue Black 10B
 CN Acid Blue Black 10BX
 CN Acid Blue Black B
 CN Acid Blue Black BG
 CN Acid Blue Black Double 600
 CN Acid Blue Black Sh
 CN Acid Leather Blue IGM
 CN Acid Leather Dark Blue G
 CN Acid Leather Fast Blue Black G
 CN Acidal Black 10B
 CN Acidal Black MV
 CN Acidal Navy Blue 3BR
 CN Aciderm Black E 10B
 CN Acilan Black 10B
 CN Airedale Black 2BG
 CN Amacid Black 10BR
 CN Amide Black 10B
 CN Amido Black
 CN Amido Blue Black 12B
 CN Apollo Acid Blue Black 10B
 CN Atul Acid Black 10BX
 CN Atul Acid Black BX
 CN Azanol Fast Acid Black 10B
 CN Azo Dark Blue C 2B
 CN Azo Dark Blue HR
 CN Azo Dark Blue S
 CN Azo Dark Blue SH
 CN Best Acid Dark Blue B
 CN Black 401
 CN Blue Black 12B
 CN Blue Black SX
 CN Borunil Grey A 10B

ADDITIONAL NAMES NOT AVAILABLE IN THIS FORMAT - Use FCN, FIDE, or ALL for
 DISPLAY

DR 12042-02-3, 68417-62-9, 84842-81-9, 86923-11-7, 31258-44-3

MF C22 H16 N6 O9 S2 . 2 Na

CI COM


LC STN Files: AGRICOLA, ANABSTR, AQUIRE, BEILSTEIN*, BIOSIS, BIOTECHNO, CA,
 CAOLD, CAPLUS, CASREACT, CHEMCATS, CHEMLIST, CSCHEM, EMBASE, IFICDB,
 IFIPAT, IFIUDB, MEDLINE, MSDS-OHS, PROMT, RTECS*, TOXCENTER, USPAT2,
 USPATFULL, USPATOLD

(*File contains numerically searchable property data)

Other Sources: DSL**, EINECS**, TSCA**

(**Enter CHEMLIST File for up-to-date regulatory information)

CRN (3121-74-2)



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

925 REFERENCES IN FILE CA (1907 TO DATE)
5 REFERENCES TO NON-SPECIFIC DERIVATIVES IN FILE CA
926 REFERENCES IN FILE CAPLUS (1907 TO DATE)
10 REFERENCES IN FILE CAOLD (PRIOR TO 1967)

L7 ANSWER 32 OF 32 REGISTRY COPYRIGHT 2008 ACS on STN
RN 147-14-8 REGISTRY
ED Entered STN: 16 Nov 1984
CN Copper, [29H,31H-phthalocyaninato(2)-
κN29,κN30,κN31,κN32]-, (SP-4-1)- (CA INDEX NAME)

OTHER CA INDEX NAMES:

CN 29H,31H-Phthalocyanine, copper complex
CN 29H,31H-Phthalocyanine, copper deriv.

OTHER NAMES:

CN (Phthalocyaninato)copper
CN α-Copper phthalocyanine
CN α-Copper phthalocyanine blue
CN α-Phthalocyanine blue
CN β-Copper phthalocyanine blue
CN β-Phthalocyanine blue
CN ε-Copper phthalocyanine
CN 127EPS
CN 405D
CN 7075M
CN 79S26C
CN 79S26C chip
CN Accospense Cyan Blue GT
CN Acnalin Supra Blue G
CN Acramin Blue F 3G
CN Akrochem 626
CN Aqualine Blue
CN Aquis BW 3571
CN Arlocyanine Blue PS
CN Aztech Chemisperse Cyan 1541
CN B 4G-KR
CN B 702W
CN B 705H
CN B 736
CN B 8M25
CN Bahama Blue BC
CN Bahama Blue BNC
CN Bahama Blue Lake NCF
CN Bahama Blue WD
CN Bermuda Blue
CN BFD 1121
CN BGS 1
CN BGSG-C
CN BL 1531
CN Blue 7110V
CN Blue GLA
CN Blue GLA-SD
CN Blue GLSM
CN Blue Microdis
CN Blue phthalocyanine α-form
CN Blue pigment
CN Blue Toner GTNF
CN BRS 1
CN BRX
CN BT 4651

CN C.I. 74160
CN C.I. Pigment Blue 15
CN C.I. Pigment Blue 15:1

ADDITIONAL NAMES NOT AVAILABLE IN THIS FORMAT - Use FCN, FIDE, or ALL for
DISPLAY

DR 807622-86-2, 819860-69-0, 819860-85-0, 878390-73-9, 924902-00-1,
12767-67-8, 10482-39-0, 11097-56-6, 11129-84-3, 177529-54-3, 177646-05-8,
158853-86-2, 172308-31-5, 172826-46-9, 53802-06-5, 57916-96-8, 57425-52-2,
55819-49-3, 59518-91-1, 59966-88-0, 64333-57-9, 95660-31-4, 95917-74-1,
96024-35-0, 104921-99-5, 51331-32-9, 115284-42-9, 60880-51-5, 60937-79-3,
61489-66-5, 61489-77-8, 61537-10-8, 109675-77-6, 109766-95-2, 66121-19-5,
37223-81-7, 69431-77-2, 78170-27-1, 78413-59-9, 85255-95-4, 85256-77-5,
92909-14-3, 90452-20-3, 34567-54-9, 39378-75-1, 39473-10-4, 53028-77-6,
175386-67-1, 184007-78-1, 209343-48-6, 211564-97-5, 211925-80-3,
213190-86-4, 244244-86-8, 345338-75-2, 392718-62-6, 681847-78-9

MF C32 H16 Cu N8

CI CCS, COM


LC STN Files: ADISNEWS, AGRICOLA, ANABSTR, BIOSIS, BIOTECHNO, CA, CAOLD,
CAPLUS, CASREACT, CSNB, CHEMCATS, CHEMLIST, CIN, CSChem, CSNB, DETHERM*,
EMBASE, Gmelin*, HSDB*, IFICDB, IFIPAT, IFIUDb, IPA, MEDLINE, MRCK*,
MSDS-OHS, PIRA, PROMT, RTECS*, SPECINFO, TOXCENTER, USPAT2, USPATFULL,
USPATOLD

(*File contains numerically searchable property data)

Other Sources: DSL**, EINECS**, TSCA**

(**Enter CHEMLIST File for up-to-date regulatory information)

PAGE 1-A





PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

17797 REFERENCES IN FILE CA (1907 TO DATE)
 1297 REFERENCES TO NON-SPECIFIC DERIVATIVES IN FILE CA
 17840 REFERENCES IN FILE CAPLUS (1907 TO DATE)
 134 REFERENCES IN FILE CAOLD (PRIOR TO 1967)

=> file caplus		
COST IN U.S. DOLLARS	SINCE FILE	TOTAL
	ENTRY	SESSION
FULL ESTIMATED COST	85.59	300.80
DISCOUNT AMOUNTS (FOR QUALIFYING ACCOUNTS)	SINCE FILE	TOTAL
	ENTRY	SESSION
CA SUBSCRIBER PRICE	0.00	-6.40

FILE 'CAPLUS' ENTERED AT 13:20:23 ON 17 NOV 2008
 USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
 PLEASE SEE "HELP USAGETERMS" FOR DETAILS.
 COPYRIGHT (C) 2008 AMERICAN CHEMICAL SOCIETY (ACS)

Copyright of the articles to which records in this database refer is held by the publishers listed in the PUBLISHER (PB) field (available for records published or updated in Chemical Abstracts after December 26, 1996), unless otherwise indicated in the original publications. The CA Lexicon is the copyrighted intellectual property of the American Chemical Society and is provided to assist you in searching databases on STN. Any dissemination, distribution, copying, or storing of this information, without the prior written consent of CAS, is strictly prohibited.

FILE COVERS 1907 - 17 Nov 2008 VOL 149 ISS 21
 FILE LAST UPDATED: 16 Nov 2008 (20081116/ED)

Caplus now includes complete International Patent Classification (IPC) reclassification data for the third quarter of 2008.

Effective October 17, 2005, revised CAS Information Use Policies apply. They are available for your review at:

<http://www.cas.org/legal/infopolicy.html>

=> s (l5 of l7 or arimoclomol) and (aml or sclerosis)
 MISSING OPERATOR L5 OF
 The search profile that was entered contains terms or
 nested terms that are not separated by a logical operator.

=> s (l5 or l7 or arimoclomol) and (aml or sclerosis)
 10 L5

19197 L7
9 ARIMOCLOMOL
8038 AML
253 AMLS
8079 AML
(AML OR AMLS)

33016 SCLEROSIS
30 SCLEROSSES
33031 SCLEROSIS
(SCLEROSIS OR SCLEROSSES)

L8 11 (L5 OR L7 OR ARIMOCLOMOL) AND (AML OR SCLEROSIS)

=> d l8 ibib abs 1-11

L8 ANSWER 1 OF 11 CAPLUS COPYRIGHT 2008 ACS on STN

ACCESSION NUMBER: 2008:1320737 CAPLUS
TITLE: Late stage treatment with arimoclomol delays
disease progression and prevents protein aggregation
in the SOD1G93A mouse model of ALS
AUTHOR(S): Kalmar, Bernadett; Novoselov, Sergey; Gray, Anna;
Cheetham, Michael E.; Margulis, Boris; Greensmith,
Linda
CORPORATE SOURCE: Institute of Neurology, University College London,
London, UK
SOURCE: Journal of Neurochemistry (2008), 107(2), 339-350
CODEN: JONRA9; ISSN: 0022-3042
PUBLISHER: Wiley-Blackwell
DOCUMENT TYPE: Journal
LANGUAGE: English

AB Amyotrophic lateral sclerosis (ALS) is a progressive neurodegenerative disorder characterized by motoneuron degeneration, resulting in muscle paralysis and death, typically within 1-5 years of diagnosis. Although the pathogenesis of ALS remains unclear, there is evidence for the involvement of proteasome dysfunction and heat shock proteins in the disease. We have previously shown that treatment with a co-inducer of the heat shock response called arimoclomol is effective in the SOD1G93A mouse model of ALS, delaying disease progression and extending the lifespan of SOD1G93A mice. However, this previous study only examined the effects arimoclomol when treatment was initiated in pre- or early symptomatic stages of the disease. Clearly, to be of benefit to the majority of ALS patients, any therapy must be effective after symptom onset. In order to establish whether post-symptomatic treatment with arimoclomol is effective, in this study we carried out a systematic assessment of different treatment regimes in SOD1G93A mice. Treatment with arimoclomol from early (75 days) or late (90 days) symptomatic stages significantly improved muscle function. Treatment from 75 days also significantly increased the lifespan of SOD1G93A mice, although treatment from 90 days has no significant effect on lifespan. The mechanism of action of arimoclomol involves potentiation of the heat shock response, and treatment with arimoclomol increased Hsp70 expression. Interestingly, this up-regulation in Hsp70 was accompanied by a decrease in the number of ubiquitinated aggregates in the spinal cord of treated SOD1G93A mice, suggesting that arimoclomol directly effects protein aggregation and degradation

L8 ANSWER 2 OF 11 CAPLUS COPYRIGHT 2008 ACS on STN

ACCESSION NUMBER: 2008:918262 CAPLUS
DOCUMENT NUMBER: 149:258394
TITLE: Arimoclomol at dosages up to 300 Mg/day is
well tolerated and safe in amyotrophic lateral
sclerosis

AUTHOR(S): Cudkowicz, Merit E.; Shefner, Jeremy M.; Simpson, Elizabeth; Grasso, Daniela; Yu, Hong; Zhang, Hui; Shui, Amy; Schoenfeld, David; Brown, Robert H.; Wieland, Scott; Barber, Jack R.

CORPORATE SOURCE: NORTHEAST ALS CONSORTIUM, Neurology Clinical Trials Unit, Massachusetts General Hospital, Charlestown, MA, 02129, USA

SOURCE: Muscle & Nerve (2008), 38(1), 837-844
CODEN: MUNED; ISSN: 0148-639X

PUBLISHER: John Wiley & Sons, Inc.

DOCUMENT TYPE: Journal

LANGUAGE: English

AB Arimoclomol is an investigational drug for amyotrophic lateral sclerosis (ALS) that amplifies heat shock protein gene expression during cell stress. The objectives of the present study were to assess the safety, tolerability, and pharmacokinetics of arimoclomol in ALS. Eighty-four participants with ALS received arimoclomol at one of three oral doses (25, 50, or 100 mg three times daily) or placebo. The primary outcome measure was safety and tolerability. A subset of 44 participants provided serum and cerebrospinal fluid (CSF) samples for pharmacokinetic anal. Participants who completed 12 wk of treatment could enroll in a 6-mo open-label study. Arimoclomol at doses up to 300 mg/day was well tolerated and safe. Arimoclomol resulted in dose-linear pharmacol. exposures and the half-life did not change with continued treatment. Arimoclomol CSF levels increased with dose. Arimoclomol was shown to be safe, and it crosses the blood-brain barrier. Serum pharmacokinetic profiles support dosing of three times per day. An efficacy study in ALS is planned.

REFERENCE COUNT: 27 THERE ARE 27 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L8 ANSWER 3 OF 11 CAPLUS COPYRIGHT 2008 ACS on STN

ACCESSION NUMBER: 2008:223578 CAPLUS

DOCUMENT NUMBER: 148:269430

TITLE: Methods and compositions for the treatment of neurodegenerative disorders such as Huntington's disease

INVENTOR(S): Jin, Xiaowei; Wilson, Amy Beth; Staunton, Jane; MacDonald, Douglas

PATENT ASSIGNEE(S): Combinatorx, Incorporated, USA; Chdi, Inc.

SOURCE: PCT Int. Appl., 127pp.

CODEN: PIXXD2

DOCUMENT TYPE: Patent

LANGUAGE: English

FAMILY ACC. NUM. COUNT: 1

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2008021210	A2	20080221	WO 2007-US17751	20070810
WO 2008021210	A3	20081030		
W:	AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BH, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LT, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RS, RU, SC, SD, SE, SG, SK, SL, SM, SV, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW			
RW:	AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, LV, MC, MT, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, HN, NE, SN, TD, TG, BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ,			

BY, KG, KZ, MD, RU, TJ, TM, AP, EA, EP, OA
 US 20080044390 A1 20080221 US 2007-891552 20070810
 PRIORITY APPLN. INFO.: US 2006-837448P P 20060811
 US 2007-898479P P 20070131
 US 2007-925777P P 20070423
 US 2007-958832P P 20070709

AB The present invention features compns., kits, and methods for treating, preventing, and ameliorating neurodegenerative disorders, e.g., Huntington's disease (HD). Screening methods for identifying candidate compds. that treat, prevent, or ameliorate neurodegenerative disorders, e.g., HD, are provided. Thus, N-terminal fragment of Htt has been shown to form protein aggregates in the nucleus, cytoplasm and processes of neurons in human HD patients and in HD animal models, as well as in many cellular models. Because of their similarities to neurons, rat pheochromocytoma PC12 cells have provided a useful model for studying neuronal cell biol.; in addition, PC12 cells are readily transfected, selected and cloned. In order to perform screening according to a method of the present invention, PC12 cells were obtained that stably incorporated a plasmid that inducibly expresses a toxic expanded polyglutamine (103 glutamine) form of exon 1 of Htt, fused to the marker EGFP. Using the engineered PC12/HttN90Q103 cell line, a high throughput assay to screen small molcs. for their ability to prevent mutant Htt exon 1-induced cell death was developed and optimized.

L8 ANSWER 4 OF 11 CAPLUS COPYRIGHT 2008 ACS on STN

ACCESSION NUMBER: 2007:1424894 CAPLUS
 DOCUMENT NUMBER: 148:492092
 TITLE: Heat shock proteins and protection of the nervous system
 AUTHOR(S): Brown, Ian R.
 CORPORATE SOURCE: Center for the Neurobiology of Stress, University of Toronto at Scarborough, Toronto, ON, Can.
 SOURCE: Annals of the New York Academy of Sciences (2007), 1113(Stress Responses in Biology and Medicine), 147-158
 CODEN: ANYAA9; ISSN: 0077-8923
 PUBLISHER: Blackwell Publishing, Inc.
 DOCUMENT TYPE: Journal; General Review
 LANGUAGE: English

AB A review. Manipulation of the cellular stress response offers strategies to protect brain cells from damage induced by ischemia and neurodegenerative diseases. Overexpression of Hsp70 reduced ischemic injury in the mammalian brain. Investigation of the domains within Hsp70 that confers ischemic neuroprotection revealed the importance of the carboxyl-terminal domain. Arimoclomol, a coinducer of heat shock proteins, delayed progression of amyotrophic lateral sclerosis (ALS) in a mouse model in which motor neurons in the spinal cord and motor cortex degenerate. Celastrol, a promising candidate as an agent to counter neurodegenerative diseases, induced expression of a set of Hsps in differentiated neurons grown in tissue culture. Heat shock "preconditioning" protected the nervous system at the functional level of the synapse and selective overexpression of Hsp70 enhanced the level of synaptic protection. Following hyperthermia, constitutively expressed Hsc70 increased in synapse-rich areas of the brain where it assoc. with Hsp40 to form a complex that can refold denatured proteins. Stress tolerance in neurons is not solely dependent on their own Hsps but can be supplemented by Hsps from adjacent glial cells. Hence, application of exogenous Hsps at neural injury sites is an effective strategy to maintain neuronal viability.

REFERENCE COUNT: 72 THERE ARE 72 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L8 ANSWER 5 OF 11 CAPLUS COPYRIGHT 2008 ACS on STN

ACCESSION NUMBER: 2007:1207486 CAPLUS

DOCUMENT NUMBER: 147:466838

TITLE: Identifying signal transduction pathways that mediate nervous system plasticity by gene expression profiling and the selection of pathway modulators for therapeutic use

INVENTOR(S): Sur, Mriganka; Tropea, Daniela; Kreiman, Gabriel

PATENT ASSIGNEE(S): Massachusetts Institute of Technology, USA

SOURCE: PCT Int. Appl., 407pp.

CODEN: PIXXD2

DOCUMENT TYPE: Patent

LANGUAGE: English

FAMILY ACC. NUM. COUNT: 1

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2007120847	AZ	20071025	WO 2007-US9172	20070412
W:	AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BH, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LT, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RS, RU, SC, SD, SE, SG, SK, SL, SM, SV, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW			
RW:	AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, LV, MC, MT, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG, BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM			

PRIORITY APPLN. INFO.:

US 2006-792275P P 20060414

AB Methods for identifying genes and pathways involved in neuronal plasticity by anal. of the effects of deprivation and stimulation on patterns of gene expression in nervous tissue are described. The invention applies some of these methods to identify genes that are differentially regulated in at least a portion of the nervous system of an individual subjected to conditions known to result in altered nervous system plasticity, i.e., dark rearing (DR) or monocular deprivation (MD). The genes are targets for pharmacol. agents that modify plasticity and candidate agents modifying neuronal plasticity are identified. The invention also identifies biol. pathways that are enriched in the products of genes that are differentially regulated under conditions known to result in altered nervous system plasticity. The methods and compns. may be administered to a subject suffering from damage to the nervous system or from a neuropsychiatric disorder in order to enhance recovery, reorganization, or function of the nervous system. The methods optionally include administering a proteolysis-enhancing agent to the subject.

L8 ANSWER 6 OF 11 CAPLUS COPYRIGHT 2008 ACS on STN

ACCESSION NUMBER: 2007:711978 CAPLUS

DOCUMENT NUMBER: 147:377138

TITLE: Emerging disease-modifying therapies for the treatment of motor neuron disease/amyotrophic lateral sclerosis

AUTHOR(S): Bedlack, Richard S.; Traynor, Bryan J.; Cudkowicz, Merit E.

CORPORATE SOURCE: Duke University Medical Center, Durham, NC, USA

SOURCE: Expert Opinion on Emerging Drugs (2007), 12(2), 229-252

CODEN: EOEDA3

PUBLISHER: Informa Healthcare

DOCUMENT TYPE: Journal; General Review
LANGUAGE: English

AB A review. It has been > 130 years since the first description of the upper and lower motor neuron disease called amyotrophic lateral sclerosis (ALS). Sadly, there has been little change in the long interval over which this disease is diagnosed, or in its poor prognosis. Significant gains have been made, however, in understanding its pathophysiol. and in symptomatic care. Disease-causing mutations have been identified and used to create animal models. Other identified mutations may increase susceptibility and cause disease only in a particular environment and at a particular age. A number of 'downstream' mol. pathways have been implicated, including transcriptional disturbances, protein aggregation, excitotoxicity, mitochondrial dysfunction, oxidative stress, neuroinflammation, cytoskeletal and axonal transport derangements, growth factor dysregulation and apoptosis. This knowledge has led to an impressive pipeline of candidate therapies that offer hope for finally being able to alter ALS disease progression. These are described and prioritized herein, and suggestions are offered for efficiently sifting through them.

REFERENCE COUNT: 148 THERE ARE 148 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L8 ANSWER 7 OF 11 CAPLUS COPYRIGHT 2008 ACS ON STN

ACCESSION NUMBER: 2006:598700 CAPLUS

DOCUMENT NUMBER: 145:499471

TITLE: Neuroprotective agents for clinical trials in ALS

AUTHOR(S): Traynor, B. J.; Bruijn, L.; Conwit, R.; Beal, F.;

CORPORATE SOURCE: O'Neill, G.; Fagan, S. C.; Cudkowicz, M. E.
Neurology Clinical Trials Unit, Department of
Neurology, Massachusetts General Hospital, Boston, MA,
USA

SOURCE: Neurology (2006), 67(1), 20-27

CODEN: NEURAI; ISSN: 0028-3878

PUBLISHER: Lippincott Williams & Wilkins

DOCUMENT TYPE: Journal; General Review

LANGUAGE: English

AB A review. Background: Riluzole is currently the only Food and Drug Administration-approved treatment for ALS, but its effect on survival is modest. Objective: To identify potential neuroprotective agents for testing in phase III clin. trials and to outline which data need to be collected for each drug. Methods: The authors identified 113 compds. by inviting input from academic clinicians and researchers and via literature review to identify agents that have been tested in ALS animal models and in patients with ALS. The list was initially narrowed to 24 agents based on an evaluation of scientific rationale, toxicity, and efficacy in previous animal and human studies. These 24 drugs underwent more detailed pharmacol. evaluation. Results: Twenty drugs were selected as suitable for further development as treatments for patients with ALS. Talampanel and tamoxifen have completed early phase II trials and have demonstrated preliminary efficacy. Other agents (ceftriaxone, minocycline, ONO-2506, and IGF-1 polypeptide) are already in phase III trials involving large nos. of patients with ALS. Remaining agents (AEOL 10150, arimoclonol, celastrol, coenzyme Q10, copaxone, IGF-1-viral delivery, memantine, NAALADase inhibitors, nimesulide, scriptaid, sodium phenylbutyrate, thalidomide, trehalose) require addnl. preclin. animal data, human toxicity and pharmacokinetic data including CNS penetration prior to proceeding to large scale phase III human testing. Further development of riluzole analogs should be considered. Conclusions: Several potential neuroprotective compds., representing a wide range of mechanisms, are available and merit further investigation in ALS.

REFERENCE COUNT: 86 THERE ARE 86 CITED REFERENCES AVAILABLE FOR THIS

RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L8 ANSWER 8 OF 11 CAPLUS COPYRIGHT 2008 ACS ON STN
 ACCESSION NUMBER: 2005:409316 CAPLUS
 DOCUMENT NUMBER: 142:441894
 TITLE: Use of a hydroxamic acid halide derivative in the treatment of neurodegenerative diseases
 INVENTOR(S): Greensmith, Linda; Burnstock, Geoffrey; Urbanics, Rudolf
 PATENT ASSIGNEE(S): Biorex Kutato es Fejlesztő Rt., Hung.
 SOURCE: PCT Int. Appl., 24 pp.
 CODEN: PIXXD2
 DOCUMENT TYPE: Patent
 LANGUAGE: English
 FAMILY ACC. NUM. COUNT: 1
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2005041965	A1	20050512	WO 2004-HU98	20041025
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
RW: BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
AU 2004285343	A1	20050512	AU 2004-285343	20041025
CA 2544332	A1	20050512	CA 2004-2544332	20041025
EP 1696922	A1	20060906	EP 2004-791657	20041025
EP 1696922	B1	20080924		
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, PL, SK, HR				
BR 2004015625	A	20061212	BR 2004-15625	20041025
CN 1901913	A	20070124	CN 2004-80039619	20041025
JP 2007509920	T	20070419	JP 2006-537449	20041025
AT 409038	T	20081015	AT 2004-791657	20041025
MX 2006PA04814	A	20061211	MX 2006-PA4814	20060428
NO 2006002401	A	20060727	NO 2006-2401	20060526
IN 2006KN01464	A	20070504	IN 2006-KN1464	20060530
US 20080039497	A1	20080214	US 2007-582124	20070510
PRIORITY APPLN. INFO.:			HU 2003-3584	A 20031030
			WO 2004-HU98	W 20041025

AB The invention relates to the use of a chemical substance selected from the group consisting of N-[2-hydroxy-3-(1-piperidinyl)-propoxyl]-pyridine-1-oxide-3-carboximidoyl chloride, the optically active enantiomers and the mixts. of enantiomers thereof and pharmaceutically acceptable salts of the racemic and optically active compds. in the preparation of a pharmaceutical composition for the treatment or prevention of neurodegenerative diseases.
 REFERENCE COUNT: 8 THERE ARE 8 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L8 ANSWER 9 OF 11 CAPLUS COPYRIGHT 2008 ACS ON STN
 ACCESSION NUMBER: 2004:263763 CAPLUS
 DOCUMENT NUMBER: 140:399884
 TITLE: Treatment with arimoclomol, a coinducer of heat shock proteins, delays disease progression in ALS mice

AUTHOR(S): Kieran, Dairin; Kalmar, Bernadett; Dick, James R. T.; Riddoch-Contreras, Joanna; Burnstock, Geoffrey; Greensmith, Linda

CORPORATE SOURCE: The National Hospital for Neurology and Neurosurgery, Institute of Neurology, Sobell Department of Motor Neuroscience and Movement Disorders, The Graham Watts Laboratory, University College London, London, WC1N 3BG, UK

SOURCE: Nature Medicine (New York, NY, United States) (2004), 10(4), 402-405
CODEN: NAMEFI; ISSN: 1078-8956

PUBLISHER: Nature Publishing Group

DOCUMENT TYPE: Journal

LANGUAGE: English

AB Amyotrophic lateral sclerosis (ALS) is a fatal neurodegenerative condition in which motoneurons of the spinal cord and motor cortex die, resulting in progressive paralysis. This condition has no cure and results in eventual death, usually within 1-5 yr of diagnosis. Although the specific etiol. of ALS is unknown, 20% of familial cases of the disease carry mutations in the gene encoding Cu/Zn superoxide dismutase-1 (SOD1). Transgenic mice overexpressing human mutant SOD1 have a phenotype and pathol. that are very similar to that seen in human ALS patients. Here we show that treatment with arimoclomol, a coinducer of heat shock proteins (HSPs), significantly delays disease progression in mice expressing a SOD1 mutant in which glycine is substituted with alanine at position 93 (SOD1G93A). Arimoclomol-treated SOD1G93A mice show marked improvement in hind limb muscle function and motoneuron survival in the later stages of the disease, resulting in a 22% increase in lifespan. Pharmacol. activation of the heat shock response may therefore be a successful therapeutic approach to treating ALS, and possibly other neurodegenerative diseases.

REFERENCE COUNT: 20 THERE ARE 20 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L8 ANSWER 10 OF 11 CAPLUS COPYRIGHT 2008 ACS on STN

ACCESSION NUMBER: 1971:401127 CAPLUS

DOCUMENT NUMBER: 75:1127

ORIGINAL REFERENCE NO.: 75:187a,190a

TITLE: Histochemistry of myelin. XII. Anionic staining of myelin basic proteins for histology, electrophoresis, and electron microscopy

AUTHOR(S): Adams, Colin W. M.; Bayliss, Olga B.; Hallpike, J. F.; Turner, D. R.

CORPORATE SOURCE: Med. Sch., Guy's Hosp., London, UK

SOURCE: Journal of Neurochemistry (1971), 18(3), 389-94
CODEN: JONRA9; ISSN: 0022-3042

DOCUMENT TYPE: Journal

LANGUAGE: English

AB Phosphotungstic acid hematoxylin, trypan blue, and amido black techniques were developed as anionic dye methods for staining myelin basic proteins. All methods displayed central and peripheral nervous system myelin in histochem. preps, and stained brain basic proteins in electrophoretic polyacrylamide gels: phosphotungstic acid hematoxylin appeared to be the most selective of these techniques. Electron photomicrographs of peripheral nerve stained by phosphotungstic acid hematoxylin showed that the major part of myelin basic protein is located in the period dense line. The basic proteins stained by phosphotungstic acid hematoxylin showed an early loss in rat sciatic nerve undergoing Wallerian degeneration and had completely disappeared from the center of 20 plaques of multiple sclerosis.

L8 ANSWER 11 OF 11 CAPLUS COPYRIGHT 2008 ACS on STN

ACCESSION NUMBER: 1959:73788 CAPLUS
 DOCUMENT NUMBER: 53:73788
 ORIGINAL REFERENCE NO.: 53:13384b
 TITLE: Histochemistry and classification of the
 Pelizaeus-Merzbacher disease
 AUTHOR(S): Seitelberger, Franz
 CORPORATE SOURCE: Univ. Vienna, Munich, Germany
 SOURCE: Cerebral Lipidoses (J. N. Cumings and A Lowenthal,
 editors. Charles C Thomas, publisher) (1957), Volume
 Date 1955, (Symposium, Antwerp), 92-7
 DOCUMENT TYPE: Journal
 LANGUAGE: Unavailable
 AB Review with reference.

=>
 Connecting via Winsock to STN

Welcome to STN International! Enter x:X

LOGINID:ssptacrs1614

PASSWORD:

TERMINAL (ENTER 1, 2, 3, OR ?):2

***** Welcome to STN International *****

NEWS 1 Web Page for STN Seminar Schedule - N. America
 NEWS 2 DEC 01 ChemPort single article sales feature unavailable
 NEWS 3 JAN 06 The retention policy for unread STNmail messages
 will change in 2009 for STN-Columbus and STN-Tokyo
 NEWS 4 JAN 07 WPIDS, WPINDEX, and WPIX enhanced Japanese Patent
 Classification Data
 NEWS 5 FEB 02 Simultaneous left and right truncation (SLART) added
 for CERAB, COMPUAB, ELCOM, and SOLIDSTATE
 NEWS 6 FEB 02 GENBANK enhanced with SET PLURALS and SET SPELLING
 NEWS 7 FEB 06 Patent sequence location (PSL) data added to USGENE
 NEWS 8 FEB 10 COMPENDEX reloaded and enhanced
 NEWS 9 FEB 11 WTEXTILES reloaded and enhanced
 NEWS 10 FEB 19 New patent-examiner citations in 300,000 CA/CAPLUS
 patent records provide insights into related prior
 art
 NEWS 11 FEB 19 Increase the precision of your patent queries -- use
 terms from the IPC Thesaurus, Version 2009.01
 NEWS 12 FEB 23 Several formats for image display and print options
 discontinued in USPATFULL and USPAT2
 NEWS 13 FEB 23 MEDLINE now offers more precise author group fields
 and 2009 MeSH terms
 NEWS 14 FEB 23 TOXCENTER updates mirror those of MEDLINE - more
 precise author group fields and 2009 MeSH terms
 NEWS 15 FEB 23 Three million new patent records blast AEROSPACE into
 STN patent clusters
 NEWS 16 FEB 25 USGENE enhanced with patent family and legal status
 display data from INPADOCDB
 NEWS 17 MAR 06 INPADOCDB and INPAFAMDB enhanced with new display
 formats
 NEWS 18 MAR 11 EPFULL backfile enhanced with additional full-text
 applications and grants

NEWS 19 MAR 11 ESBIODBASE reloaded and enhanced
 NEWS 20 MAR 20 CAS databases on STN enhanced with new super role
 for nanomaterial substances
 NEWS 21 MAR 23 CA/Caplus enhanced with more than 250,000 patent
 equivalents from China
 NEWS 22 MAR 30 IMSPATENTS reloaded and enhanced
 NEWS 23 APR 03 CAS coverage of exemplified prophetic substances
 enhanced
 NEWS 24 APR 07 STN is raising the limits on saved answers

 NEWS EXPRESS JUNE 27 08 CURRENT WINDOWS VERSION IS V8.3,
 AND CURRENT DISCOVER FILE IS DATED 23 JUNE 2008.

 NEWS HOURS STN Operating Hours Plus Help Desk Availability
 NEWS LOGIN Welcome Banner and News Items
 NEWS IPC8 For general information regarding STN implementation of IPC 8

Enter NEWS followed by the item number or name to see news on that
 specific topic.

All use of STN is subject to the provisions of the STN customer
 agreement. This agreement limits use to scientific research. Use
 for software development or design, implementation of commercial
 gateways, or use of CAS and STN data in the building of commercial
 products is prohibited and may result in loss of user privileges
 and other penalties.

***** STN Columbus *****

FILE 'HOME' ENTERED AT 14:57:49 ON 22 APR 2009

=> file registry caplus

COST IN U.S. DOLLARS	SINCE FILE ENTRY	TOTAL SESSION
FULL ESTIMATED COST	0.22	0.22

FILE 'REGISTRY' ENTERED AT 14:58:11 ON 22 APR 2009

USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
 PLEASE SEE "HELP USAGETERMS" FOR DETAILS.
 COPYRIGHT (C) 2009 American Chemical Society (ACS)

FILE 'CAPLUS' ENTERED AT 14:58:11 ON 22 APR 2009

USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
 PLEASE SEE "HELP USAGETERMS" FOR DETAILS.
 COPYRIGHT (C) 2009 AMERICAN CHEMICAL SOCIETY (ACS)

=> file registry

COST IN U.S. DOLLARS	SINCE FILE ENTRY	TOTAL SESSION
FULL ESTIMATED COST	0.98	1.20

FILE 'REGISTRY' ENTERED AT 14:58:22 ON 22 APR 2009

USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
 PLEASE SEE "HELP USAGETERMS" FOR DETAILS.
 COPYRIGHT (C) 2009 American Chemical Society (ACS)

Property values tagged with IC are from the ZIC/VINITI data file
 provided by InfoChem.

STRUCTURE FILE UPDATES: 21 APR 2009 HIGHEST RN 1137826-72-2
 DICTIONARY FILE UPDATES: 21 APR 2009 HIGHEST RN 1137826-72-2

New CAS Information Use Policies, enter HELP USAGETERMS for details.

TSCA INFORMATION NOW CURRENT THROUGH January 9, 2009.

Please note that search-term pricing does apply when conducting SmartSELECT searches.

REGISTRY includes numerically searchable data for experimental and predicted properties as well as tags indicating availability of experimental property data in the original document. For information on property searching in REGISTRY, refer to:

<http://www.cas.org/support/stngen/stndoc/properties.html>

=> e ariclomol

E1	1	ARICIRESIN/BI
E2	1	ARICIRESINOL/BI
E3	0 -->	ARICLOMOL/BI
E4	2	ARICOL/BI
E5	2	ARICOLA/BI
E6	2	ARICRSARI/BI
E7	3	ARICYL/BI
E8	9	ARID/BI
E9	2	ARID1/BI
E10	2	ARID1A/BI
E11	2	ARID1B/BI
E12	8	ARID2/BI

=> e arimoclomol

E1	1	ARIMIDS/BI
E2	1	ARIMOCLOM/BI
E3	1 -->	ARIMOCLOMOL/BI
E4	2	ARIMOL/BI
E5	2	ARIMOSA/BI
E6	1	ARIMOTO/BI
E7	130	ARIN/BI
E8	17	ARINA/BI
E9	13	ARINAE/BI
E10	1	ARINAMINE/BI
E11	4	ARINATE/BI
E12	56	ARINE/BI

=> s e3

L1 1 ARIMOCLOMOL/BI

=> d l1

L1 ANSWER 1 OF 1 REGISTRY COPYRIGHT 2009 ACS on STN

RN 289893-25-0 REGISTRY

ED Entered STN: 21 Sep 2000

CN 3-Pyridinecarboximidoyl chloride, N-[(2R)-2-hydroxy-3-(1-piperidinyl)propoxy]-, 1-oxide (CA INDEX NAME)

OTHER NAMES:

CN Arimoclomol

FS STEREOSEARCH

MF C14 H20 Cl N3 O3


CI COM

SR CA

LC STN Files: ADISINSIGHT, CA, CAPLUS, CBNB, EMBASE, IMSRESEARCH, PHAR, PROUSDDR, SYNTHLINE, TOXCENTER, USAN, USPAT2, USPATFULL

Absolute stereochemistry.

Double bond geometry unknown.



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

14 REFERENCES IN FILE CA (1907 TO DATE)
1 REFERENCES TO NON-SPECIFIC DERIVATIVES IN FILE CA
14 REFERENCES IN FILE CAPLUS (1907 TO DATE)

=> file caplus embase biosis
COST IN U.S. DOLLARS

SINCE FILE	TOTAL
ENTRY	SESSION
12.68	13.88

FULL ESTIMATED COST

FILE 'CAPLUS' ENTERED AT 15:04:53 ON 22 APR 2009
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.
COPYRIGHT (C) 2009 AMERICAN CHEMICAL SOCIETY (ACS)

FILE 'EMBASE' ENTERED AT 15:04:53 ON 22 APR 2009
Copyright (c) 2009 Elsevier B.V. All rights reserved.

FILE 'BIOSIS' ENTERED AT 15:04:53 ON 22 APR 2009
Copyright (c) 2009 The Thomson Corporation

=> s l1 or (arimoclomol or (brx (a) 220)
UNMATCHED LEFT PARENTHESIS 'OR (ARIMOCLOMO'
The number of right parentheses in a query must be equal to the
number of left parentheses.

=> s l1 or (arimoclomol or (brx (a) 220))
L2 80 L1 OR (ARIMOCLOMOL OR (BRX (A) 220))

=> dup rem l2
PROCESSING COMPLETED FOR L2
L3 62 DUP REM L2 (18 DUPLICATES REMOVED)

=> s l3 and @py<=2004
'2004' NOT A VALID FIELD CODE
'2004' NOT A VALID FIELD CODE
'2004' NOT A VALID FIELD CODE
L4 0 L3 AND @PY<=2004

=> s l3 and py<=2004
L5 14 L3 AND PY<=2004

=> d l5 ibib abs 1-14

L5 ANSWER 1 OF 14 CAPLUS COPYRIGHT 2009 ACS ON STN
ACCESSION NUMBER: 2004:263763 CAPLUS
DOCUMENT NUMBER: 140:399884
TITLE: Treatment with arimoclomol, a coinducer of

heat shock proteins, delays disease progression in ALS mice

AUTHOR(S): Kieran, Dairin; Kalmar, Bernadett; Dick, James R. T.; Riddoch-Contreras, Joanna; Burnstock, Geoffrey; Greensmith, Linda

CORPORATE SOURCE: The National Hospital for Neurology and Neurosurgery, Institute of Neurology, Sobell Department of Motor Neuroscience and Movement Disorders, The Graham Watts Laboratory, University College London, London, WC1N 3BG, UK

SOURCE: Nature Medicine (New York, NY, United States) (2004), 10(4), 402-405
CODEN: NAMEFI; ISSN: 1078-8956

PUBLISHER: Nature Publishing Group

DOCUMENT TYPE: Journal

LANGUAGE: English

AB Amyotrophic lateral sclerosis (ALS) is a fatal neurodegenerative condition in which motoneurons of the spinal cord and motor cortex die, resulting in progressive paralysis. This condition has no cure and results in eventual death, usually within 1-5 yr of diagnosis. Although the specific etiol. of ALS is unknown, 20% of familial cases of the disease carry mutations in the gene encoding Cu/Zn superoxide dismutase-1 (SOD1). Transgenic mice overexpressing human mutant SOD1 have a phenotype and pathol. that are very similar to that seen in human ALS patients. Here we show that treatment with arimoclomol, a coinducer of heat shock proteins (HSPs), significantly delays disease progression in mice expressing a SOD1 mutant in which glycine is substituted with alanine at position 93 (SOD1G93A). Arimoclomol-treated SOD1G93A mice show marked improvement in hind limb muscle function and motoneuron survival in the later stages of the disease, resulting in a 22% increase in lifespan. Pharmacol. activation of the heat shock response may therefore be a successful therapeutic approach to treating ALS, and possibly other neurodegenerative diseases.

REFERENCE COUNT: 20 THERE ARE 20 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L5 ANSWER 2 OF 14 CAPLUS COPYRIGHT 2009 ACS ON STN

ACCESSION NUMBER: 2004:100113 CAPLUS

DOCUMENT NUMBER: 141:17416

TITLE: The effect of treatment with BRX-220
a co-inducer of heat shock proteins, on sensory fibers of the rat following peripheral nerve injury

AUTHOR(S): Kalmar, B.; Greensmith, L.; Malcangio, M.; McMahon, S. B.; Cserehely, P.; Burnstock, G.

CORPORATE SOURCE: Sobell Department of Motor Neuroscience and Movement Disorders, Institute of Neurology, London, WC1N 3BG, UK

SOURCE: Experimental Neurology (2003), 184(2), 636-647
CODEN: EXNEAC; ISSN: 0014-4886

PUBLISHER: Elsevier Science

DOCUMENT TYPE: Journal

LANGUAGE: English

AB In this study, we examined the effect BRX-220, a co-inducer of heat shock proteins, in injury-induced peripheral neuropathy. Following sciatic nerve injury in adult rats and treatment with BRX-220, the following features of the sensory system were studied: (a) expression of calcitonin gene-related peptide (CGRP); (b) binding of isolectin B4 (IB4) in dorsal root ganglia (DRG) and spinal cord; (c) stimulation-evoked release of substance P (SP) in an in vitro spinal cord preparation and (d) nociceptive responses of partially denervated rats. BRX-220 partially reverses

axotomy-induced changes in the sensory system. In vehicle-treated rats there is a decrease in IB4 binding and CGRP expression in injured neurons, while in BRX-220-treated rats these markers were better preserved. Thus, $7.0 \pm 0.6\%$ of injured DRG neurons bound IB4 in vehicle-treated rats compared to $14.4 \pm 0.9\%$ in BRX-220-treated animals. Similarly, $4.5 \pm 0.5\%$ of DRG neurons expressed CGRP in the vehicle-treated group, whereas $9.0 \pm 0.3\%$ were pos. in the BRX-220-treated group. BRX-220 also partially restored SP release from spinal cord sections to elec. stimulation of primary sensory neurons. Behavioral tests carried out on partially denervated animals showed that BRX-220 treatment did not prevent the emergence of mech. or thermal hyperalgesia. However, oral treatment for 4 wk lead to reduced pain-related behavior suggesting either slowly developing analgesic actions or enhancement of recovery processes. Thus, the morphol. improvement seen in sensory neuron markers was accompanied by restored functional activity. Therefore, treatment with BRX-220 promotes restoration of morphol. and functional properties in the sensory system following peripheral nerve injury.

REFERENCE COUNT: 33 THERE ARE 33 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L5 ANSWER 3 OF 14 CAPLUS COPYRIGHT 2009 ACS ON STN

ACCESSION NUMBER: 2002:587024 CAPLUS

DOCUMENT NUMBER: 138:130888

TITLE: Effect of BRX-220 against peripheral neuropathy and insulin resistance in diabetic rat models

AUTHOR(S): Kurthy, Maria; Mogyrosi, Tamas; Nagy, Karoly; Kukorelli, Tibor; Jednakovits, Andrea; Talosi, Laszlo; Biro, Katalin

CORPORATE SOURCE: Biorex Research and Development Company, Veszprem, Hung.

SOURCE: Annals of the New York Academy of Sciences (2002), 967(Lipids and Insulin Resistance), 482-489

CODEN: ANYAA9; ISSN: 0077-8923

PUBLISHER: New York Academy of Sciences

DOCUMENT TYPE: Journal

LANGUAGE: English

AB Bimoclomol (BML), a symptomatic antidiabetic agent, was developed by Biorex R&D Co. to treat diabetic neuropathy and retinopathy. BRX-220, an orally active member of the BRX family, was developed to treat diabetic complications and insulin resistance (IR) as a follow-up compound. The effect of BRX-220 on peripheral neuropathy was examined in rats with diabetes (type 1) induced by administration of a β -cell toxin, streptozotocin (STZ, 45 mg/kg iv). Nerve functions were evaluated by electrophysiol. measurements of muscle motor and sensory nerve conduction velocities (MNCV and SNCV, resp.). MNCV and SNCV decreased in diabetic rats by 25%. A 1-mo preventive treatment with BRX-220 (2.5, 5, 10, and 20 mg/kg po) dose-dependently improved diabetes-related deficits in MNCV (51.3, 71.3, 86.1, and 91.3%) and SNCV (48.9, 68.5, 86.1, and 93.2%). Insulin sensitivity was measured using the insulin tolerance test (ITT), both in STZ diabetic and in Zucker diabetic fatty (ZDF) rats (model of type 2 diabetes). Severe IR was detected in STZ diabetic and ZDF rats. This resistance was significantly reduced by BRX-220 treatment.

REFERENCE COUNT: 19 THERE ARE 19 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L5 ANSWER 4 OF 14 CAPLUS COPYRIGHT 2009 ACS ON STN

ACCESSION NUMBER: 2002:587016 CAPLUS

DOCUMENT NUMBER: 138:130887
 TITLE: Comparison of the extrapancreatic action of
 BRX-220 and pioglitazone in the
 high-fat diet-induced insulin resistance
 AUTHOR(S): Sebokova, Elena; Kurthy, Maria; Mogyrosi, T.; Nagy,
 Karoly; Demcakova, Edit; Ukropec, Jozef; Koranyi,
 Laszlo; Klimes, Iwar
 CORPORATE SOURCE: Diabetes and Nutrition Research Laboratory, Institute
 of Experimental Endocrinology, Slovak Academy of
 Sciences, Bratislava, SK-83306, Slovakia
 SOURCE: Annals of the New York Academy of Sciences (2002), 967(Lipids and Insulin Resistance), 424-430
 CODEN: ANYAA9; ISSN: 0077-8923
 PUBLISHER: New York Academy of Sciences
 DOCUMENT TYPE: Journal
 LANGUAGE: English
 AB A new Biorex mol., BRX-220, was shown to be effective
 in animal models of diabetic neuro- and retinopathy. Recent in vitro
 studies showed that it might also have an insulin-sensitizing action.
 Therefore, the effect of BRX-220 on insulin
 sensitivity was compared with the action of pioglitazone (PGZ) in high fat
 (HF) diet-induced insulin resistance (IR) of rats. Methods-Male Wistar
 rats were fed for 3 wk a standard chow (PD) or the HF (70-cal%) diet. The
 HF-fed rats were also given daily BRX-220 (20 mg/kg
 BW) or PGZ (6 mg/kg BW) by gavage. In vivo insulin action was assessed by
 the euglycemic hyperinsulinemic clamp. Glucose, insulin, FFA,
 triglyceride (TG), and glycerol levels in blood were also measured, as
 well as tissue TG content. Results-Increased levels of fed TG in
 circulation after HF diet (PD: 2.0 vs. HF: 5.0 mmol/L) were partially corrected
 by BRX-220 (HF+BRX: 3.8) and normalized by PGZ
 (HF+PGZ: 2.6). Both mols. prevented the increase in fed serum FFA levels
 after HF diet (PD: 0.5; HF: 1.8±0.2 mmol/L), with a more pronounced
 effect of PGZ (HF+BRX: 1.2; HF+PGZ: 0.7). Tissue TG levels increased
 significantly in response to HF feeding in both liver (HF: 16; PD: 6.4
 µmol/g) and skeletal muscle (HF: 7.7; PD: 2.4). This increase was
 completely normalized by both agents in the liver (HF+BRX: 8.8; HF+PGZ:
 8.8), and only partially in the skeletal muscles. HF diet-induced in vivo
 IR (PD: 25.4; HF: 15.7 mg/kg/min) was significantly reduced by BRX
 -220 (HF+BRX: 18.7) and PGZ (HF+PGZ: 22.8) treatment.
 Conclusions-(1) Subchronic administration of BRX-220
 leads to an improvement of in vivo insulin action. (2) This
 insulin-sensitizing effect is, however, not as pronounced as that of PGZ.
 (3) It is accompanied by a decrease of circulating TG and FFA levels in
 the postprandial state and (4) by lower TG content in liver and skeletal
 muscle.
 REFERENCE COUNT: 30 THERE ARE 30 CITED REFERENCES AVAILABLE FOR THIS
 RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L5 ANSWER 5 OF 14 CAPLUS COPYRIGHT 2009 ACS on STN
 ACCESSION NUMBER: 2002:496814 CAPLUS
 DOCUMENT NUMBER: 137:362925
 TITLE: Upregulation of Heat Shock Proteins Rescues
 Motoneurons from Axotomy-Induced Cell Death in
 Neonatal Rats
 AUTHOR(S): Kalmar, B.; Burnstock, G.; Vrbova, G.; Urbanics, R.;
 Csermely, P.; Greensmith, L.
 CORPORATE SOURCE: Sobell Department of Motor Neuroscience and Movement
 Disorders, Institute of Neurology, London, WC1N 3BG,
 UK
 SOURCE: Experimental Neurology (2002), 176(1), 87-97
 CODEN: EXNEAC; ISSN: 0014-4886

PUBLISHER: Elsevier Science
DOCUMENT TYPE: Journal
LANGUAGE: English

AB Heat shock proteins (hsps) are induced in a variety of cells following periods of stress, where they promote cell survival. In this study, we examined the effect of upregulating hsp expression by treatment with BRX-220, a co-inducer of hsps, on the survival of injured motoneurons. Following sciatic nerve crush at birth, rat pups were treated daily with BRX-220. The expression of hsp70 and hsp90, motoneurone survival, and muscle function was examined at various intervals later and the number of functional motor units was assessed by *in vivo* isometric tension recordings. Fourteen days after injury, significantly more motoneurons survived in the BRX-220 -treated group ($39 \pm 2.8\%$) compared to the saline-treated group ($21 \pm 1.7\%$). Moreover, in the BRX-220-treated group no further loss of motoneurons occurred, so that at 10 wk $42 \pm 2.1\%$ of motoneurons survived compared to $15 \pm 0.6\%$ in the untreated group. There were also more functional motor units in the hindlimb muscles of BRX-220-treated animals. In addition, treatment with BRX-220 resulted in a significant increase in the expression of hsp70 and hsp90 in glia and neurons. Thus, treatment with BRX-220, a co-inducer of hsps, protects motoneurons from axotomy-induced cell death.

REFERENCE COUNT: 52 THERE ARE 52 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L5 ANSWER 6 OF 14 CAPLUS COPYRIGHT 2009 ACS on STN

ACCESSION NUMBER: 2002:418232 CAPLUS

DOCUMENT NUMBER: 138:49725

TITLE: Nontoxic heat shock protein coinducer BRX-220 protects against acute pancreatitis in rats

AUTHOR(S): Rakonczay, Zoltan; Ivanyi, Bela; Varga, Ilona; Boros, Imre; Jednakovits, Andrea; Nemeth, Ilona; Lonovics, Janos; Takacs, Tamas

CORPORATE SOURCE: First Department of Medicine, University of Szeged, Szeged, Hung.

SOURCE: Free Radical Biology & Medicine (2002), 32(12), 1283-1292
CODEN: FRBMEH; ISSN: 0891-5849

PUBLISHER: Elsevier Science Inc.

DOCUMENT TYPE: Journal

LANGUAGE: English

AB Nontoxic heat shock protein (HSP) inducer compds. open up promising therapeutic possibilities by activating one of the natural and highly conserved defense mechanisms of the organism. In the present expts., we examined the effects of a HSP coinducer drug-candidate, BRX-220, on the cholecystokinin-octapeptide (CCK)-induced acute pancreatitis in rats. Male Wistar rats weighing 240 to 270 g were divided into two groups. In group B, 20 mg/kg BRX-220 was administered orally, followed by 75 μ g/kg CCK s.c. three times, after 1, 3, and 5 h. This whole procedure was repeated for 5 d. The animals in group B received physiol. saline orally instead of BRX-220, but otherwise the protocol was the same as in group B. The rats were exsanguinated through the abdominal aorta 12 h after the last administration of CCK. We determined the serum amylase activity, the plasma trypsinogen activation peptide concentration, the pancreatic weight/body weight ratio, the DNA and total protein contents of the pancreas, the levels of pancreatic HSP60 and HSP72, the activities of pancreatic amylase, lipase, trypsinogen, and free radical scavenger enzymes (superoxide dismutase, catalase, and glutathione peroxidase), the degree of lipid peroxidn.,

protein oxidation, and the reduced glutathione level. Histopathol. investigation of the pancreas was also performed in all cases. Repeated CCK treatment resulted in the typical laboratory and morphol. changes of exptl. induced pancreatitis. The pancreatic levels of HSP60 and HSP72 were significantly increased in the animals treated with BRX-220. In group B, the pancreatic total protein content and the amylase and trypsinogen activities were significantly higher vs. group B. The plasma trypsinogen activation peptide concentration, and the pancreatic

lipid peroxidn., protein oxidation, and the activity of Cu/Zn-superoxide dismutase were significantly decreased in group B vs. group B, whereas the glutathione peroxidase activity was increased. The morphol. damage in group B was significantly lower than that in group B. The HSP coinducer BRX-220, administered for 5 d, has a protective effect against CCK-induced acute pancreatitis.

REFERENCE COUNT: 35 THERE ARE 35 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L5 ANSWER 7 OF 14 CAPLUS COPYRIGHT 2009 ACS ON STN

ACCESSION NUMBER: 2001:780856 CAPLUS

DOCUMENT NUMBER: 135:318423

TITLE: Preparation of

N-[2-hydroxy-3-(1-piperidinyl)propoxy]pyridine-1-oxide-3-carboxamidine,
N-[2-hydroxy-3-(1-piperidinyl)propoxy]pyridine-1-oxide-3-carboximidoyl chloride, and enantiomers thereof.

INVENTOR(S): Ueroegdi, Laszlo; Jeges Csakai, Zita; Gruber, Lajos; Oetvoes, Laszlo; Toth, Jozsef; Toemoeskoeki, Istvan; Szakacs Schmidt, Aniko; Reider, Ferencne; Schneidern Barlay, Maria

PATENT ASSIGNEE(S): Biorex Kutato es Fejlesztzo, Hung.

SOURCE: PCT Int. Appl., 29 pp.

CODEN: PIXXD2

DOCUMENT TYPE: Patent

LANGUAGE: English

FAMILY ACC. NUM. COUNT: 1

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2001079174	A1	20011025	WO 2001-HU46	20010417 <--
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW				
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG				
HU 2000001583	A2	20021128	HU 2000-1583	20000418 <--
CA 2406266	A1	20011025	CA 2001-2406266	20010417 <--
EP 1274685	A1	20030115	EP 2001-928133	20010417 <--
EP 1274685	B1	20060712		
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR				
BR 2001010184	A	20030617	BR 2001-10184	20010417 <--
JP 2004501080	T	20040115	JP 2001-576775	20010417 <--
EE 200200591	A	20040415	EE 2002-591	20010417 <--
EE 5085	B1	20081015		
NZ 522017	A	20040625	NZ 2001-522017	20010417 <--
CN 1216868	C	20050831	CN 2001-810831	20010417

RU 2281282	C2	20060810	RU 2002-130710	20010417
AT 332894	T	20060815	AT 2001-928133	20010417
AU 2001254997	B2	20061123	AU 2001-254997	20010417
ES 2267758	T3	20070316	ES 2001-928133	20010417
IL 152337	A	20071031	IL 2001-152337	20010417
BG 107199	A	20030731	BG 2002-107199	20021016 <--
NO 2002005015	A	20021216	NO 2002-5015	20021018 <--
NO 323535	B1	20070604		
ZA 2002008460	A	20031020	ZA 2002-8460	20021018 <--
MX 2002010320	A	20040906	MX 2002-10320	20021018 <--
IN 2002KN1301	A	20050311	IN 2002-KN1301	20021018
KR 742482	B1	20070725	KR 2002-714047	20021018
US 20040006232	A1	20040108	US 2003-257755	20030128 <--
US 7126002	B2	20061024		
HK 1055741	A1	20060407	HK 2003-108135	20031110
PRIORITY APPLN. INFO.:			HU 2000-1583	A 20000418
			WO 2001-HU46	W 20010417

OTHER SOURCE(S): CASREACT 135:318423

AB Title compds. were prepared Thus, 2-hydroxy-4-azoniaspiro[3.5]nonane chloride was stirred in aqueous NaOH for 40 min. at 5-10°; EtOH and 3-pyridinamidoxime 1-oxide (preparation given) was added and the mixture was refluxed 2 h to give 62% N-[2-hydroxy-3-(1-piperidinyl)propoxy]pyridine-1-oxide-3-carboximidine. The latter in aqueous HCl at -5° was treated with aqueous NaNO₂ followed by stirring for 1.5 h to give 85% N-[2-hydroxy-3-(1-piperidinyl)propoxy]pyridine-1-oxide-3-carboximidoyl chloride.

REFERENCE COUNT: 4 THERE ARE 4 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L5 ANSWER 8 OF 14 CAPLUS COPYRIGHT 2009 ACS ON STN

ACCESSION NUMBER: 2000:608728 CAPLUS

DOCUMENT NUMBER: 133:207815

TITLE: Preparation of N-[2-hydroxy-3-(1-piperidinyl)propoxy]pyridine-1-oxide-3-carboximidoyl chloride and its use in the treatment of insulin resistance

INVENTOR(S): Kurthy, Maria; Biro, Katalin; Nagy, Karoly; Urogdi, Laszlo; Csakai, Zita; Szilbereky, Jeno; Mogyorosi, Tamas; Torok, Magdolna; Komaromi, Andras; Marvanyos, Ede; Barabas, Mihaly; Kardos, Mihalyne; Nagy, Zoltan; Koranyi, Laszlo; Nagy, Melinda

PATENT ASSIGNEE(S): Biorex Kutato Es Fejleszto Rt., Hung.

SOURCE: PCT Int. Appl., 36 pp.

CODEN: PIXXD2

DOCUMENT TYPE: Patent

LANGUAGE: English

FAMILY ACC. NUM. COUNT: 1

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
-----	----	-----	-----	-----
WO 2000050403	A1	20000831	WO 2000-HU15	20000224 <--
W: AU, BG, BR, CA, CZ, EE, HR, IL, IN, JP, KR, LT, LV, NO, PL, RO, RU, SI, SK, UA, US, YU, ZA				
RW: AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE				
CA 2360451	A1	20000831	CA 2000-2360451	20000224 <--
BR 2000008969	A	20011127	BR 2000-8969	20000224 <--
EP 1163224	A1	20011219	EP 2000-909542	20000224 <--
EP 1163224	B1	20030416		
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO				

JP 2002537384	T	20021105	JP 2000-600986	20000224 <--
EE 200100447	A	20021216	EE 2001-447	20000224 <--
EE 4961	B1	20080215		
AT 237590	T	20030515	AT 2000-909542	20000224 <--
PT 1163224	T	20030731	PT 2000-909542	20000224 <--
ES 2193055	T3	20031101	ES 2000-909542	20000224 <--
AU 779096	B2	20050106	AU 2000-31824	20000224
RU 2250901	C2	20050427	RU 2001-126126	20000224
CZ 297386	B6	20061115	CZ 2001-3053	20000224
IL 144866	A	20070704	IL 2000-144866	20000224
PL 197692	B1	20080430	PL 2000-350915	20000224
IN 2001KN00785	A	20050311	IN 2001-KN785	20010731
ZA 2001006488	A	20020807	ZA 2001-6488	20010807 <--
HR 2001000584	A1	20020831	HR 2001-584	20010807 <--
BG 105837	A	20020329	BG 2001-105837	20010822 <--
BG 65178	B1	20070531		
NO 2001004103	A	20011022	NO 2001-4103	20010823 <--
NO 319793	B1	20050912		
US 6649628	B1	20031118	US 2001-913263	20011218 <--

PRIORITY APPLN. INFO.:

AB	N-[2-hydroxy-3-(1-piperidinyl)propoxy]pyridine-1-oxide-3-carboximidoyl chloride, its stereoisomers, and their acid addition salts, useful in treatment of pathol. insulin resistance, and for the treatment of pathol. conditions associated therewith, for the treatment of pathol. insulin resistance, were prepared
REFERENCE COUNT:	4
	THERE ARE 4 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L5 ANSWER 9 OF 14 EMBASE COPYRIGHT (c) 2009 Elsevier B.V. All rights reserved on STN

ACCESSION NUMBER: 2005111731 EMBASE
 TITLE: [Mice and humans [8]].
 Mus og menn.
 AUTHOR: Holmoy, Trygve
 CORPORATE SOURCE: Ulleval Universitetssykehus.
 SOURCE: Tidsskrift for den Norske Lægeforening, (26 Aug 2004) Vol. 124, No. 16, pp. 2156.
 Refs: 2
 ISSN: 0029-2001 CODEN: TNLAHH
 COUNTRY: Norway
 DOCUMENT TYPE: Journal; Letter
 FILE SEGMENT: 037 Drug Literature Index
 008 Neurology and Neurosurgery
 LANGUAGE: Norwegian
 ENTRY DATE: Entered STN: 24 Mar 2005
 Last Updated on STN: 24 Mar 2005

L5 ANSWER 10 OF 14 EMBASE COPYRIGHT (c) 2009 Elsevier B.V. All rights reserved on STN

ACCESSION NUMBER: 2004177118 EMBASE
 TITLE: Putting the heat on ALS.
 AUTHOR: Benn, Susanna C. (correspondence); Brown Jr., Robert H.
 CORPORATE SOURCE: Day Lab. for Neuromuscular Research, Massachusetts General Hospital, Charlestown, MA 02129, United States. sbenn@partners.org; rhbrown@partners.org
 SOURCE: Nature Medicine, (Apr 2004) Vol. 10, No. 4, pp. 345-347.
 Refs: 15
 ISSN: 1078-8956 CODEN: NAMEFI
 COUNTRY: United Kingdom
 DOCUMENT TYPE: Journal; (Short Survey)
 FILE SEGMENT: 030 Clinical and Experimental Pharmacology

037 Drug Literature Index
005 General Pathology and Pathological Anatomy
008 Neurology and Neurosurgery

LANGUAGE: English
ENTRY DATE: Entered STN: 28 May 2004
Last Updated on STN: 28 May 2004

L5 ANSWER 11 OF 14 BIOSIS COPYRIGHT (c) 2009 The Thomson Corporation on STN

ACCESSION NUMBER: 2003:32824 BIOSIS
DOCUMENT NUMBER: PREV200300032824
TITLE: Effect of BRX-220 against peripheral neuropathy and insulin resistance in diabetic rat models.
AUTHOR(S): Kurthy, Maria [Reprint Author]; Mogyorosi, Tamas; Nagy, Karoly; Kukorelli, Tibor; Jednakovits, Andrea; Talosi, Laszlo; Biro, Katalin
CORPORATE SOURCE: Biorex Research and Development Company, P. O. Box 348, Veszprem-Szabadsagpuszta, H-8201, Hungary
Maria.Kurthy@biorex.hu
SOURCE: Klimes, Iwar [Editor, Reprint Author]; Sebokova, Elena [Editor]; Howard, Barbara V. [Editor]; Ravussin, Eric [Editor]. (2002) pp. 482-489. Lipids and insulin resistance: The role of fatty acid metabolism and fuel partitioning. print.
Publisher: New York Academy of Sciences, 2 East 63rd Street, New York, NY, 10021, USA. Series: Annals of the New York Academy of Sciences.
Meeting Info.: Fourth International Smolenice Insulin Symposium on Lipids and Insulin Resistance: The Role of Fatty Acid Metabolism and Fuel Partitioning. Smolenice, Slovakia. August 29-September 02, 2001.
ISSN: 0077-8923 (ISSN print). ISBN: 1-57331-368-8 (cloth), 1-57331-369-6 (paper).
DOCUMENT TYPE: Book; (Book Chapter)
Conference; (Meeting)
Conference; (Meeting Paper)
LANGUAGE: English
ENTRY DATE: Entered STN: 8 Jan 2003
Last Updated on STN: 11 Feb 2003

L5 ANSWER 12 OF 14 BIOSIS COPYRIGHT (c) 2009 The Thomson Corporation on STN

ACCESSION NUMBER: 2003:32816 BIOSIS
DOCUMENT NUMBER: PREV200300032816
TITLE: Comparison of the extrapancreatic action of BRX-220 and pioglitazone in the high-fat diet-induced insulin resistance.
AUTHOR(S): Sebokova, Elena; Kurthy, Maria; Mogyorosi, T.; Nagy, Karoly; Demcakova, Edit; Ukropec, Jozef; Koranyi, Laszlo; Klimes, Iwar [Reprint Author]
CORPORATE SOURCE: Diabetes and Nutrition Research Laboratory, Institute of Experimental Endocrinology, Slovak Academy of Sciences, Vlarska 3, SK-83306, Bratislava, Slovakia
ueeniwar@savba.sk
SOURCE: Klimes, Iwar [Editor, Reprint Author]; Sebokova, Elena [Editor]; Howard, Barbara V. [Editor]; Ravussin, Eric [Editor]. (2002) pp. 424-430. Lipids and insulin resistance: The role of fatty acid metabolism and fuel partitioning. print.
Publisher: New York Academy of Sciences, 2 East 63rd Street, New York, NY, 10021, USA. Series: Annals of the New York Academy of Sciences.

Meeting Info.: Fourth International Smolenice Insulin Symposium on Lipids and Insulin Resistance: The Role of Fatty Acid Metabolism and Fuel Partitioning. Smolenice, Slovakia. August 29-September 02, 2001.
ISSN: 0077-8923 (ISSN print). ISBN: 1-57331-368-8 (cloth), 1-57331-369-6 (paper).

DOCUMENT TYPE: Book; (Book Chapter)
Conference; (Meeting)
Conference; (Meeting Paper)
LANGUAGE: English
ENTRY DATE: Entered STN: 8 Jan 2003
Last Updated on STN: 11 Feb 2003

L5 ANSWER 13 OF 14 BIOSIS COPYRIGHT (c) 2009 The Thomson Corporation on STN

ACCESSION NUMBER: 2002:542301 BIOSIS
DOCUMENT NUMBER: PREV200200542301
TITLE: Non-toxic heat shock protein co-inducer BRX-220 protects against acute pancreatitis in rats.
AUTHOR(S): Rakonczay, Zoltan, Jr. [Reprint author]; Ivanyi, Bela; Varga, Ilona; Boros, Imre; Jednakovits, Andrea; Lonovics, Janos; Takacs, Tamas
CORPORATE SOURCE: Szeged, Hungary
SOURCE: Gastroenterology, (April, 2002) Vol. 122, No. 4
Suppl. 1, pp. A-283. print.
Meeting Info.: Digestive Disease Week and the 103rd Annual Meeting of the American Gastroenterological Association. San Francisco, CA, USA. May 19-22, 2002.
CODEN: GASTAB. ISSN: 0016-5085.

DOCUMENT TYPE: Conference; (Meeting)
Conference; Abstract; (Meeting Abstract)
LANGUAGE: English
ENTRY DATE: Entered STN: 23 Oct 2002
Last Updated on STN: 23 Oct 2002

L5 ANSWER 14 OF 14 BIOSIS COPYRIGHT (c) 2009 The Thomson Corporation on STN

ACCESSION NUMBER: 2002:4500 BIOSIS
DOCUMENT NUMBER: PREV200200004500
TITLE: Prevention of axotomy-induced motoneuron death by treatment with BRX-220, a co-inducer of heat shock proteins.
AUTHOR(S): Kalmar, B. [Reprint author]; Burnstock, G.; Vrbova, G.; Hargitai, J.; Urbanics, R.; Greensmith, L. [Reprint author]
CORPORATE SOURCE: Inst Neurology, University College London, London, UK
SOURCE: Society for Neuroscience Abstracts, (2001) Vol. 27, No. 2, pp. 2477. print.
Meeting Info.: 31st Annual Meeting of the Society for Neuroscience. San Diego, California, USA. November 10-15, 2001.
ISSN: 0190-5295.

DOCUMENT TYPE: Conference; (Meeting)
Conference; Abstract; (Meeting Abstract)
LANGUAGE: English
ENTRY DATE: Entered STN: 28 Dec 2001
Last Updated on STN: 25 Feb 2002

AB Heat shock proteins (hsps) are induced in a variety of cells in response to stress. We examined the effect of BRX-220, a co-inducer of hsps, on axotomized motoneurons. Following sciatic nerve crush at birth, rat pups were treated daily with BRX-220 (10 mg/kg, i.p.). The effect on motoneuron survival was assessed by counting the number of Nissl-stained motoneurons. The number of

functional motor units was assessed by in vivo isometric tension recordings. Hsp expression was examined both in vivo and in vitro by immunostaining, western blot analysis and Elisa. BRX-220 treatment significantly improved the survival of injured motoneurons. Thus, 39% (+2.8 SEM., n=7) of motoneurons survived 14 days after injury in the treated group compared to only 21% (+1.7 SEM., n=7) in untreated group. This improvement in motoneuron survival was also observed 10 weeks after injury and was reflected in an increase in the number of functional motor units in the hindlimb muscles. The expression of hsp 70 and 90 was found to increase following BRX-220 treatment both in vivo in axotomised spinal cords and in vitro in heat shocked H9c2, 3T3 and Wehi-164 cells, where 10-5-10-6 M BRX-220 increased hsp70 levels by approximately 30 to 50%, as measured by ELISA and western blot analysis. Therefore, BRX-220 protects motoneurons from axotomy-induced cell death. This effect may be due to its ability to act as a co-inducer of hsps. Thus, it may be possible to rescue injured neurons by enhancing their own cellular defence mechanisms.

Connecting via Winsock to STN

Welcome to STN International! Enter x:X

LOGINID:ssptacrs1614

PASSWORD:

TERMINAL (ENTER 1, 2, 3, OR ?):2

* * * * * Welcome to STN International * * * * *

NEWS	1		Web Page for STN Seminar Schedule - N. America
NEWS	2	AUG 10	Time limit for inactive STN sessions doubles to 40 minutes
NEWS	3	AUG 18	COMPENDEX indexing changed for the Corporate Source (CS) field
NEWS	4	AUG 24	ENCOMPLIT/ENCOMPLIT2 reloaded and enhanced
NEWS	5	AUG 24	CA/CAPLUS enhanced with legal status information for U.S. patents
NEWS	6	SEP 09	50 Millionth Unique Chemical Substance Recorded in CAS REGISTRY
NEWS	7	SEP 11	WPIDS, WPINDEX, and WPIX now include Japanese FTERM thesaurus
NEWS	8	OCT 21	Derwent World Patents Index Coverage of Indian and Taiwanese Content Expanded
NEWS	9	OCT 21	Derwent World Patents Index enhanced with human translated claims for Chinese Applications and Utility Models

NEWS EXPRESS MAY 26 09 CURRENT WINDOWS VERSION IS V8.4,
AND CURRENT DISCOVER FILE IS DATED 06 APRIL 2009.

NEWS HOURS STN Operating Hours Plus Help Desk Availability
NEWS LOGIN Welcome Banner and News Items

Enter NEWS followed by the item number or name to see news on that specific topic.

All use of STN is subject to the provisions of the STN customer agreement. This agreement limits use to scientific research. Use for software development or design, implementation of commercial gateways, or use of CAS and STN data in the building of commercial products is prohibited and may result in loss of user privileges and other penalties.

***** STN Columbus *****

FILE 'HOME' ENTERED AT 10:07:08 ON 23 OCT 2009

=> file registry

COST IN U.S. DOLLARS	SINCE FILE ENTRY	TOTAL SESSION
FULL ESTIMATED COST	0.22	0.22

FILE 'REGISTRY' ENTERED AT 10:07:33 ON 23 OCT 2009

USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.

PLEASE SEE "HELP USAGETERMS" FOR DETAILS.

COPYRIGHT (C) 2009 American Chemical Society (ACS)

Property values tagged with IC are from the ZIC/VINITI data file provided by InfoChem.

STRUCTURE FILE UPDATES: 22 OCT 2009 HIGHEST RN 1189642-14-5

DICTIONARY FILE UPDATES: 22 OCT 2009 HIGHEST RN 1189642-14-5

New CAS Information Use Policies, enter HELP USAGETERMS for details.

TSCA INFORMATION NOW CURRENT THROUGH June 26, 2009.

Please note that search-term pricing does apply when conducting SmartSELECT searches.

REGISTRY includes numerically searchable data for experimental and predicted properties as well as tags indicating availability of experimental property data in the original document. For information on property searching in REGISTRY, refer to:

<http://www.cas.org/support/stngen/stndoc/properties.html>

=> e brx

E1	6	BRWR1/BI
E2	1	BRWY/BI
E3	32 -->	BRX/BI
E4	6	BRX1/BI
E5	2	BRX1A/BI
E6	2	BRX1B/BI
E7	6	BRXE/BI
E8	2	BRXE10/BI
E9	2	BRXE11/BI
E10	2	BRXE12/BI
E11	2	BRXE13/BI
E12	2	BRXE14/BI

=> e brx220

E1	2	BRX1A/BI
E2	2	BRX1B/BI
E3	0 -->	BRX220/BI
E4	6	BRXE/BI
E5	2	BRXE10/BI

E6 2 BRXE11/BI
E7 2 BRXE12/BI
E8 2 BRXE13/BI
E9 2 BRXE14/BI
E10 2 BRXE15/BI
E11 2 BRXE16/BI
E12 3 BRXE2/BI

=> s e3

L1 0 BRX220/BI

=> e brx

E1 6 BRWR1/BI
E2 1 BRWY/BI
E3 32 --> BRX/BI
E4 6 BRX1/BI
E5 2 BRX1A/BI
E6 2 BRX1B/BI
E7 6 BRXE/BI
E8 2 BRXE10/BI
E9 2 BRXE11/BI
E10 2 BRXE12/BI
E11 2 BRXE13/BI
E12 2 BRXE14/BI

=> s e3

L2 32 BRX/BI

=> d 12 1-32

L2 ANSWER 1 OF 32 REGISTRY COPYRIGHT 2009 ACS on STN

RN 909311-85-9 REGISTRY

ED Entered STN: 02 Oct 2006

CN Glucagon-like peptide 1 [2-glycine,28-alanine,31-glycine] (human clone
WO2006/096515-SEQID-12) fusion protein with peptide (synthetic) fusion
protein with transferrin (human) (9CI) (CA INDEX NAME)

OTHER NAMES:

CN 20: PN: WO2006096515 SEQID: 12 claimed protein

CN BRX 0585

CN GLP 1Tf

FS PROTEIN SEQUENCE

MF Unspecified

CI MAN

SR CA

LC STN Files: CA, CAPLUS, TOXCENTER, USPATFULL

RELATED SEQUENCES AVAILABLE WITH SEQLINK

*** STRUCTURE DIAGRAM IS NOT AVAILABLE ***

*** USE 'SQD' OR 'SQIDE' FORMATS TO DISPLAY SEQUENCE ***

2 REFERENCES IN FILE CA (1907 TO DATE)

2 REFERENCES IN FILE CAPLUS (1907 TO DATE)

L2 ANSWER 2 OF 32 REGISTRY COPYRIGHT 2009 ACS on STN

RN 889930-43-2 REGISTRY

ED Entered STN: 28 Jun 2006

CN Protein (Arabidopsis thaliana strain ecotype-Uk-2 gene BRX (BREVIS
RADIX)) (9CI) (CA INDEX NAME)

OTHER NAMES:

CN GenBank ABG25053

CN GenBank ABG25053 (Translated from: GenBank AY702649)

FS PROTEIN SEQUENCE

MF Unspecified
CI MAN
SR GenBank
LC STN Files: CA, CAPLUS

*** STRUCTURE DIAGRAM IS NOT AVAILABLE ***
*** USE 'SQD' OR 'SQIDE' FORMATS TO DISPLAY SEQUENCE ***
1 REFERENCES IN FILE CA (1907 TO DATE)
1 REFERENCES IN FILE CAPLUS (1907 TO DATE)

L2 ANSWER 3 OF 32 REGISTRY COPYRIGHT 2009 ACS on STN
RN 889930-42-1 REGISTRY
ED Entered STN: 28 Jun 2006
CN DNA (Arabidopsis thaliana strain ecotype-Uk-2 gene BRX (BREVIS RADIX)
protein cDNA) (9CI) (CA INDEX NAME)

OTHER NAMES:
CN GenBank AY702649
FS NUCLEIC ACID SEQUENCE
MF Unspecified
CI MAN
SR GenBank
LC STN Files: CA, CAPLUS, GENBANK

*** STRUCTURE DIAGRAM IS NOT AVAILABLE ***
*** USE 'SQD' OR 'SQIDE' FORMATS TO DISPLAY SEQUENCE ***
1 REFERENCES IN FILE CA (1907 TO DATE)
1 REFERENCES IN FILE CAPLUS (1907 TO DATE)

L2 ANSWER 4 OF 32 REGISTRY COPYRIGHT 2009 ACS on STN
RN 889930-41-0 REGISTRY
ED Entered STN: 28 Jun 2006
CN Protein (Arabidopsis thaliana strain ecotype-Uk-1 gene BRX (BREVIS
RADIX) truncated isoform) (9CI) (CA INDEX NAME)

OTHER NAMES:
CN GenBank ABG25052
CN GenBank ABG25052 (Translated from: GenBank AY702648)
FS PROTEIN SEQUENCE
MF Unspecified
CI MAN
SR GenBank
LC STN Files: CA, CAPLUS

*** STRUCTURE DIAGRAM IS NOT AVAILABLE ***
*** USE 'SQD' OR 'SQIDE' FORMATS TO DISPLAY SEQUENCE ***
1 REFERENCES IN FILE CA (1907 TO DATE)
1 REFERENCES IN FILE CAPLUS (1907 TO DATE)

L2 ANSWER 5 OF 32 REGISTRY COPYRIGHT 2009 ACS on STN
RN 889930-40-9 REGISTRY
ED Entered STN: 28 Jun 2006
CN DNA (Arabidopsis thaliana strain ecotype-Uk-1 gene BRX (BREVIS RADIX)
protein truncated isoform cDNA plus 3'-flank) (9CI) (CA INDEX NAME)

OTHER NAMES:
CN GenBank AY702648
FS NUCLEIC ACID SEQUENCE
MF Unspecified
CI MAN
SR GenBank
LC STN Files: CA, CAPLUS, GENBANK

*** STRUCTURE DIAGRAM IS NOT AVAILABLE ***
*** USE 'SQD' OR 'SQIDE' FORMATS TO DISPLAY SEQUENCE ***

```

L2 ANSWER 6 OF 32 REGISTRY COPYRIGHT 2009 ACS on STN
RN 850069-82-8 REGISTRY
ED Entered STN: 09 May 2005
CN Propanedioic acid, (6aS,11bR)-3-(acetyloxy)-7,11b-dihydrobenz[b]indeno[1,2-
d]pyran-6a,9,10(6H)-triyl trimethyl ester (9CI) (CA INDEX NAME)
OTHER NAMES:
CN BRX 018
FS STEREOSEARCH
MF C30 H28 O15
SR CA
LC STN Files: CA, CAPLUS

```

```

L2 ANSWER 7 OF 32 REGISTRY COPYRIGHT 2009 ACS on STN
RN 688066-21-9 REGISTRY
ED Entered STN: 01 Jun 2004
CN Protein (Arabidopsis thaliana gene BRX) (9CI) (CA INDEX NAME)
FS PROTEIN SEQUENCE
MF Unspecified
CI MAN
SR CA
LC STN Files: CA, CAPLUS

```

```

L2 ANSWER 8 OF 32 REGISTRY COPYRIGHT 2009 ACS on STN
RN 502923-63-9 REGISTRY
ED Entered STN: 14 Apr 2003
CN Amplex BRX (9CI) (CA INDEX NAME)
ENTE An activator for pectinase mixture biopolishing agent (Color Center S.A.,
Spain)
MF Unspecified
CI MAN
SR CA
LC STN Files: CA, CAPLUS

```

*** STRUCTURE DIAGRAM IS NOT AVAILABLE ***

1 REFERENCES IN FILE CA (1907 TO DATE)

1 REFERENCES IN FILE CAPLUS (1907 TO DATE)

L2 ANSWER 9 OF 32 REGISTRY COPYRIGHT 2009 ACS on STN

RN 496816-64-9 REGISTRY

ED Entered STN: 03 Mar 2003

CN 3-Pyridinecarboximidoyl chloride, N-[(2R)-2-hydroxy-3-(1-piperidinyl)propoxy]-, [C(Z)]-, (2Z)-2-butenedioate (1:1) (9CI) (CA INDEX NAME)

OTHER NAMES:

CN BRX 51

FS STEREOSEARCH

MF C14 H20 Cl N3 O2 . C4 H4 O4

SR CA

LC STN Files: CA, CAPLUS


CM 1

CRN 496816-63-8

CMF C14 H20 Cl N3 O2

Absolute stereochemistry.

Double bond geometry as shown.




CM 2

CRN 110-16-7

CMF C4 H4 O4

Double bond geometry as shown.



1 REFERENCES IN FILE CA (1907 TO DATE)

1 REFERENCES IN FILE CAPLUS (1907 TO DATE)

L2 ANSWER 10 OF 32 REGISTRY COPYRIGHT 2009 ACS on STN

RN 496816-62-7 REGISTRY

ED Entered STN: 03 Mar 2003

CN 3-Pyridinecarboximidoyl chloride, N-[(2S)-2-hydroxy-3-(1-piperidinyl)propoxy]-, [C(Z)]-, (2Z)-2-butenedioate (1:1) (9CI) (CA INDEX NAME)

OTHER NAMES:

CN BRX 53

FS STEREOSEARCH


MF C14 H20 Cl N3 O2 . C4 H4 O4

SR CA
LC STN Files: CA, CAPLUS

CM 1

CRN 496816-61-6
CMF C14 H20 Cl N3 O2


Absolute stereochemistry. Rotation (-).
Double bond geometry as shown.



CM 2

CRN 110-16-7
CMF C4 H4 O4

Double bond geometry as shown.



1 REFERENCES IN FILE CA (1907 TO DATE)
1 REFERENCES IN FILE CAPLUS (1907 TO DATE)

L2 ANSWER 11 OF 32 REGISTRY COPYRIGHT 2009 ACS on STN
RN 412507-73-4 REGISTRY
ED Entered STN: 08 May 2002
CN DNA (mouse strain C57BL/6J clone UI-M-BH3-brx-a-05-0-UI EST
(expressed sequence tag)) (CA INDEX NAME)

OTHER NAMES:

CN GenBank BM933144
FS NUCLEIC ACID SEQUENCE
MF Unspecified
CI MAN
SR GenBank
LC STN Files: CA, CAPLUS, GENBANK, TOXCENTER

*** STRUCTURE DIAGRAM IS NOT AVAILABLE ***
*** USE 'SQD' OR 'SQIDE' FORMATS TO DISPLAY SEQUENCE ***
1 REFERENCES IN FILE CA (1907 TO DATE)
1 REFERENCES IN FILE CAPLUS (1907 TO DATE)

L2 ANSWER 12 OF 32 REGISTRY COPYRIGHT 2009 ACS on STN
RN 392081-00-4 REGISTRY
ED Entered STN: 13 Feb 2002
CN DNA (human clone pDR2 gene BRX breast cancer nuclear receptor-binding
auxiliary protein cDNA) (CA INDEX NAME)

OTHER NAMES:

CN 469: PN: WO2007132883 PAGE: 41 unclaimed DNA

CN GenBank AF126008
FS NUCLEIC ACID SEQUENCE
MF Unspecified
CI MAN
SR GenBank
LC STN Files: CA, CAPLUS, GENBANK, TOXCENTER

RELATED SEQUENCES AVAILABLE WITH SEQLINK

*** STRUCTURE DIAGRAM IS NOT AVAILABLE ***
*** USE 'SQD' OR 'SQIDE' FORMATS TO DISPLAY SEQUENCE ***
1 REFERENCES IN FILE CA (1907 TO DATE)
1 REFERENCES IN FILE CAPLUS (1907 TO DATE)

L2 ANSWER 13 OF 32 REGISTRY COPYRIGHT 2009 ACS on STN
RN 388566-72-1 REGISTRY
ED Entered STN: 31 Jan 2002
CN BRX-Q (9CI) (CA INDEX NAME)
ENTE An experimental acrylamido-based ion-exchanger for protein chromatography
(Bio-Rad Laboratories, Hercules, CA)
MF Unspecified
CI PMS, MAN
PCT Manual registration
SR CA
LC STN Files: CA, CAPLUS

*** STRUCTURE DIAGRAM IS NOT AVAILABLE ***
1 REFERENCES IN FILE CA (1907 TO DATE)
1 REFERENCES IN FILE CAPLUS (1907 TO DATE)

L2 ANSWER 14 OF 32 REGISTRY COPYRIGHT 2009 ACS on STN
RN 344670-25-3 REGISTRY
ED Entered STN: 05 Jul 2001
CN DNA (mouse strain C57BL/6J clone UI-M-BH3-brx-b-05-0-UI EST
(expressed sequence tag)) (CA INDEX NAME)

OTHER NAMES:

CN GenBank BI133445
FS NUCLEIC ACID SEQUENCE
MF Unspecified
CI MAN
SR GenBank
LC STN Files: CA, CAPLUS, GENBANK, TOXCENTER

*** STRUCTURE DIAGRAM IS NOT AVAILABLE ***
*** USE 'SQD' OR 'SQIDE' FORMATS TO DISPLAY SEQUENCE ***
1 REFERENCES IN FILE CA (1907 TO DATE)
1 REFERENCES IN FILE CAPLUS (1907 TO DATE)

L2 ANSWER 15 OF 32 REGISTRY COPYRIGHT 2009 ACS on STN
RN 326984-24-1 REGISTRY
ED Entered STN: 13 Mar 2001
CN DNA (Rattus norvegicus strain Sprague-Dawley clone
UI-R-CV1-brx-h-03-0-UI EST (expressed sequence tag)) (9CI) (CA INDEX
NAME)

OTHER NAMES:

CN 410: PN: US20050084872 TABLE: 9 claimed DNA
CN GenBank BG373361
FS NUCLEIC ACID SEQUENCE
MF Unspecified
CI MAN
SR GenBank
LC STN Files: CA, CAPLUS, GENBANK, TOXCENTER, USPATFULL

*** STRUCTURE DIAGRAM IS NOT AVAILABLE ***
*** USE 'SQD' OR 'SQIDE' FORMATS TO DISPLAY SEQUENCE ***
1 REFERENCES IN FILE CA (1907 TO DATE)
1 REFERENCES IN FILE CAPLUS (1907 TO DATE)

L2 ANSWER 16 OF 32 REGISTRY COPYRIGHT 2009 ACS on STN
RN 308063-34-5 REGISTRY *

* Use of this CAS Registry Number alone as a search term in other STN files may result in incomplete search results. For additional information, enter HELP RN* at an online arrow prompt (=>).

ED Entered STN: 12 Dec 2000

CN Rubber, butadiene, of cis-1,4-configuration (CA INDEX NAME)

OTHER NAMES:

CN Afdene Buna CB 11

CN Ameripol CB

CN Ameripol CB 200

CN Ameripol CB 220

CN Ameripol CB 221

CN B 27

CN B 27 (rubber)

CN B 37

CN B 37 (rubber)

CN BCP 820

CN BR 01

CN BR 10

CN BR 11

CN BR 1208

CN BR 1220

CN BR 1220N

CN BR 1220SG

CN BR 1241

CN BR 1280

CN BR 130B

CN BR 133P

CN BR 150

CN BR 150B

CN BR 150L

CN BR 153A

CN BR 18

CN BR 230

CN BR 305

CN BR 31

CN BR 360L

CN BR 40

CN BR 51

CN BR 60

CN BR 700

CN BR 700 (rubber)

CN BR 701

CN BR 730

CN BR 9000

CN BR 9002

CN BR 9002L

CN BR 9004

CN BR 9053

CN BRX 5000

CN Bud 1207

CN Bud 1254

CN Budene 1207

CN Budene 1208

CN Budene 1254

CN Budene 1280
 CN Budene 207
 CN Nipol BRX 5000
 ADDITIONAL NAMES NOT AVAILABLE IN THIS FORMAT - Use FCN, FIDE, or ALL for
 DISPLAY
 MF Unspecified
 CI MAN, CTS
 SR CA


*** STRUCTURE DIAGRAM IS NOT AVAILABLE ***

L2 ANSWER 17 OF 32 REGISTRY COPYRIGHT 2009 ACS on STN
 RN 289893-26-1 REGISTRY
 ED Entered STN: 21 Sep 2000
 CN 3-Pyridinecarboximidoyl chloride, N-[(2R)-2-hydroxy-3-(1-
 piperidinyl)propoxy]-, 1-oxide, (2Z)-2-butenedioate (1:1) (CA INDEX NAME)
 OTHER CA INDEX NAMES:
 CN 3-Pyridinecarboximidoyl chloride, N-[(2R)-2-hydroxy-3-(1-
 piperidinyl)propoxy]-, 1-oxide, (2Z)-2-butenedioate (1:1) (salt) (9CI)
 OTHER NAMES:
 CN BRX 220
 FS STEREOSEARCH
 MF C14 H20 Cl N3 O3 . C4 H4 O4
 SR CA
 LC STN Files: BIOSIS, CA, CAPLUS, IMSDRUGNEWS, IMSRESEARCH, PROUSDDR,
 SYNTHLINE, TOXCENTER, USPAT2, USPATFULL

CM 1

CRN 289893-25-0
 CMF C14 H20 Cl N3 O3


Absolute stereochemistry.
 Double bond geometry unknown.



CM 2

CRN 110-16-7
 CMF C4 H4 O4

Double bond geometry as shown.



8 REFERENCES IN FILE CA (1907 TO DATE)
 8 REFERENCES IN FILE CAPLUS (1907 TO DATE)

L2 ANSWER 18 OF 32 REGISTRY COPYRIGHT 2009 ACS on STN

RN 222187-17-9 REGISTRY
ED Entered STN: 07 May 1999
CN DNA (human clone 11.1/2.2 gene brx protein cDNA plus flanks) (9CI)
(CA INDEX NAME)
OTHER NAMES:
CN DNA (human clone 11.1/2.2 gene brx nuclear receptor-binding auxiliary
protein Brx cDNA plus flanks)
CN DNA (human clone 11.1/2.2 gene brx putative rho guanine nucleotide
exchange factor cDNA plus flanks)
FS NUCLEIC ACID SEQUENCE
MF Unspecified
CI MAN
SR CA
LC STN Files: CA, CAPLUS, TOXCENTER


*** STRUCTURE DIAGRAM IS NOT AVAILABLE ***
*** USE 'SQD' OR 'SQIDE' FORMATS TO DISPLAY SEQUENCE ***
1 REFERENCES IN FILE CA (1907 TO DATE)
1 REFERENCES IN FILE CAPLUS (1907 TO DATE)

L2 ANSWER 19 OF 32 REGISTRY COPYRIGHT 2009 ACS on STN
RN 222187-15-7 REGISTRY
ED Entered STN: 07 May 1999
CN Protein (human clone 11.1/2.2 gene brx reduced) (9CI) (CA INDEX
NAME)
OTHER NAMES:
CN Nuclear receptor-binding auxiliary protein Brx (human clone 11.1/2.2
gene brx reduced)
CN Putative Rho guanine nucleotide exchange factor (human clone 11.1/2.2
gene brx reduced)
FS PROTEIN SEQUENCE
MF Unspecified
CI MAN
SR CA
LC STN Files: CA, CAPLUS, TOXCENTER

RELATED SEQUENCES AVAILABLE WITH SEQLINK

*** STRUCTURE DIAGRAM IS NOT AVAILABLE ***
*** USE 'SQD' OR 'SQIDE' FORMATS TO DISPLAY SEQUENCE ***
1 REFERENCES IN FILE CA (1907 TO DATE)
1 REFERENCES IN FILE CAPLUS (1907 TO DATE)

L2 ANSWER 20 OF 32 REGISTRY COPYRIGHT 2009 ACS on STN
RN 215233-82-2 REGISTRY
ED Entered STN: 08 Dec 1998
CN Benzenecarboximidamide, N-[3-[(1,1-dimethylethyl)amino]-2-hydroxypropoxy]-
N'-phenyl-, monohydrochloride (9CI) (CA INDEX NAME)
OTHER NAMES:
CN BRX 156
MF C20 H27 N3 O2 . Cl H
SR CA
LC STN Files: BIOSIS, CA, CAPLUS, TOXCENTER, USPATFULL
CRN (774166-55-1)



● HCl

3 REFERENCES IN FILE CA (1907 TO DATE)
3 REFERENCES IN FILE CAPLUS (1907 TO DATE)


L2 ANSWER 21 OF 32 REGISTRY COPYRIGHT 2009 ACS on STN
RN 210170-31-3 REGISTRY
ED Entered STN: 20 Aug 1998
CN Protein Brx (human) (9CI) (CA INDEX NAME)
FS PROTEIN SEQUENCE
MF Unspecified
CI MAN
SR CA
LC STN Files: CA, CAPLUS

*** STRUCTURE DIAGRAM IS NOT AVAILABLE ***
*** USE 'SQD' OR 'SQIDE' FORMATS TO DISPLAY SEQUENCE ***
1 REFERENCES IN FILE CA (1907 TO DATE)
1 REFERENCES IN FILE CAPLUS (1907 TO DATE)

L2 ANSWER 22 OF 32 REGISTRY COPYRIGHT 2009 ACS on STN
RN 203805-20-3 REGISTRY
ED Entered STN: 08 Apr 1998
CN 2H-1,2,4-Oxadiazine, 5,6-dihydro-5-(1-piperidinylmethyl)-3-(3-pyridinyl)-
(CA INDEX NAME)

OTHER NAMES:

CN BRX 005
CN BRX 235
DR 191159-87-2
MF C14 H20 N4 O
SR CA
LC STN Files: BIOSIS, CA, CAPLUS, CHEMCATS, PROUSDDR, SYNTHLINE, TOXCENTER,
USPAT2, USPATFULL



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

6 REFERENCES IN FILE CA (1907 TO DATE)
6 REFERENCES IN FILE CAPLUS (1907 TO DATE)

L2 ANSWER 23 OF 32 REGISTRY COPYRIGHT 2009 ACS on STN
RN 201556-27-6 REGISTRY

ED Entered STN: 19 Feb 1998
CN BRX 5 (primer) (9CI) (CA INDEX NAME)
OTHER NAMES:
CN BRX 5
ENTE A polyimide primer (Cytec)
MF Unspecified
CI PMS, MAN
PCT Manual registration
SR CA
LC STN Files: BIOSIS, CA, CAPLUS, TOXCENTER, USPATFULL

*** STRUCTURE DIAGRAM IS NOT AVAILABLE ***
4 REFERENCES IN FILE CA (1907 TO DATE)
4 REFERENCES IN FILE CAPLUS (1907 TO DATE)

L2 ANSWER 24 OF 32 REGISTRY COPYRIGHT 2009 ACS on STN
RN 181858-04-8 REGISTRY
ED Entered STN: 10 Oct 1996
CN RNA (measles virus strain Brx hemagglutinin gene
fragment-complementary) (9CI) (CA INDEX NAME)
OTHER NAMES:
CN GenBank Z80797
FS NUCLEIC ACID SEQUENCE
MF Unspecified
CI MAN
SR GenBank
LC STN Files: CA, CAPLUS, GENBANK

*** STRUCTURE DIAGRAM IS NOT AVAILABLE ***
*** USE 'SQD' OR 'SQIDE' FORMATS TO DISPLAY SEQUENCE ***
1 REFERENCES IN FILE CA (1907 TO DATE)
1 REFERENCES IN FILE CAPLUS (1907 TO DATE)

L2 ANSWER 25 OF 32 REGISTRY COPYRIGHT 2009 ACS on STN
RN 164479-36-1 REGISTRY
ED Entered STN: 07 Jul 1995
CN RNA (measles virus strain Brx nucleocapsid protein gene fragment)
(9CI) (CA INDEX NAME)
OTHER CA INDEX NAMES:
CN Ribonucleic acid (measles virus strain Brx nucleocapsid protein gene
fragment)
OTHER NAMES:
CN GenBank X84879
FS NUCLEIC ACID SEQUENCE
MF Unspecified
CI MAN
SR GenBank
LC STN Files: CA, CAPLUS, GENBANK

*** STRUCTURE DIAGRAM IS NOT AVAILABLE ***
*** USE 'SQD' OR 'SQIDE' FORMATS TO DISPLAY SEQUENCE ***
1 REFERENCES IN FILE CA (1907 TO DATE)
1 REFERENCES IN FILE CAPLUS (1907 TO DATE)

L2 ANSWER 26 OF 32 REGISTRY COPYRIGHT 2009 ACS on STN
RN 63394-00-3 REGISTRY *
* Use of this CAS Registry Number alone as a search term in other STN files may
result in incomplete search results. For additional information, enter HELP
RN* at an online arrow prompt (=>).
ED Entered STN: 16 Nov 1984
CN Rubber, butadiene (CA INDEX NAME)
OTHER NAMES:

CN 150L
 CN 150L (rubber)
 CN 60P
 CN A 24
 CN Alkadienes, rubber
 CN Ameripol CB 441
 CN Ameripol CB 880
 CN Asadene
 CN Asadene 35AS
 CN Asadene 35NF
 CN Asadene 55AE
 CN Asadene 55AS
 CN Asadene 55NF
 CN Asadene AS
 CN Asadene NF 35A
 CN Asadene NF 35AS
 CN Asadene NF 50R
 CN Asaprene 610AX
 CN Asaprene 700A
 CN Asaprene 720A
 CN Asaprene 720AX
 CN Asaprene 730AX
 CN Asaprene 755A
 CN Asaprene 756A
 CN Asaprene 760A
 CN Asaprene BR 730A
 CN Austrapoi 1220
 CN Bayer 550
 CN Bon RI 1
 CN BR 02L
 CN BR 02LL
 CN BR 1200
 CN BR 1202G
 CN BR 1203
 CN BR 1207
 CN BR 1220L
 CN BR 1220SU
 CN BR 1250
 CN BR 1441
 CN BR 15HB
 CN BR 200
 CN BR 200 (rubber)
 CN BR 23SH
 CN BR 3505
 CN BR 401
 CN BR 401 (rubber)
 CN BR 55F
 CN BR 90
 CN BR 900
 CN BR 9001
 CN BRX 3000

ADDITIONAL NAMES NOT AVAILABLE IN THIS FORMAT - Use FCN, FIDE, or ALL for
 DISPLAY

DR 62361-95-9, 51426-11-0, 178234-67-8

MF Unspecified


CI PMS, MAN, CTS

PCT Manual registration

LC STN Files: ADISNEWS, AGRICOLA, BIOSIS, CA, CAPLUS, CHEMCATS, CHEMLIST,
 CIN, CSCHEM, TOXCENTER

*** STRUCTURE DIAGRAM IS NOT AVAILABLE ***

L2 ANSWER 27 OF 32 REGISTRY COPYRIGHT 2009 ACS on STN
 RN 3701-40-4 REGISTRY
 ED Entered STN: 16 Nov 1984
 CN 2,7-Naphthalenedisulfonic acid, 4-hydroxy-3-[2-[4'-(2-(2-hydroxy-1-naphthalenyl)diazenyl)-2,2'-dimethyl[1,1'-biphenyl]-4-yl]diazenyl]-, sodium salt (1:2) (CA INDEX NAME)
 OTHER CA INDEX NAMES:
 CN 2,7-Naphthalenedisulfonic acid, 4-hydroxy-3-[[4'-(2-hydroxy-1-naphthalenyl)azo]-2,2'-dimethyl[1,1'-biphenyl]-4-yl]azo]-, disodium salt (9CI)
 CN C.I. Acid Red 99 (7CI)
 CN C.I. Acid Red 99, disodium salt (8CI)
 OTHER NAMES:
 CN Acid Leather Red 2BG
 CN Acid Red 99
 CN Acidine Red RD
 CN Airedale Red RM
 CN Benzyl Fast Red 2BG
 CN Best Acid Milling Red FRS
 CN Brilliant Milling Red
 CN C.I. 23285
 CN Calcocid Milling Red RC
 CN Coomassie Red R
 CN Dynacid Red RS
 CN Elite Fast Red BG
 CN Elite Fast Red R
 CN Elite Fast Red RS
 CN Kayanol Red RS
 CN Levanol Brilliant Red BB
 CN Milling Fast Red R
 CN Milling Fast Red RS
 CN Milling Fast Red RX
 CN Milling Red PRX
 CN Multicuer Red BRX
 CN Naphthalene Leather Red R
 CN Optanol Red R
 CN Pharmanil Red RB
 CN Polar Red GBD
 CN Polar Red R
 CN Shikiso Acid Red RS
 CN Sulfonine Red RS
 CN Suminol Milling Red GRS
 CN Suminol Red RS
 CN Supranol Fast Red RX
 CN Takaoaka Acid Red RS
 CN Triacid Fast Red GRS
 MF C34 H26 N4 O8 S2 . 2 Na
 LC STN Files: CA, CAPLUS, CHEMLIST, RTECS*, TOXCENTER, USPATFULL, USPATOLD
 (*File contains numerically searchable property data)
 Other Sources: DSL**, EINECS**, TSCA**
 (**Enter CHEMLIST File for up-to-date regulatory information)
 CRN (25317-42-4)



● 2 Na

21 REFERENCES IN FILE CA (1907 TO DATE)
21 REFERENCES IN FILE CAPLUS (1907 TO DATE)

L2 ANSWER 28 OF 32 REGISTRY COPYRIGHT 2009 ACS on STN

RN 2241-61-4 REGISTRY

ED Entered SIN: 16 Nov 1984

CN Benz[b]indeno[1,2-d]pyran-3,6a,9,10(6H)-tetrol, 7,11b-dihydro-,
3,6a,9,10-tetraacetate, (6aS,11bR)- (CA INDEX NAME)

OTHER CA INDEX NAMES:

CN Benz[b]indeno[1,2-d]pyran-3,6a,9,10(6H)-tetrol, 7,11b-dihydro-,
tetraacetate (7CI)

CN Benz[b]indeno[1,2-d]pyran-3,6a,9,10(6H)-tetrol, 7,11b-dihydro-,
tetraacetate, (6aS,11bR)- (9CI)

CN Benz[b]indeno[2,1-d]pyran-3,6a,9,10(6H)-tetrol, 7,10b-dihydro-,
tetraacetate, (6aS-cis)-

OTHER NAMES:

CN BRX 019

CN Tetraacetylbrasilin


FS STEREOSEARCH

MF C24 H22 O9

LC STN Files: BEILSTEIN*, BIOSIS, CA, CAPLUS, MEDLINE, PROUSDDR, SYNTHLINE,
TOXCENTER

(*File contains numerically searchable property data)

Absolute stereochemistry. Rotation (+).




PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

5 REFERENCES IN FILE CA (1907 TO DATE)
5 REFERENCES IN FILE CAPLUS (1907 TO DATE)

L2 ANSWER 29 OF 32 REGISTRY COPYRIGHT 2009 ACS on STN
RN 1658-56-6 REGISTRY
ED Entered STN: 16 Nov 1984
CN 1-Naphthalenesulfonic acid, 4-[2-(2-hydroxy-1-naphthalenyl)diazenyl]-,
sodium salt (1:1) (CA INDEX NAME)
OTHER CA INDEX NAMES:
CN 1-Naphthalenesulfonic acid, 4-[(2-hydroxy-1-naphthalenyl)azo]-, monosodium
salt (9CI)
CN C.I. Acid Red 88, monosodium salt (8CI)
OTHER NAMES:
CN 11391 Red
CN 2-Naphthol Red J
CN Acid Cardinal G
CN Acid Fast Red A
CN Acid Leather Red ROC
CN Acid Red 88
CN Acid Red A
CN Acid Red A (Chinese)
CN Acid Red AV
CN Acid Red G
CN Acid Rose AV
CN Acid Scarlet G
CN Airedale Red A
CN Amacid Fast Red A
CN Ambicid Fast Red E
CN Anadurm Red A-ROC
CN Anthrosin BRX
CN Apollo Acid Roccelline
CN Atul Acid Fast Red A
CN Azo Acid Red GS
CN Basacid Red 340
CN Benzyl Red ROC
CN Benzyl Red S
CN Brasilan Red S
CN Bucacid Fast Red A
CN C.I. 15620
CN C.I. Acid Red 88
CN Calcocid Fast Red A
CN Cavaleine Red A
CN Colacid Red AV
CN Colocid Fast Red A
CN Conacid Red MM
CN Daedo Acid Roccelline NS
CN Dai-ei Roccelline
CN Derma Fur Red R 150
CN Diacid Red A
CN Dinacid Fast Red A
CN Dyacid Red J
CN Dycosacid Red A
CN Eniacid Fast Red A
CN Eriodin Roccelline
CN Eriodin Roccelline SS
CN Ext D and C Red No. 8
CN Fabracid Red S-A
CN Fast Acid Red G
CN Fast Red A
CN Fast Red A (acid dye)
CN Fast Red AE

ADDITIONAL NAMES NOT AVAILABLE IN THIS FORMAT - Use FCN, FIDE, or ALL for

DISPLAY
 DR 163442-07-7, 39309-87-0
 MF C20 H14 N2 O4 S . Na
 CI COM
 LC STN Files: AGRICOLA, ANABSTR, BEILSTEIN*, BIOSIS, CA, CAPLUS, CASREACT,
 CHEMCATS, CHEMLIST, CSChem, DETHERM*, IFICDB, IFIPAT, IFIUDb, MEDLINE,
 MSDS-OHS, PIRA, PROMT, RTECS*, TOXCENTER, USPAT2, USPATFULL, USPATOLD
 (*File contains numerically searchable property data)
 Other Sources: DSL**, EINECS**, TSCA**
 (**Enter CHEMLIST File for up-to-date regulatory information)
 CRN (18268-54-7)



● Na

PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

452 REFERENCES IN FILE CA (1907 TO DATE)
 10 REFERENCES TO NON-SPECIFIC DERIVATIVES IN FILE CA
 454 REFERENCES IN FILE CAPLUS (1907 TO DATE)

L2 ANSWER 30 OF 32 REGISTRY COPYRIGHT 2009 ACS on STN

RN 1326-85-8 REGISTRY

ED Entered STN: 16 Nov 1984

CN C.I. Sulphur Black 2 (8CI, 9CI) (CA INDEX NAME)

OTHER NAMES:

CN C.I. 53195
 CN C.I. Sulfur Black 2
 CN Calcogene Black 2R-CF
 CN Calcogene Black RB-CF
 CN Diresul Black 2R
 CN Diresul Black 3R
 CN Diresul Black EV-PL
 CN Eclipse Deep Black BG
 CN Fenoxyl Black 2R
 CN Katigen Deep Black RRND-CF
 CN Kayaku Sulphur Black BRX
 CN Mitsui Sulphur Black ABR
 CN Mitsui Sulphur Black BBRO
 CN Mitsui Sulphur Black BR
 CN Mitsui Sulphur Black R
 CN Mitsui Sulphur Black RC
 CN Nissen Black BRX

CN Sodyesul Black MCF
 CN Solfo Black 3R
 CN Solfo Black R
 CN Sulfanol Black 2R
 CN Sulfogene Carbon 4RCF
 CN Sulfogene Carbon MCF
 CN Sulfogene Carbon Supra CF Grains
 CN Sulfogene Carbon T
 CN Sulfogene Grey H1A grai
 CN Sulfur Black 2
 CN Sulfur Black 2RD
 CN Sulfur Black 4RD
 CN Sulfur Black DR
 CN Sulfur Black RND
 CN Sulphol Black BSP
 CN Sulphol Black BSP Paste
 CN Sulphol Black No. 44
 CN Sulphol Black PG
 CN Sulphol Black PXR Ex. Conc
 CN Sulphol Black PXR Paste
 CN Sulphol Black RS Grains
 CN Sulphol Liquid Black QR
 CN Sulphur Black 2
 CN Thionol Black R
 DEF This substance is identified in the COLOUR INDEX by Colour Index
 Constitution Number, C.I. 53195.
 MF Unspecified
 CI MAN
 LC STN Files: CA, CAPLUS, CHEMCATS, CHEMLIST, CSCHEM, TOXCENTER, USPAT2,
 USPATFULL
 Other Sources: NDSL**, TSCA**
 (**Enter CHEMLIST File for up-to-date regulatory information)

*** STRUCTURE DIAGRAM IS NOT AVAILABLE ***
 11 REFERENCES IN FILE CA (1907 TO DATE)
 11 REFERENCES IN FILE CAPLUS (1907 TO DATE)

L2 ANSWER 31 OF 32 REGISTRY COPYRIGHT 2009 ACS on STN
 RN 1064-48-8 REGISTRY
 ED Entered STN: 16 Nov 1984
 CN 2,7-Naphthalenedisulfonic acid, 4-amino-5-hydroxy-3-[2-(4-nitrophenyl)diazenyl]-6-(2-phenyldiazenyl)-, sodium salt (1:2) (CA INDEX NAME)
 OTHER CA INDEX NAMES:
 CN 2,7-Naphthalenedisulfonic acid, 4-amino-5-hydroxy-3-[(4-nitrophenyl)azo]-6-(phenylazo)-, disodium salt (9CI)
 CN Amido Black 10B (6CI)
 OTHER NAMES:
 CN Acid Black 1
 CN Acid Black 10A
 CN Acid Black 10B
 CN Acid Black 10BA
 CN Acid Black 10BN
 CN Acid Black 10BX
 CN Acid Black 12B
 CN Acid Black 4BN
 CN Acid Black 4BNU
 CN Acid Black 8GB
 CN Acid Black Base M
 CN Acid Black BRX
 CN Acid Black BX
 CN Acid Black H

CN Acid Black JVS
 CN Acid Blue Black
 CN Acid Blue Black 10B
 CN Acid Blue Black 10BX
 CN Acid Blue Black B
 CN Acid Blue Black BG
 CN Acid Blue Black Double 600
 CN Acid Blue Black Sh
 CN Acid Leather Blue IGW
 CN Acid Leather Dark Blue G
 CN Acid Leather Fast Blue Black G
 CN Acidal Black 10B
 CN Acidal Black MV
 CN Acidal Navy Blue 3BR
 CN Aciderm Black E 10B
 CN Acilan Black 10B
 CN Airedale Black 2BG
 CN Amacid Black 10BR
 CN Amide Black 10B
 CN Amido Black
 CN Amido Blue Black 12B
 CN Apollo Acid Blue Black 10B
 CN Atul Acid Black 10BX
 CN Atul Acid Black BX
 CN Azanol Fast Acid Black 10B
 CN Azo Dark Blue C 2B
 CN Azo Dark Blue HR
 CN Azo Dark Blue S
 CN Azo Dark Blue SH
 CN Best Acid Dark Blue B
 CN Black 401
 CN Black No. 401
 CN Blue Black 12B
 CN Blue Black SX
 ADDITIONAL NAMES NOT AVAILABLE IN THIS FORMAT - Use FCN, FIDE, or ALL for

DISPLAY
 DR 12042-02-3, 68417-62-9, 84842-81-9, 86923-11-7, 31258-44-3

MF C22 H16 N6 O9 S2 . 2 Na
 CI COM


LC STN Files: AGRICOLA, ANABSTR, AQUIRE, BEILSTEIN*, BIOSIS, BIOTECHNO, CA,
 CAPLUS, CASREACT, CHEMCATS, CHEMLIST, CSCHEM, EMBASE, IFICDB, IFIPAT,
 IFIUIDB, MEDLINE, MSDS-OHS, PROMT, RTECS*, TOXCENTER, USPAT2, USPATFULL,
 USPATOLD

(*File contains numerically searchable property data)

Other Sources: DSL**, EINECS**, TSCA**

(**Enter CHEMLIST File for up-to-date regulatory information)

CRN (3121-74-2)



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

976 REFERENCES IN FILE CA (1907 TO DATE)

7 REFERENCES TO NON-SPECIFIC DERIVATIVES IN FILE CA

978 REFERENCES IN FILE CAPLUS (1907 TO DATE)

L2 ANSWER 32 OF 32 REGISTRY COPYRIGHT 2009 ACS on STN

RN 147-14-8 REGISTRY

ED Entered STN: 16 Nov 1984

CN Copper, [29H,31H-phthalocyaninato(2-)-
κN29,κN30,κN31,κN32]-, (SP-4-1)- (CA INDEX NAME)

OTHER CA INDEX NAMES:

CN 29H,31H-Phthalocyanine, copper complex

CN 29H,31H-Phthalocyanine, copper deriv.

OTHER NAMES:

CN (Phthalocyaninato)copper

CN α-Copper phthalocyanine

CN α-Copper phthalocyanine blue

CN α-Phthalocyanine blue

CN β-Copper phthalocyanine blue

CN β-Phthalocyanine blue

CN ε-Copper phthalocyanine

CN 127EPS

CN 405D

CN 7075M

CN 79S26C

CN 79S26C chip

CN A 220

CN Accospense Cyan Blue GT

CN Acnalin Supra Blue G

CN Acramin Blue F 3G

CN Akrochem 626

CN Aqualine Blue

CN Aquis BW 3571

CN Arlocyanine Blue PS

CN Aztech Chemisperse Cyan 1541

CN B 2G-L

CN B 4G-KR

CN B 702W

CN B 705H

CN B 736

CN B 8M25

CN Bahama Blue BC

CN Bahama Blue BNC

CN Bahama Blue Lake NCF

CN Bahama Blue WD

CN Bermuda Blue

CN BFD 1121

CN BGS 1

CN BGSG-C

CN BL 1531

CN Blue 7110V

CN Blue BT 627D

CN Blue GLA

CN Blue GLA-SD

CN Blue GLSM

CN Blue Microdis

CN Blue phthalocyanine α-form

CN Blue pigment

CN Blue Toner GTNF

CN BRS 1

CN BRX

CN BSS 4342

ADDITIONAL NAMES NOT AVAILABLE IN THIS FORMAT - Use FCN, FIDE, or ALL for
DISPLAY

DR 807622-86-2, 819860-69-0, 819860-85-0, 878390-73-9, 924902-00-1,
1082606-32-3, 12767-67-8, 10482-39-0, 11097-56-6, 11129-84-3, 177529-54-3,
177646-05-8, 158853-86-2, 172308-31-5, 172826-46-9, 53802-06-5,
57916-96-8, 57425-52-2, 55819-49-3, 59518-91-1, 59966-88-0, 64333-57-9,
95660-31-4, 95917-74-1, 96024-35-0, 104921-99-5, 51331-32-9, 115284-42-9,
60880-51-5, 60937-79-3, 61489-66-5, 61489-77-8, 61537-10-8, 109675-77-6,
109766-95-2, 66121-19-5, 37223-81-7, 69431-77-2, 78170-27-1, 78413-59-9,
85255-95-4, 85256-77-5, 92909-14-3, 90452-20-3, 34567-54-9, 39378-75-1,
39473-10-4, 53028-77-6, 175386-67-1, 184007-78-1, 209343-48-6,
211564-97-5, 211925-80-3, 213190-86-4, 220971-30-2, 244244-86-8,
345338-75-2, 392718-62-6, 681847-78-9

MF C32 H16 Cu N8


CI CCS, COM

LC STN Files: ADISNEWS, AGRICOLA, ANABSTR, BIOSIS, BIOTECHNO, CA, CAPLUS,
CASREACT, CBNB, CHEMCATS, CHEMLIST, CIN, CSCHEM, CSNB, DETHERM*, EMBASE,
GMELIN*, HSDB*, IFICDB, IFIPAT, IFIUDB, IPA, MEDLINE, MRCK*, MSDS-OHS,
PIRA, PROMT, RTECS*, SPECINFO, TOXCENTER, USPAT2, USPATFULL, USPATOLD
(*File contains numerically searchable property data)

Other Sources: DSL**, EINECS**, TSCA**

(**Enter CHEMLIST File for up-to-date regulatory information)

PAGE 1-A



PAGE 2-A



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

19281 REFERENCES IN FILE CA (1907 TO DATE)
1351 REFERENCES TO NON-SPECIFIC DERIVATIVES IN FILE CA
19324 REFERENCES IN FILE CAPLUS (1907 TO DATE)

=> file caplus
COST IN U.S. DOLLARS

SINCE FILE	TOTAL
ENTRY	SESSION
78.70	78.92

FULL ESTIMATED COST

FILE 'CAPLUS' ENTERED AT 10:10:26 ON 23 OCT 2009
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.
COPYRIGHT (C) 2009 AMERICAN CHEMICAL SOCIETY (ACS)

Copyright of the articles to which records in this database refer is held by the publishers listed in the PUBLISHER (PB) field (available for records published or updated in Chemical Abstracts after December 26, 1996), unless otherwise indicated in the original publications. The CA Lexicon is the copyrighted intellectual property of the American Chemical Society and is provided to assist you in searching databases on STN. Any dissemination, distribution, copying, or storing of this information, without the prior written consent of CAS, is strictly prohibited.

FILE COVERS 1907 - 23 Oct 2009 VOL 151 ISS 18
FILE LAST UPDATED: 22 Oct 2009 (20091022/ED)
REVISED CLASS FIELDS (/NCL) LAST RELOADED: Aug 2009
USPTO MANUAL OF CLASSIFICATIONS THESAURUS ISSUE DATE: Aug 2009

Caplus now includes complete International Patent Classification (IPC) reclassification data for the third quarter of 2009.

CAS Information Use Policies apply and are available at:

<http://www.cas.org/legal/infopolicy.html>

This file contains CAS Registry Numbers for easy and accurate substance identification.

=> s 289893-26-1/rn
8 289893-26-1
0 289893-26-1D
L3 8 289893-26-1/RN
(289893-26-1 (NOTL) 289893-26-1D)

=> d l3 ibib abs 1-8

L3 ANSWER 1 OF 8 CAPLUS COPYRIGHT 2009 ACS ON STN

ACCESSION NUMBER: 2007:363043 CAPLUS

DOCUMENT NUMBER: 147:9795

TITLE: Process for the preparation of
O-(3-piperidino-2-hydroxy-1-propyl)-hydroxamic acid
halide derivatives as antidiabetic agents

INVENTOR(S): Kuerthy, Maria; Biro, Katalin; Nagy, Karoly; Csakai,
Zita; Ueroegdi, Laszlo; Szilbereky, Jenoe; Mogyorosi,
Tamas; Toeroek, Magdolna; Barabas, Mihaly; Komaromi,

PATENT ASSIGNEE(S): Andras; Marvanyos, Ede; Kardos, Mihalyne; Nagy, Zoltan; Koranyi, Laszlo; Nagy, Melinda
 SOURCE: Biorex Kutato es Fejlesztö Rt., Hung.
 Hung. Pat. Appl., 31pp.
 CODEN: HUXXCX
 DOCUMENT TYPE: Patent
 LANGUAGE: Hungarian
 FAMILY ACC. NUM. COUNT: 1
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
HU 2000000552	A2	20011228	HU 2000-552	20000208
PRIORITY APPLN. INFO.:			HU 2000-552	20000208

AB The subject of the invention is N-[2-hydroxy-3-(1-piperidinyl)-propoxy]-pyridine-1-oxide-3-carboxy-imidoyl chloride, its stereoisomers, as well as their acid addition salts. The invention also includes the application of these compds. in the fight against abnormal insulin resistance and for the treatment of related conditions and a process for the treatment of insulin resistance and related abnormal conditions. Another subject of the invention is the pharmaceutical compns. that contain the above named compds. as their active ingredients, along with the usual auxiliary materials and carriers.

L3 ANSWER 2 OF 8 CAPLUS COPYRIGHT 2009 ACS on STN

ACCESSION NUMBER: 2004:100113 CAPLUS

DOCUMENT NUMBER: 141:17416

TITLE: The effect of treatment with BRX-220, a co-inducer of heat shock proteins, on sensory fibers of the rat following peripheral nerve injury

AUTHOR(S): Kalmár, B.; Greensmith, L.; Malcangio, M.; McMahon, S. B.; Csérmely, P.; Burnstock, G.

CORPORATE SOURCE: Sobell Department of Motor Neuroscience and Movement Disorders, Institute of Neurology, London, WC1N 3BG, UK

SOURCE: Experimental Neurology (2003), 184(2), 636-647

CODEN: EXNEAC; ISSN: 0014-4886

PUBLISHER: Elsevier Science

DOCUMENT TYPE: Journal

LANGUAGE: English

AB In this study, we examined the effect BRX-220, a co-inducer of heat shock proteins, in injury-induced peripheral neuropathy. Following sciatic nerve injury in adult rats and treatment with BRX-220, the following features of the sensory system were studied: (a) expression of calcitonin gene-related peptide (CGRP); (b) binding of isolectin B4 (IB4) in dorsal root ganglia (DRG) and spinal cord; (c) stimulation-evoked release of substance P (SP) in an in vitro spinal cord preparation and (d) nociceptive responses of partially denervated rats. BRX-220 partially reverses axotomy-induced changes in the sensory system. In vehicle-treated rats there is a decrease in IB4 binding and CGRP expression in injured neurons, while in BRX-220-treated rats these markers were better preserved. Thus, $7.0 \pm 0.6\%$ of injured DRG neurons bound IB4 in vehicle-treated rats compared to $14.4 \pm 0.9\%$ in BRX-220-treated animals. Similarly, $4.5 \pm 0.5\%$ of DRG neurons expressed CGRP in the vehicle-treated group, whereas $9.0 \pm 0.3\%$ were pos. in the BRX-220-treated group. BRX-220 also partially restored SP release from spinal cord sections to elec. stimulation of primary sensory neurons. Behavioral tests carried out on partially denervated animals showed that BRX-220 treatment did not prevent the emergence of mech. or thermal hyperalgesia. However, oral treatment for 4 wk lead to reduced pain-related behavior suggesting either slowly developing analgesic actions or enhancement of recovery processes. Thus, the morphol. improvement seen in sensory neuron markers was accompanied by

restored functional activity. Therefore, treatment with BRX-220 promotes restoration of morphol. and functional properties in the sensory system following peripheral nerve injury.

OS.CITING REF COUNT: 17 THERE ARE 17 CAPLUS RECORDS THAT CITE THIS RECORD (17 CITINGS)
REFERENCE COUNT: 33 THERE ARE 33 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L3 ANSWER 3 OF 8 CAPLUS COPYRIGHT 2009 ACS on STN

ACCESSION NUMBER: 2002:587024 CAPLUS

DOCUMENT NUMBER: 138:130888

TITLE: Effect of BRX-220 against peripheral neuropathy and insulin resistance in diabetic rat models

AUTHOR(S): Kurthy, Maria; Mogyrosi, Tamas; Nagy, Karoly; Kukorelli, Tibor; Jednakovits, Andrea; Talosi, Laszlo; Biro, Katalin

CORPORATE SOURCE: Biorex Research and Development Company, Veszprem, Hung.

SOURCE: Annals of the New York Academy of Sciences (2002), 967(Lipids and Insulin Resistance), 482-489
CODEN: ANYAA9; ISSN: 0077-8923

PUBLISHER: New York Academy of Sciences

DOCUMENT TYPE: Journal

LANGUAGE: English

AB Bimoclomol (BML), a symptomatic antidiabetic agent, was developed by Biorex R&D Co. to treat diabetic neuropathy and retinopathy. BRX-220, an orally active member of the BRX family, was developed to treat diabetic complications and insulin resistance (IR) as a follow-up compound. The effect of BRX-220 on peripheral neuropathy was examined in rats with diabetes (type 1) induced by administration of a β -cell toxin, streptozotocin (STZ, 45 mg/kg iv). Nerve functions were evaluated by electrophysiol. measurements of muscle motor and sensory nerve conduction velocities (MNCV and SNCV, resp.). MNCV and SNCV decreased in diabetic rats by 25%. A 1-mo preventive treatment with BRX-220 (2.5, 5, 10, and 20 mg/kg po) dose-dependently improved diabetes-related deficits in MNCV (51.3, 71.3, 86.1, and 91.3%) and SNCV (48.9, 68.5, 86.1, and 93.2%). Insulin sensitivity was measured using the insulin tolerance test (ITT), both in STZ diabetic and in Zucker diabetic fatty (ZDF) rats (model of type 2 diabetes). Severe IR was detected in STZ diabetic and ZDF rats. This resistance was significantly reduced by BRX-220 treatment.

OS.CITING REF COUNT: 11 THERE ARE 11 CAPLUS RECORDS THAT CITE THIS RECORD (11 CITINGS)
REFERENCE COUNT: 19 THERE ARE 19 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L3 ANSWER 4 OF 8 CAPLUS COPYRIGHT 2009 ACS on STN

ACCESSION NUMBER: 2002:587016 CAPLUS

DOCUMENT NUMBER: 138:130887

TITLE: Comparison of the extrapancreatic action of BRX-220 and pioglitazone in the high-fat diet-induced insulin resistance

AUTHOR(S): Sebokova, Elena; Kurthy, Maria; Mogyrosi, T.; Nagy, Karoly; Demcakova, Edit; Ukropec, Jozef; Koranyi, Laszlo; Klimes, Iwar

CORPORATE SOURCE: Diabetes and Nutrition Research Laboratory, Institute of Experimental Endocrinology, Slovak Academy of Sciences, Bratislava, SK-83306, Slovakia

SOURCE: Annals of the New York Academy of Sciences (2002), 967(Lipids and Insulin Resistance), 424-430
CODEN: ANYAA9; ISSN: 0077-8923

PUBLISHER: New York Academy of Sciences

DOCUMENT TYPE: Journal

LANGUAGE: English

AB A new Biorex mol., BRX-220, was shown to be effective in animal models of diabetic neuro- and retinopathy. Recent in vitro studies showed that it might also have an insulin-sensitizing action. Therefore, the effect of BRX-220 on insulin sensitivity was compared with the action of pioglitazone (PGZ) in high fat (HF) diet-induced insulin resistance (IR) of rats. Methods-Male Wistar rats were fed for 3 wk a standard chow (PD) or the HF (70-cal%) diet. The HF-fed rats were also given daily BRX-220 (20 mg/kg BW) or PGZ (6 mg/kg BW) by gavage. In vivo insulin action was assessed by the euglycemic hyperinsulinemic clamp. Glucose, insulin, FFA, triglyceride (TG), and glycerol levels in blood were also measured, as well as tissue TG content. Results-Increased levels of fed TG in circulation after HF diet (PD: 2.0 vs. HF: 5.0 mmol/L) were partially corrected by BRX-220 (HF+BRX: 3.8) and normalized by PGZ (HF+PGZ: 2.6). Both mols. prevented the increase in fed serum FFA levels after HF diet (PD: 0.5; HF: 1.8±0.2 mmol/L), with a more pronounced effect of PGZ (HF+BRX: 1.2; HF+PGZ: 0.7). Tissue TG levels increased significantly in response to HF feeding in both liver (HF: 16; PD: 6.4 µmol/g) and skeletal muscle (HF: 7.7; PD: 2.4). This increase was completely normalized by both agents in the liver (HF+BRX: 8.8; HF+PGZ: 8.8), and only partially in the skeletal muscles. HF diet-induced in vivo IR (PD: 25.4; HF: 15.7 mg/kg/min) was significantly reduced by BRX-220 (HF+BRX: 18.7) and PGZ (HF+PGZ: 22.8) treatment. Conclusions-(1) Subchronic administration of BRX-220 leads to an improvement of in vivo insulin action. (2) This insulin-sensitizing effect is, however, not as pronounced as that of PGZ. (3) It is accompanied by a decrease of circulating TG and FFA levels in the postprandial state and (4) by lower TG content in liver and skeletal muscle.

OS.CITING REF COUNT: 2 THERE ARE 2 CAPLUS RECORDS THAT CITE THIS RECORD (2 CITINGS)

REFERENCE COUNT: 30 THERE ARE 30 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L3 ANSWER 5 OF 8 CAPLUS COPYRIGHT 2009 ACS on STN

ACCESSION NUMBER: 2002:496814 CAPLUS

DOCUMENT NUMBER: 137:362925

TITLE: Upregulation of Heat Shock Proteins Rescues Motoneurons from Axotomy-Induced Cell Death in Neonatal Rats

AUTHOR(S): Kalmar, B.; Burnstock, G.; Vrbova, G.; Urbanics, R.; Csermely, P.; Greensmith, L.

CORPORATE SOURCE: Sobell Department of Motor Neuroscience and Movement Disorders, Institute of Neurology, London, WC1N 3BG, UK

SOURCE: Experimental Neurology (2002), 176(1), 87-97
CODEN: EXNEAC; ISSN: 0014-4886

PUBLISHER: Elsevier Science

DOCUMENT TYPE: Journal

LANGUAGE: English

AB Heat shock proteins (hsps) are induced in a variety of cells following periods of stress, where they promote cell survival. In this study, we examined the effect of upregulating hsp expression by treatment with BRX-220, a co-inducer of hsps, on the survival of injured motoneurons. Following sciatic nerve crush at birth, rat pups were treated daily with BRX-220. The expression of hsp70 and hsp90, motoneurone survival, and muscle function was examined at various intervals later and the number of functional motor units was assessed by in vivo isometric tension recordings. Fourteen days after injury, significantly more motoneurons survived in the BRX-220-treated group ($39 \pm 2.8\%$) compared to the saline-treated group ($21 \pm 1.7\%$). Moreover, in the BRX-220-treated group no further loss of motoneurons occurred, so that at 10 wk $42 \pm 2.1\%$ of motoneurons survived compared to $15 \pm 0.6\%$ in the untreated

group. There were also more functional motor units in the hindlimb muscles of BRX-220-treated animals. In addition, treatment with BRX-220 resulted in a significant increase in the expression of hsp70 and hsp90 in glia and neurons. Thus, treatment with BRX-220, a co-inducer of hsps, protects motoneurons from axotomy-induced cell death.

OS.CITING REF COUNT: 23 THERE ARE 23 CAPLUS RECORDS THAT CITE THIS RECORD (23 CITINGS)
 REFERENCE COUNT: 52 THERE ARE 52 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L3 ANSWER 6 OF 8 CAPLUS COPYRIGHT 2009 ACS ON SIN

ACCESSION NUMBER: 2002:418232 CAPLUS

DOCUMENT NUMBER: 138:49725

TITLE: Nontoxic heat shock protein coinducer BRX-220 protects against acute pancreatitis in rats

AUTHOR(S): Rakonczay, Zoltan; Ivanyi, Bela; Varga, Ilona; Boros, Imre; Jednakovits, Andrea; Nemeth, Ilona; Lonovics, Janos; Takacs, Tamas

CORPORATE SOURCE: First Department of Medicine, University of Szeged, Szeged, Hung.

SOURCE: Free Radical Biology & Medicine (2002), 32(12), 1283-1292

CODEN: FRMMEH; ISSN: 0891-5849

PUBLISHER: Elsevier Science Inc.

DOCUMENT TYPE: Journal

LANGUAGE: English

AB Nontoxic heat shock protein (HSP) inducer compds. open up promising therapeutic possibilities by activating one of the natural and highly conserved defense mechanisms of the organism. In the present expts., we examined the effects of a HSP coinducer drug-candidate, BRX-220, on the cholecystokinin-octapeptide (CCK)-induced acute pancreatitis in rats. Male Wistar rats weighing 240 to 270 g were divided into two groups. In group B, 20 mg/kg BRX-220 was administered orally, followed by 75 µg/kg CCK s.c. three times, after 1, 3, and 5 h. This whole procedure was repeated for 5 d. The animals in group B received physiol. saline orally instead of BRX-220, but otherwise the protocol was the same as in group B. The rats were exsanguinated through the abdominal aorta 12 h after the last administration of CCK. We determined the serum amylase activity, the plasma trypsinogen activation peptide concentration, the pancreatic weight/body weight ratio, the DNA and total protein contents of the pancreas, the levels of pancreatic HSP60 and HSP72, the activities of pancreatic amylase, lipase, trypsinogen, and free radical scavenger enzymes (superoxide dismutase, catalase, and glutathione peroxidase), the degree of lipid peroxidn., protein oxidation, and the reduced glutathione level. Histopathol. investigation of the pancreas was also performed in all cases. Repeated CCK treatment resulted in the typical laboratory and morphol. changes of exptl. induced pancreatitis. The pancreatic levels of HSP60 and HSP72 were significantly increased in the animals treated with BRX-220. In group B, the pancreatic total protein content and the amylase and trypsinogen activities were significantly higher vs. group B. The plasma trypsinogen activation peptide concentration, and the pancreatic lipid peroxidn., protein oxidation, and the activity of Cu/Zn-superoxide dismutase were significantly decreased in group B vs. group B, whereas the glutathione peroxidase activity was increased. The morphol. damage in group B was significantly lower than that in group B. The HSP coinducer BRX-220, administered for 5 d, has a protective effect against CCK-induced acute pancreatitis.

OS.CITING REF COUNT: 16 THERE ARE 16 CAPLUS RECORDS THAT CITE THIS RECORD (16 CITINGS)

REFERENCE COUNT: 35 THERE ARE 35 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L3 ANSWER 7 OF 8 CAPLUS COPYRIGHT 2009 ACS on STN

ACCESSION NUMBER: 2001:780856 CAPLUS

DOCUMENT NUMBER: 135:318423

TITLE: Preparation of
N-[2-hydroxy-3-(1-piperidinyl)propoxy]pyridine-1-oxide-3-carboxamidine,
N-[2-hydroxy-3-(1-piperidinyl)propoxy]pyridine-1-oxide-3-carboximidoyl chloride, and enantiomers thereof.

INVENTOR(S): Ueroegdi, Laszlo; Jeges Csakai, Zita; Gruber, Lajos; Oetvoes, Laszlo; Toth, Jozsef; Toemoeskozei, Istvan; Szakacs Schmidt, Aniko; Reider, Ferencne; Schneidern Barlay, Maria

PATENT ASSIGNEE(S): Biorex Kutato es Fejleszto, Hung.

SOURCE: PCT Int. Appl., 29 pp.

CODEN: PIXXD2

DOCUMENT TYPE: Patent

LANGUAGE: English

FAMILY ACC. NUM. COUNT: 1

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2001079174	A1	20011025	WO 2001-HU46	20010417
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, VZ, VN, YU, ZA, ZW				
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG				
HU 2000001583	A2	20021128	HU 2000-1583	20000418
CA 2406266	A1	20011025	CA 2001-2406266	20010417
EP 1274685	A1	20030115	EP 2001-928133	20010417
EP 1274685	B1	20060712		
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR				
BR 2001010184	A	20030617	BR 2001-10184	20010417
JP 2004501080	T	20040115	JP 2001-576775	20010417
EE 200200591	A	20040415	EE 2002-591	20010417
EE 5085	B1	20081015		
NZ 522017	A	20040625	NZ 2001-522017	20010417
CN 1216868	C	20050831	CN 2001-810831	20010417
RU 2281282	C2	20060810	RU 2002-130710	20010417
AT 332894	T	20060815	AT 2001-928133	20010417
AU 2001254997	B2	20061123	AU 2001-254997	20010417
ES 2267758	T3	20070316	ES 2001-928133	20010417
IL 152337	A	20071031	IL 2001-152337	20010417
BG 107199	A	20030731	BG 2002-107199	20021016
NO 2002005015	A	20021216	NO 2002-5015	20021018
NO 323535	B1	20070604		
ZA 2002008460	A	20031020	ZA 2002-8460	20021018
MX 2002010320	A	20040906	MX 2002-10320	20021018
IN 2002KN01301	A	20050311	IN 2002-KN1301	20021018
KR 742482	B1	20070725	KR 2002-714047	20021018
US 20040006232	A1	20040108	US 2003-257755	20030128
US 7126002	B2	20061024		
HK 1055741	A1	20060407	HK 2003-108135	20031110
PRIORITY APPLN. INFO.:			HU 2000-1583	A 20000418
			WO 2001-HU46	W 20010417

OTHER SOURCE(S): CASREACT 135:318423

AB Title compds. were prepared Thus, 2-hydroxy-4-azoniaspiro[3.5]nonane chloride was stirred in aqueous NaOH for 40 min. at 5-10°; EtOH and 3-pyridinamidoxime 1-oxide (preparation given) was added and the mixture was refluxed 2 h to give 62% N-[2-hydroxy-3-(1-piperidinyl)propoxy]pyridine-1-oxide-3-carboxamidine. The latter in aqueous HCl at -5° was treated with aqueous NaNO₂ followed by stirring for 1.5 h to give 85% N-[2-hydroxy-3-(1-piperidinyl)propoxy]pyridine-1-oxide-3-carboximidoyl chloride.

OS.CITING REF COUNT: 3 THERE ARE 3 CAPLUS RECORDS THAT CITE THIS RECORD (4 CITINGS)
 REFERENCE COUNT: 4 THERE ARE 4 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L3 ANSWER 8 OF 8 CAPLUS COPYRIGHT 2009 ACS on SIN

ACCESSION NUMBER: 2000:608728 CAPLUS

DOCUMENT NUMBER: 133:207815

TITLE: Preparation of N-[2-hydroxy-3-(1-piperidinyl)propoxy]pyridine-1-oxide-3-carboximidoyl chloride and its use in the treatment of insulin resistance

INVENTOR(S): Kurthy, Maria; Biro, Katalin; Nagy, Karoly; Urogi, Laszlo; Csakai, Zita; Szilbereky, Jeno; Mogyorosi, Tamas; Torok, Magdolna; Komaromi, Andras; Marvanyos, Ede; Barabas, Mihaly; Kardos, Mihalyne; Nagy, Zoltan; Koranyi, Laszlo; Nagy, Melinda

PATENT ASSIGNEE(S): Biorex Kutato Es Fejleszt Rt., Hung.

SOURCE: PCT Int. Appl., 36 pp.

CODEN: PIXXD2

DOCUMENT TYPE: Patent

LANGUAGE: English

FAMILY ACC. NUM. COUNT: 1

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2000050403	A1	20000831	WO 2000-HU15	20000224
W: AU, BG, BR, CA, CZ, EE, HR, IL, IN, JP, KR, LT, LV, NO, PL, RO, RU, SI, SK, UA, US, YU, ZA				
RW: AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE				
CA 2360451	A1	20000831	CA 2000-2360451	20000224
BR 2000008969	A	20011127	BR 2000-8969	20000224
EP 1163224	A1	20011219	EP 2000-909542	20000224
EP 1163224	B1	20030416		
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO				
JP 2002537384	T	20021105	JP 2000-600986	20000224
EE 200100447	A	20021216	EE 2001-447	20000224
EE 4961	B1	20080215		
AT 237590	T	20030515	AT 2000-909542	20000224
ES 2193055	T3	20031101	ES 2000-909542	20000224
AU 779096	B2	20050106	AU 2000-31824	20000224
RU 2250901	C2	20050427	RU 2001-126126	20000224
CZ 297386	B6	20061115	CZ 2001-3053	20000224
IL 144866	A	20070704	IL 2000-144866	20000224
PL 197692	B1	20080430	PL 2000-350915	20000224
IN 2001KN00785	A	20050311	IN 2001-KN785	20010731
ZA 2001006488	A	20020807	ZA 2001-6488	20010807
HR 2001000584	A1	20020831	HR 2001-584	20010807
BG 105837	A	20020329	BG 2001-105837	20010822
BG 65178	B1	20070531		
NO 2001004103	A	20011022	NO 2001-4103	20010823

NO 319793	B1	20050912		
US 6649628	B1	20031118	US 2001-913263	20011218
PRIORITY APPLN. INFO.:			HU 1999-475	A 19990226
			WO 2000-HU15	W 20000224

AB N-[2-hydroxy-3-(1-piperidinyl)propoxy]pyridine-1-oxide-3-carboximidoyl chloride, its stereoisomers, and their acid addition salts, useful in treatment of pathol. insulin resistance, and for the treatment of pathol. conditions associated therewith, for the treatment of pathol. insulin resistance, were prepared

OS.CITING REF COUNT: 5 THERE ARE 5 CAPLUS RECORDS THAT CITE THIS RECORD (6 CITINGS)

REFERENCE COUNT: 4 THERE ARE 4 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

=>
Connecting via Winsock to STN

Welcome to STN International! Enter x:X

LOGINID:ssptacrs1614

PASSWORD:

TERMINAL (ENTER 1, 2, 3, OR ?):2

* * * * * Welcome to STN International * * * * *

NEWS 1		Web Page for STN Seminar Schedule - N. America
NEWS 2	JAN 12	Match STN Content and Features to Your Information Needs, Quickly and Conveniently
NEWS 3	JAN 25	Annual Reload of MEDLINE database
NEWS 4	FEB 16	STN Express Maintenance Release, Version 8.4.2, Is Now Available for Download
NEWS 5	FEB 16	Derwent World Patents Index (DWPI) Revises Indexing of Author Abstracts
NEWS 6	FEB 16	New FASTA Display Formats Added to USGENE and PCTGEN
NEWS 7	FEB 16	INPADOCDB and INPAFAMDB Enriched with New Content and Features
NEWS 8	FEB 16	INSPEC Adding Its Own IPC codes and Author's E-mail Addresses
NEWS 9	APR 02	CAS Registry Number Crossover Limits Increased to 500,000 in Key STN Databases
NEWS 10	APR 02	PATDPAFULL: Application and priority number formats enhanced
NEWS 11	APR 02	DWPI: New display format ALLSTR available
NEWS 12	APR 02	New Thesaurus Added to Derwent Databases for Smooth Sailing through U.S. Patent Codes
NEWS 13	APR 02	EMBASE Adds Unique Records from MEDLINE, Expanding Coverage back to 1948
NEWS 14	APR 07	CA/Caplus CLASS Display Streamlined with Removal of Pre-IPC 8 Data Fields
NEWS 15	APR 07	50,000 World Traditional Medicine (WTM) Patents Now Available in Caplus
NEWS 16	APR 07	MEDLINE Coverage Is Extended Back to 1947

NEWS EXPRESS FEBRUARY 15 10 CURRENT WINDOWS VERSION IS V8.4.2,
AND CURRENT DISCOVER FILE IS DATED 15 JANUARY 2010.

NEWS HOURS STN Operating Hours Plus Help Desk Availability
NEWS LOGIN Welcome Banner and News Items

Enter NEWS followed by the item number or name to see news on that specific topic.

All use of STN is subject to the provisions of the STN customer agreement. This agreement limits use to scientific research. Use for software development or design, implementation of commercial gateways, or use of CAS and STN data in the building of commercial products is prohibited and may result in loss of user privileges and other penalties.

* * * * * STN Columbus * * * * *

FILE 'HOME' ENTERED AT 10:17:48 ON 04 MAY 2010

=> e arimoclomol
THIS COMMAND NOT AVAILABLE IN THE CURRENT FILE
The EXPAND command is used to look at the index in a file which has an index. This file does not have an index.

=> file registry	SINCE FILE	TOTAL
COST IN U.S. DOLLARS	ENTRY	SESSION
FULL ESTIMATED COST	0.22	0.22

FILE 'REGISTRY' ENTERED AT 10:18:14 ON 04 MAY 2010
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.
COPYRIGHT (C) 2010 American Chemical Society (ACS)

Property values tagged with IC are from the ZIC/VINITI data file provided by InfoChem.

STRUCTURE FILE UPDATES: 3 MAY 2010 HIGHEST RN 1221227-20-8
DICTIONARY FILE UPDATES: 3 MAY 2010 HIGHEST RN 1221227-20-8

New CAS Information Use Policies, enter HELP USAGETERMS for details.

TSCA INFORMATION NOW CURRENT THROUGH January 8, 2010.

Please note that search-term pricing does apply when conducting SmartSELECT searches.

REGISTRY includes numerically searchable data for experimental and predicted properties as well as tags indicating availability of experimental property data in the original document. For information on property searching in REGISTRY, refer to:

<http://www.cas.org/support/stngen/stdoc/properties.html>

=> e arimoclomol
E1 1 ARIMIDS/BI
E2 1 ARIMOCLOM/BI
E3 1 --> ARIMOCLOMOL/BI
E4 2 ARIMOL/BI
E5 2 ARIMOSA/BI
E6 1 ARIMOTO/BI
E7 151 ARIN/BI
E8 17 ARINA/BI
E9 18 ARINAE/BI

E10 1 ARINAMINE/BI
 E11 4 ARINATE/BI
 E12 56 ARINE/BI

=> s e3

L1 1 ARIMOCLOMOL/BI

=> d l1

L1 ANSWER 1 OF 1 REGISTRY COPYRIGHT 2010 ACS on STN

RN 289893-25-0 REGISTRY

ED Entered STN: 21 Sep 2000

CN 3-Pyridinecarboximidoyl chloride, N-[(2R)-2-hydroxy-3-(1-piperidinyl)propoxy]-, 1-oxide (CA INDEX NAME)

OTHER NAMES:

CN Arimoclomol

FS STEREOSEARCH

MF C14 H20 Cl N3 O3

CI COM


SR CA

LC STN Files: ADISINSIGHT, CA, CAPLUS, CBNB, CHEMCATS, EMBASE, IMSDRUGNEWS, IMSRESEARCH, MRCK*, PROUSDDR, SYNTHLINE, TOXCENTER, USAN, USPAT2, USPATFULL

(*File contains numerically searchable property data)

Absolute stereochemistry.

Double bond geometry unknown.



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

20 REFERENCES IN FILE CA (1907 TO DATE)
 2 REFERENCES TO NON-SPECIFIC DERIVATIVES IN FILE CA
 20 REFERENCES IN FILE CAPLUS (1907 TO DATE)

=> file caplus

COST IN U.S. DOLLARS

SINCE FILE

TOTAL

ENTRY

SESSION

FULL ESTIMATED COST

8.09

8.31

FILE 'CAPLUS' ENTERED AT 10:18:35 ON 04 MAY 2010

USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.

PLEASE SEE "HELP USAGETERMS" FOR DETAILS.

COPYRIGHT (C) 2010 AMERICAN CHEMICAL SOCIETY (ACS)

Copyright of the articles to which records in this database refer is held by the publishers listed in the PUBLISHER (PB) field (available for records published or updated in Chemical Abstracts after December 26, 1996), unless otherwise indicated in the original publications. The CA Lexicon is the copyrighted intellectual property of the American Chemical Society and is provided to assist you in searching

databases on STN. Any dissemination, distribution, copying, or storing of this information, without the prior written consent of CAS, is strictly prohibited.

FILE COVERS 1907 - 4 May 2010 VOL 152 ISS 19
FILE LAST UPDATED: 3 May 2010 (20100503/ED)
REVISED CLASS FIELDS (/NCL) LAST RELOADED: Feb 2010
USPTO MANUAL OF CLASSIFICATIONS THESAURUS ISSUE DATE: Feb 2010

CAPLUS now includes complete International Patent Classification (IPC) reclassification data for the first quarter of 2010.

CAS Information Use Policies apply and are available at:

<http://www.cas.org/legal/infopolicy.html>

This file contains CAS Registry Numbers for easy and accurate substance identification.

=> s 11
L2 20 L1

=> d 12 ibib abs

L2 ANSWER 1 OF 20 CAPLUS COPYRIGHT 2010 ACS on STN
ACCESSION NUMBER: 2010:238350 CAPLUS
DOCUMENT NUMBER: 152:304131
TITLE: Compositions and methods of using (R)-pramipexole in combination with other agents for the treatment of neurodegenerative diseases
INVENTOR(S): Bozik, Michael; Gribkoff, Valentin
PATENT ASSIGNEE(S): Knopp Neurosciences, Inc., USA
SOURCE: PCT Int. Appl., 118pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2010022140	A1	20100225	WO 2009-US54292	20090819
W: AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LT, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PE, PG, PH, PL, PT, RO, RS, RU, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW				
RW: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, SE, SI, SK, SM, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG, BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
PRIORITY APPLN. INFO.:			US 2008-90094P P 20080819 US 2008-113680P P 20081112	
AB	Pharmaceutical compns. of (R)-pramipexole (preparation included) and one or more secondary therapeutic agents, e.g. dopamine agonists, dopaminergic agonists, COMT inhibitors, MOA inhibitors, excitatory amino acid antagonists, growth factors, neurotrophic factors, antioxidants, antiinflammatory agents, immunomodulators, antilglutamatergics, ion channel blockers, α -amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid			

(AMPA) receptor antagonists, heat shock protein inducers/protein disaggregators and downregulators, monoamine oxidase type B (MOAB) inhibitors, multi-target agents, kinase inhibitors, Bcl inducers, histone deacetylase (HDAC) mediators, glial modulators, mitochondrial energy promoting agents, myostatin inhibitors, caspase inhibitors and combinations thereof, or those related to mitochondrial dysfunction or increased oxidative stress, are disclosed. The comps. and methods of the invention may be used to treat a neurodegenerative disease in a patient.

REFERENCE COUNT: 9 THERE ARE 9 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

=> d 12 ibib abs 2-20

L2 ANSWER 2 OF 20 CAPLUS COPYRIGHT 2010 ACS on STN

ACCESSION NUMBER: 2009:1617712 CAPLUS

DOCUMENT NUMBER: 152:111720

TITLE: Use of Hsp70 as a regulator of enzymatic activity, and treatment of lysosomal storage diseases

INVENTOR(S): Jensen, Thomas Kirkegaard; Jaattela, Marja Helena

PATENT ASSIGNEE(S): Orphazyme Aps, Den.

SOURCE: PCT Int. Appl., 169pp.

CODEN: PIXXD2

DOCUMENT TYPE: Patent

LANGUAGE: English

FAMILY ACC. NUM. COUNT: 1

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2009155936	A1	20091230	WO 2009-DK50151	20090626
W:	AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LT, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PE, PG, PH, PL, PT, RO, RS, RU, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW			
RW:	AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG, BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM			

PRIORITY APPLN. INFO.: DK 2008-885 A 20080626

AB The invention discloses a method for modulating the enzymic activity of an enzyme, wherein the enzyme interacts with BMP [bis(monoacylglycerol)phosphate], the method comprising administering or inducing Hsp70, or a functional fragment or variant thereof, in a form suitable for allowing interaction between BMP and Hsp70, or the functional fragment or variant thereof, and thereby modulating the enzymic activity of an enzyme interacting with BMP. The method of the invention may be used in the treatment of lysosomal storage disorders.

REFERENCE COUNT: 7 THERE ARE 7 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L2 ANSWER 3 OF 20 CAPLUS COPYRIGHT 2010 ACS on STN

ACCESSION NUMBER: 2009:1472488 CAPLUS

DOCUMENT NUMBER: 152:110625

TITLE: Arimoclomol: a potential therapy under development for ALS

AUTHOR(S): Lanka, Veena; Wieland, Scott; Barber, Jack; Cudkowicz, Merit

CORPORATE SOURCE: Neurology Clinical Trial Unit, Charlestown, MA, 02129, USA
 SOURCE: Expert Opinion on Investigational Drugs (2009), 18(12), 1907-1918
 CODEN: EOIDER; ISSN: 1354-3784
 PUBLISHER: Informa Healthcare
 DOCUMENT TYPE: Journal; General Review
 LANGUAGE: English

AB A review. Arimoclomol, an amplifier of heat shock protein expression involved in cellular stress response, has emerged as a potential therapeutic candidate in amyotrophic lateral sclerosis (ALS) in recent years. Treatment with arimoclomol was reported to improve survival and muscle function in a mouse model of motor neuron disease. Several single- and multiple-dose safety studies have been completed in healthy control subjects. A 3-mo Phase IIa study in people with ALS demonstrated safety at dosages up to 300 mg/day and another study is currently recruiting participants with familial ALS caused by mutations in the superoxide dismutase gene. We review the rationale for testing arimoclomol in sporadic and familial ALS in the context of available safety and pharmacokinetic data. Published and unpublished literature relative to the drug in the past two decades is discussed. The current review attempts to bring together our existing understanding of the actions of arimoclomol with the disease profile of ALS. The pharmacol. profile of arimoclomol and the available preclin. data make it a promising therapeutic possibility in ALS.

REFERENCE COUNT: 86 THERE ARE 86 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L2 ANSWER 4 OF 20 CAPLUS COPYRIGHT 2010 ACS on STN
 ACCESSION NUMBER: 2009:1139300 CAPLUS
 DOCUMENT NUMBER: 151:350861
 TITLE: Use of hydroxylamine derivatives in stroke recovery
 INVENTOR(S): Barber, Jack R.
 PATENT ASSIGNEE(S): Cytrx Corporation, USA
 SOURCE: U.S. Pat. Appl. Publ., 48 pp., Cont.-in-part of Appl. No. PCT/US2007/024711.
 CODEN: USXXCO

DOCUMENT TYPE: Patent
 LANGUAGE: English
 FAMILY ACC. NUM. COUNT: 2
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
US 20090233917	A1	20090917	US 2009-381033	20090306
WO 2008070010	A2	20080612	WO 2007-US24711	20071130
WO 2008070010	A3	20080724		
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BH, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LT, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RS, RU, SC, SD, SE, SG, SK, SL, SM, SV, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW				
RW: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, LV, MC, MT, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GO, GW, ML, MR, NE, SN, TD, TG, BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AP, EA, EP, OA				

PRIORITY APPLN. INFO.:
 US 2006-872329P P 20061201
 US 2007-920396P P 20070327
 US 2007-993848P P 20070914

ASSIGNMENT HISTORY FOR US PATENT AVAILABLE IN LSUS DISPLAY FORMAT

OTHER SOURCE(S): MARPAT 151:350861

AB The invention provides methods for treating stroke, comprising administering an effective amount of one or more of certain hydroxylamine derivs. to a subject in need thereof. The invention also provides pharmaceutical compns. comprising a certain hydroxylamine derivative or a pharmaceutically acceptable salt thereof, optionally in combination with one or more addnl. therapeutic agents. In certain compns., the addnl. therapeutic agent is a second hydroxylamine derivative or a pharmaceutically acceptable salt thereof.

L2 ANSWER 5 OF 20 CAPLUS COPYRIGHT 2010 ACS ON STN

ACCESSION NUMBER: 2009:1108506 CAPLUS

DOCUMENT NUMBER: 151:344649

TITLE: Treatment of diabetic wounds and peripheral neuropathies

INVENTOR(S): Barber, Jack R.; Ng, Shi Chung

PATENT ASSIGNEE(S): CytRx Corp., USA

SOURCE: U.S. Pat. Appl. Publ., 47pp., Cont.-in-part of Appl.

No. PCT/US2008/005794.

CODEN: USXXCO

DOCUMENT TYPE: Patent

LANGUAGE: English

FAMILY ACC. NUM. COUNT: 2

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
US 20090227572	A1	20090910	US 2009-405915	20090317
WO 2008137149	A1	20081113	WO 2008-US5794	20080505
W: AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LT, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RS, RU, SC, SD, SE, SG, SK, SL, SM, SV, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW RW: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MT, NL, NO, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, ML, MR, NE, SN, TD, TG, BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				

PRIORITY APPLN. INFO.: US 2007-927603P P 20070504

WO 2008-US5794 A2 20080505

ASSIGNMENT HISTORY FOR US PATENT AVAILABLE IN LSUS DISPLAY FORMAT

OTHER SOURCE(S): MARPAT 151:344649

AB The present invention provides methods of enhancing healing of wound associated with diabetes, comprising administering an effective amount of one or more of certain hydroxylamine derivs. to a subject in need thereof. In another aspect, the instant invention provides methods of treating or preventing peripheral nervous system neuropathies. Peripheral nervous system neuropathies may but need not be diabetic neuropathies, and may but need not be associated with a diabetic wound. The invention also provides pharmaceutical compns. comprising a certain hydroxylamine derivative or a pharmaceutically acceptable salt thereof, optionally in combination with one or more addnl. therapeutic agents. In certain compns. and methods, the addnl. therapeutic agent is a second hydroxylamine derivative or a pharmaceutically acceptable salt thereof.

L2 ANSWER 6 OF 20 CAPLUS COPYRIGHT 2010 ACS ON STN

ACCESSION NUMBER: 2009:1044258 CAPLUS

DOCUMENT NUMBER: 151:297806
 TITLE: Methods and compositions for the treatment of disorders associated with defects of the cystic fibrosis transmembrane conductance regulator gene or protein
 INVENTOR(S): Lin, Stephen; Staunton, Jane; Sui, Jinliang
 PATENT ASSIGNEE(S): Combinatorx, Incorporated, USA
 SOURCE: PCT Int. Appl., 108pp.
 CODEN: PIXXD2
 DOCUMENT TYPE: Patent
 LANGUAGE: English
 FAMILY ACC. NUM. COUNT: 1
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2009105234	A2	20090827	WO 2009-US1061	20090219
WO 2009105234	A3	20091112		

W: AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LT, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RS, RU, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW
 RW: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LI, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG, BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AP, EA, EP, OA

PRIORITY APPLN. INFO.: US 2008-66259P P 20080219
 AB The present invention features compns., methods, and kits for treating, or ameliorating disorders associated with a defect in the cystic fibrosis transmembrane conductance regulator (CFTR) gene or protein (e.g., cystic fibrosis).

L2 ANSWER 7 OF 20 CAPLUS COPYRIGHT 2010 ACS on STN

ACCESSION NUMBER: 2009:335388 CAPLUS

DOCUMENT NUMBER: 150:322735

TITLE: Method of treating binge eating disorder, obesity resulting from binge eating behavior and depressive disorders

INVENTOR(S): Sanfilippo, Louis C.

PATENT ASSIGNEE(S): Lcs Group, LLC, USA; Sanfilippo, Louis, C.

SOURCE: PCT Int. Appl., 45 pp.

CODEN: PIXXD2

DOCUMENT TYPE: Patent

LANGUAGE: English

FAMILY ACC. NUM. COUNT: 1

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2009035473	A2	20090319	WO 2008-US1002	20080124
WO 2009035473	A3	20091203		

W: AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LT, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RS, RU, SC, SD, SE, SG, SK, SL, SM, SV, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW

RW: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU,
 IE, IS, IT, LT, LU, LV, MC, MT, NL, NO, PL, PT, RO, SE, SI, SK,
 TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD,
 TG, BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW,
 AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AP, EA, EP, OA

PRIORITY APPLN. INFO.: US 2007-972046P P 20070913

AB The invention provides methods of treating binge eating disorders, obesity resulting from binge eating behavior, and depression. The invention includes methods of treating certain co-morbidities in ADHD and ADD patients; for example the invention includes methods of treating generalized anxiety disorder, obsessional and ruminative thought disorders, and obsessive/ compulsive behavior in ADHD and ADD patients. The invention also includes combination methods of treatment in which an amphetamine prodrug, methylphenidate prodrug, or methylphenidate analog is administered with one or more other active agents. Packaged pharmaceutical comps. containing an amphetamine or methylphenidate prodrug, instructions for using the prodrug to treat certain disorders, and optionally one or more other active agents are provided by the invention.

L2 ANSWER 8 OF 20 CAPLUS COPYRIGHT 2010 ACS on STN

ACCESSION NUMBER: 2008:1364025 CAPLUS

DOCUMENT NUMBER: 149:548966

TITLE: Methods for enhancing diabetic wound healing with hydroxylamine derivs.

INVENTOR(S): Barber, Jack R.

PATENT ASSIGNEE(S): CytRx Corp., USA

SOURCE: PCT Int. Appl., 84 pp.

CODEN: PIXXD2

DOCUMENT TYPE: Patent

LANGUAGE: English

FAMILY ACC. NUM. COUNT: 2

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2008137149	A1	20081113	WO 2008-US5794	20080505
W: AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LT, LU, LY, MA, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RS, RU, SC, SD, SE, SG, SK, SL, SM, SV, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW				
RW: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MT, NL, NO, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG, BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
AU 2008248139	A1	20081113	AU 2008-248139	20080505
CA 2686063	A1	20081113	CA 2008-2686063	20080505
EP 2152257	A1	20100217	EP 2008-767586	20080505
R: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LI, LT, LU, LV, MC, MT, NL, NO, PL, PT, RO, SE, SI, SK, TR, AL, BA, MK, RS				
US 20090227572	A1	20090910	US 2009-405915	20090317
MX 2009011900	A	20100120	MX 2009-11900	20091103
IN 2009KN03994	A	20100305	IN 2009-KN3994	20091118
PRIORITY APPLN. INFO.:			US 2007-927603P	P 20070504
			WO 2008-US5794	W 20080505

ASSIGNMENT HISTORY FOR US PATENT AVAILABLE IN LSUS DISPLAY FORMAT

OTHER SOURCE(S): MARPAT 149:548966

AB The invention provides methods of enhancing healing of wound associated with

diabetes, comprising administering an effective amount of one or more of certain hydroxylamine derivs. to a subject in need thereof. The invention also provides pharmaceutical compns. comprising a certain hydroxylamine derivative or a pharmaceutically acceptable salt thereof, optionally in combination with one or more addnl. therapeutic agents. In certain compns. and methods, the addnl. therapeutic agent is a second hydroxylamine derivative or a pharmaceutically acceptable salt thereof.

REFERENCE COUNT: 6 THERE ARE 6 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L2 ANSWER 9 OF 20 CAPLUS COPYRIGHT 2010 ACS on STN
 ACCESSION NUMBER: 2008:1337969 CAPLUS
 DOCUMENT NUMBER: 149:525459
 TITLE: Methods and compositions for the treatment of neurodegenerative disorders
 INVENTOR(S): Jin, Xiaowei; Staunton, Jane; Macdonald, Douglas; Dong, Hualing; Kifle, Lydia
 PATENT ASSIGNEE(S): Combinatorx, Incorporated, USA; CHDI, Inc.
 SOURCE: PCT Int. Appl., 123pp.
 CODEN: PIXXD2
 DOCUMENT TYPE: Patent
 LANGUAGE: English
 FAMILY ACC. NUM. COUNT: 1
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2008133884	AZ	20081106	WO 2008-US5194	20080423
W:	AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LT, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RS, RU, SC, SD, SE, SG, SK, SL, SM, SV, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW			
RW:	AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MT, NL, NO, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG, BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM			

PRIORITY APPLN. INFO.: US 2007-925753P P 20070423
 US 2007-958774P P 20070709
 AB The invention provides compns., kits, methods, and combinations of agents for treating, preventing, and ameliorating neurodegenerative disorders, e.g., Huntington's disease.
 OS.CITING REF COUNT: 3 THERE ARE 3 CAPLUS RECORDS THAT CITE THIS RECORD (3 CITINGS)

L2 ANSWER 10 OF 20 CAPLUS COPYRIGHT 2010 ACS on STN
 ACCESSION NUMBER: 2008:1320737 CAPLUS
 DOCUMENT NUMBER: 149:548757
 TITLE: Late stage treatment with arimoclomol delays disease progression and prevents protein aggregation in the SOD1G93A mouse model of ALS
 AUTHOR(S): Kalmar, Bernadett; Novoselov, Sergey; Gray, Anna; Cheetham, Michael E.; Margulis, Boris; Greensmith, Linda
 CORPORATE SOURCE: Institute of Neurology, University College London, London, UK
 SOURCE: Journal of Neurochemistry (2008), 107(2), 339-350
 CODEN: JONRA9; ISSN: 0022-3042
 PUBLISHER: Wiley-Blackwell

DOCUMENT TYPE: Journal
LANGUAGE: English

AB Amyotrophic lateral sclerosis (ALS) is a progressive neurodegenerative disorder characterized by motoneuron degeneration, resulting in muscle paralysis and death, typically within 1-5 years of diagnosis. Although the pathogenesis of ALS remains unclear, there is evidence for the involvement of proteasome dysfunction and heat shock proteins in the disease. We have previously shown that treatment with a co-inducer of the heat shock response called arimoclomol is effective in the SODG93A mouse model of ALS, delaying disease progression and extending the lifespan of SODG93A mice. However, this previous study only examined the effects of arimoclomol when treatment was initiated in pre- or early symptomatic stages of the disease. Clearly, to be of benefit to the majority of ALS patients, any therapy must be effective after symptom onset. In order to establish whether post-symptomatic treatment with arimoclomol is effective, in this study we carried out a systematic assessment of different treatment regimes in SODG93A mice. Treatment with arimoclomol from early (75 days) or late (90 days) symptomatic stages significantly improved muscle function. Treatment from 75 days also significantly increased the lifespan of SODG93A mice, although treatment from 90 days has no significant effect on lifespan. The mechanism of action of arimoclomol involves potentiation of the heat shock response, and treatment with arimoclomol increased Hsp70 expression. Interestingly, this up-regulation in Hsp70 was accompanied by a decrease in the number of ubiquitin-pos. aggregates in the spinal cord of treated SODG93A mice, suggesting that arimoclomol directly effects protein aggregation and degradation

OS.CITING REF COUNT: 6 THERE ARE 6 CAPLUS RECORDS THAT CITE THIS RECORD (6 CITINGS)

REFERENCE COUNT: 34 THERE ARE 34 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L2 ANSWER 11 OF 20 CAPLUS COPYRIGHT 2010 ACS on STN

ACCESSION NUMBER: 2008:918262 CAPLUS

DOCUMENT NUMBER: 149:258394

TITLE: Arimoclomol at dosages up to 300 Mg/day is well tolerated and safe in amyotrophic lateral sclerosis
AUTHOR(S): Cudkovicz, Merit E.; Shefner, Jeremy M.; Simpson, Elizabeth; Grasso, Daniela; Yu, Hong; Zhang, Hui; Shui, Amy; Schoenfeld, David; Brown, Robert H.; Wieland, Scott; Barber, Jack R.

CORPORATE SOURCE: NORTHEAST ALS CONSORTIUM, Neurology Clinical Trials Unit, Massachusetts General Hospital, Charlestown, MA, 02129, USA

SOURCE: Muscle & Nerve (2008), 38(1), 837-844

CODEN: MUNEDJ; ISSN: 0148-639X

PUBLISHER: John Wiley & Sons, Inc.

DOCUMENT TYPE: Journal

LANGUAGE: English

AB Arimoclomol is an investigational drug for amyotrophic lateral sclerosis (ALS) that amplifies heat shock protein gene expression during cell stress. The objectives of the present study were to assess the safety, tolerability, and pharmacokinetics of arimoclomol in ALS. Eighty-four participants with ALS received arimoclomol at one of three oral doses (25, 50, or 100 mg three times daily) or placebo. The primary outcome measure was safety and tolerability. A subset of 44 participants provided serum and cerebrospinal fluid (CSF) samples for pharmacokinetic anal. Participants who completed 12 wk of treatment could enroll in a 6-mo open-label study. Arimoclomol at doses up to 300 mg/day was well tolerated and safe. Arimoclomol resulted in dose-linear pharmacol. exposures and the half-life did not change with continued treatment. Arimoclomol CSF levels increased with dose. Arimoclomol was shown to be

safe, and it crosses the blood-brain barrier. Serum pharmacokinetic profiles support dosing of three times per day. An efficacy study in ALS is planned.

OS.CITING REF COUNT: 6 THERE ARE 6 CAPLUS RECORDS THAT CITE THIS RECORD (6 CITINGS)
REFERENCE COUNT: 27 THERE ARE 27 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L2 ANSWER 12 OF 20 CAPLUS COPYRIGHT 2010 ACS on STN
ACCESSION NUMBER: 2008:699886 CAPLUS
DOCUMENT NUMBER: 149:45258
TITLE: Treatment of stroke using hydroxylamine derivatives
INVENTOR(S): Barber, Jack R.
PATENT ASSIGNEE(S): Cytrx Corporation, USA
SOURCE: PCT Int. Appl., 84pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 2
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2008070010	A2	20080612	WO 2007-US24711	20071130
WO 2008070010	A3	20080724		
W:	AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BH, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LT, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RS, RU, SC, SD, SE, SG, SK, SL, SM, SV, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW			
RW:	AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, LV, MC, MT, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG, BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AP, EA, EP, OA			
AU 2007328280	A1	20080612	AU 2007-328280	20071130
CA 2671049	A1	20080612	CA 2007-2671049	20071130
EP 2089033	A2	20090819	EP 2007-862419	20071130
R:	AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LI, LT, LU, LV, MC, MT, NL, PL, PT, RO, SE, SI, SK, TR			
JP 2010511622	T	20100415	JP 2009-539359	20071130
US 20090233917	A1	20090917	US 2009-381033	20090306
MX 2009005798	A	20090812	MX 2009-5798	20090601
IN 2009KN02136	A	20090626	IN 2009-KN2136	20090605
CN 101600434	A	20091209	CN 2007-80050594	20090729
PRIORITY APPLN. INFO.:			US 2006-872329P	P 20061201
			US 2007-920396P	P 20070327
			US 2007-993848P	P 20070914
			WO 2007-US24711	W 20071130

ASSIGNMENT HISTORY FOR US PATENT AVAILABLE IN LSUS DISPLAY FORMAT

OTHER SOURCE(S): MARPAT 149:45258

AB The present invention provides methods of treating stroke comprising administering an effective amount of one or more of certain hydroxylamine derivs. to a subject in need thereof. The invention also provides pharmaceutical compns. comprising a certain hydroxylamine derivative or a pharmaceutically acceptable salt thereof, optionally in combination with one or more addnl. therapeutic agents. In certain compns., the addnl. therapeutic agent is a second hydroxylamine derivative or a pharmaceutically acceptable salt thereof.

L2 ANSWER 13 OF 20 CAPLUS COPYRIGHT 2010 ACS on STN

ACCESSION NUMBER: 2008:223578 CAPLUS

DOCUMENT NUMBER: 148:269430

TITLE: Methods and compositions for the treatment of neurodegenerative disorders such as Huntington's disease

INVENTOR(S): Jin, Xiaowei; Wilson, Amy Beth; Staunton, Jane; MacDonald, Douglas

PATENT ASSIGNEE(S): CombinatoRx, Incorporated, USA; CHDI, Inc.

SOURCE: PCT Int. Appl., 12/ pp.

CODEN: PIXXD2

DOCUMENT TYPE: Patent

LANGUAGE: English

FAMILY ACC. NUM. COUNT: 1

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2008021210	A2	20080221	WO 2007-US17751	20070810
WO 2008021210	A3	20081030		
W:	AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BH, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LT, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RS, RU, SC, SD, SE, SG, SK, SL, SM, SV, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW			
RW:	AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, LV, MC, MT, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG, BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AP, EA, EP, OA			
US 20080044390	A1	20080221	US 2007-891552	20070810
PRIORITY APPLN. INFO.:			US 2006-837448P	P 20060811
			US 2007-898479P	P 20070131
			US 2007-925777P	P 20070423
			US 2007-958832P	P 20070709

ASSIGNMENT HISTORY FOR US PATENT AVAILABLE IN LSUS DISPLAY FORMAT

AB The present invention features comps., kits, and methods for treating, preventing, and ameliorating neurodegenerative disorders, e.g., Huntington's disease (HD). Screening methods for identifying candidate comps. that treat, prevent, or ameliorate neurodegenerative disorders, e.g., HD, are provided. Thus, N-terminal fragment of Htt has been shown to form protein aggregates in the nucleus, cytoplasm and processes of neurons in human HD patients and in HD animal models, as well as in many cellular models. Because of their similarities to neurons, rat pheochromocytoma PC12 cells have provided a useful model for studying neuronal cell biol.; in addition, PC12 cells are readily transfected, selected and cloned. In order to perform screening according to a method of the present invention, PC12 cells were obtained that stably incorporated a plasmid that inducibly expresses a toxic expanded polyglutamine (103 glutamine) form of exon 1 of Htt, fused to the marker EGFP. Using the engineered PC12/HttN90Q103 cell line, a high throughput assay to screen small mol.s. for their ability to prevent mutant Htt exon 1-induced cell death was developed and optimized.

OS.CITING REF COUNT: 1 THERE ARE 1 CAPLUS RECORDS THAT CITE THIS RECORD (1 CITINGS)

L2 ANSWER 14 OF 20 CAPLUS COPYRIGHT 2010 ACS on STN

ACCESSION NUMBER: 2007:1424894 CAPLUS

DOCUMENT NUMBER: 148:492092

TITLE: Heat shock proteins and protection of the nervous

system
 AUTHOR(S): Brown, Ian R.
 CORPORATE SOURCE: Center for the Neurobiology of Stress, University of
 Toronto at Scarborough, Toronto, ON, Can.
 SOURCE: Annals of the New York Academy of Sciences (2007),
 1113(Stress Responses in Biology and Medicine),
 147-158
 CODEN: ANYAA9; ISSN: 0077-8923
 PUBLISHER: Blackwell Publishing, Inc.
 DOCUMENT TYPE: Journal; General Review
 LANGUAGE: English
 AB A review. Manipulation of the cellular stress response offers strategies
 to protect brain cells from damage induced by ischemia and
 neurodegenerative diseases. Overexpression of Hsp70 reduced ischemic
 injury in the mammalian brain. Investigation of the domains within Hsp70
 that confers ischemic neuroprotection revealed the importance of the
 carboxyl-terminal domain. Arimoclomol, a coinducer of heat shock
 proteins, delayed progression of amyotrophic lateral sclerosis (ALS) in a
 mouse model in which motor neurons in the spinal cord and motor cortex
 degenerate. Celastrol, a promising candidate as an agent to counter
 neurodegenerative diseases, induced expression of a set of Hsps in
 differentiated neurons grown in tissue culture. Heat shock
 "preconditioning" protected the nervous system at the functional level of
 the synapse and selective overexpression of Hsp70 enhanced the level of
 synaptic protection. Following hyperthermia, constitutively expressed
 Hsc70 increased in synapse-rich areas of the brain where it assoc. with
 Hsp40 to form a complex that can refold denatured proteins. Stress
 tolerance in neurons is not solely dependent on their own Hsps but can be
 supplemented by Hsps from adjacent glial cells. Hence, application of
 exogenous Hsps at neural injury sites is an effective strategy to maintain
 neuronal viability.
 OS.CITING REF COUNT: 20 THERE ARE 20 CAPLUS RECORDS THAT CITE THIS
 RECORD (20 CITINGS)
 REFERENCE COUNT: 72 THERE ARE 72 CITED REFERENCES AVAILABLE FOR THIS
 RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT
 L2 ANSWER 15 OF 20 CAPLUS COPYRIGHT 2010 ACS on STN
 ACCESSION NUMBER: 2007:1278300 CAPLUS
 DOCUMENT NUMBER: 148:93263
 TITLE: Pharmaceutical composition affecting neuronal nitric
 oxide synthase containing bimoclomol or arimoclomol
 INVENTOR(S): Laszlo, Lajos
 PATENT ASSIGNEE(S): Hung.
 SOURCE: Hung. Pat. Appl., 19pp.
 CODEN: HUXXCV
 DOCUMENT TYPE: Patent
 LANGUAGE: Hungarian
 FAMILY ACC. NUM. COUNT: 1
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
-----	----	-----	-----	-----
HU 2005000755	A2	20070529	HU 2005-755	20050809
HU 2005000755	A3	20080328		
PRIORITY APPLN. INFO.:			HU 2005-755	20050809

AB The subject of the invention is the general formula

$$\text{Ar}-\text{C}(\text{X})=\text{N}-\text{O}-\text{CH}_2-\text{CH}(\text{OH})-\text{CH}_2-\text{NR}_1\text{R}_2$$
 compound where Ar represents a Ph group,
 naphthyl group or pyridyl group, X represents a halogen atom, R1 and R2,
 together with the neighboring nitrogen atom form a 5-7 member saturated
 heterocyclic group, or the use of its N-oxide or of their pharmaceutically
 appropriate salts in the preparation of a pharmaceutical composition that
 restores

and/or enhances the function of the neuronal nitric oxide synthase enzyme or that is suitable to treat irregularities in the mouth cavity.

L2 ANSWER 16 OF 20 CAPLUS COPYRIGHT 2010 ACS on STN

ACCESSION NUMBER: 2006:598700 CAPLUS

DOCUMENT NUMBER: 145:499471

TITLE: Neuroprotective agents for clinical trials in ALS

AUTHOR(S): Traynor, B. J.; Bruijn, L.; Conwit, R.; Beal, F.;

O'Neill, G.; Fagan, S. C.; Cudkowicz, M. E.

CORPORATE SOURCE: Neurology Clinical Trials Unit, Department of Neurology, Massachusetts General Hospital, Boston, MA, USA

SOURCE: Neurology (2006), 67(1), 20-27

CODEN: NEURAI; ISSN: 0028-3878

PUBLISHER: Lippincott Williams & Wilkins

DOCUMENT TYPE: Journal; General Review

LANGUAGE: English

AB A review. Background: Riluzole is currently the only Food and Drug Administration-approved treatment for ALS, but its effect on survival is modest. Objective: To identify potential neuroprotective agents for testing in phase III clin. trials and to outline which data need to be collected for each drug. Methods: The authors identified 113 compds. by inviting input from academic clinicians and researchers and via literature review to identify agents that have been tested in ALS animal models and in patients with ALS. The list was initially narrowed to 24 agents based on an evaluation of scientific rationale, toxicity, and efficacy in previous animal and human studies. These 24 drugs underwent more detailed pharmacol. evaluation. Results: Twenty drugs were selected as suitable for further development as treatments for patients with ALS. Talampanel and tamoxifen have completed early phase II trials and have demonstrated preliminary efficacy. Other agents (ceftriaxone, minocycline, ONO-2506, and IGF-1 polypeptide) are already in phase III trials involving large nos. of patients with ALS. Remaining agents (AEOL 10150, arimoclomol, celestrol, coenzyme Q10, copaxone, IGF-1-viral delivery, memantine, NAAALADase inhibitors, nimesulide, scriptaid, sodium phenylbutyrate, thalidomide, trehalose) require addnl. preclin. animal data, human toxicity and pharmacokinetic data including CNS penetration prior to proceeding to large scale phase III human testing. Further development of riluzole analogs should be considered. Conclusions: Several potential neuroprotective compds., representing a wide range of mechanisms, are available and merit further investigation in ALS.

OS.CITING REF COUNT: 39 THERE ARE 39 CAPLUS RECORDS THAT CITE THIS RECORD (39 CITINGS)

REFERENCE COUNT: 86 THERE ARE 86 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L2 ANSWER 17 OF 20 CAPLUS COPYRIGHT 2010 ACS on STN

ACCESSION NUMBER: 2005:409316 CAPLUS

DOCUMENT NUMBER: 142:441894

TITLE: Use of a hydroximic acid halide derivative in the treatment of neurodegenerative diseases

INVENTOR(S): Greensmith, Linda; Burnstock, Geoffrey; Urbanics, Rudolf

PATENT ASSIGNEE(S): Biorex Kutato es Fejlesztoe Rt., Hung.

SOURCE: PCT Int. Appl., 24 pp.

CODEN: PIXXD2

DOCUMENT TYPE: Patent

LANGUAGE: English

FAMILY ACC. NUM. COUNT: 1

PATENT INFORMATION:

PATENT NO.

KIND DATE

APPLICATION NO.

DATE

WO 2005041965	A1	20050512	WO 2004-HU98	20041025			
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW							
RW: BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG							
HU 20033584	A3	20091228	HU 2003-3584	20031030			
AU 2004285343	A1	20050512	AU 2004-285343	20041025			
CA 2544332	A1	20050512	CA 2004-2544332	20041025			
EP 1696922	A1	20060906	EP 2004-791657	20041025			
EP 1696922	B1	20080924					
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, PL, SK, HR							
BR 2004015625	A	20061212	BR 2004-15625	20041025			
CN 1901913	A	20070124	CN 2004-80039619	20041025			
JP 2007509920	T	20070419	JP 2006-537449	20041025			
AT 409038	T	20081015	AT 2004-791657	20041025			
PT 1696922	E	20081017	PT 2004-791657	20041025			
EP 2020233	A2	20090204	EP 2008-157425	20041025			
EP 2020233	A3	20090930					
R: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LI, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, AL, HR, LT, LV, MK							
ES 2314458	T3	20090316	ES 2004-791657	20041025			
NZ 547216	A	20090331	NZ 2004-547216	20041025			
ZA 2006004376	A	20090429	ZA 2006-4376	20041025			
MX 2006004814	A	20061211	MX 2006-4814	20060428			
NO 2006002401	A	20060727	NO 2006-2401	20060526			
IN 2006KN01464	A	20070504	IN 2006-KN1464	20060530			
HK 1097438	A1	20090612	HK 2007-102495	20070306			
US 20080039497	A1	20080214	US 2007-582124	20070510			
IN 2009KN01591	A	20090605	IN 2009-KN1591	20090428			
PRIORITY APPLN. INFO.:			HU 2003-3584	A 20031030			
			EP 2004-791657	A3 20041025			
			WO 2004-HU98	W 20041025			
			IN 2006-KN1464	A3 20060530			
AB	The invention relates to the use of a chemical substance selected from the group consisting of N-[2-hydroxy-3-(1-piperidinyl)-propoxyl]-pyridine-1-oxide-3-carboximidoyl chloride, the optically active enantiomers and the mixts. of enantiomers thereof and pharmaceutically acceptable salts of the racemic and optically active compds. in the preparation of a pharmaceutical composition for the treatment or prevention of neurodegenerative diseases.						
OS.CITING REF COUNT:	2	THERE ARE 2 CAPLUS RECORDS THAT CITE THIS RECORD (2 CITINGS)					
REFERENCE COUNT:	8	THERE ARE 8 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT					
L2 ANSWER 18 OF 20	CAPLUS COPYRIGHT 2010 ACS on STN						
ACCESSION NUMBER:	2004:263763 CAPLUS						
DOCUMENT NUMBER:	140:399884						
TITLE:	Treatment with arimoclomol, a coinducer of heat shock proteins, delays disease progression in ALS mice						
AUTHOR(S):	Kieran, Dairin; Kalmr, Bernadett; Dick, James R. T.; Riddoch-Contreras, Joanna; Burnstock, Geoffrey; Greensmith, Linda						
CORPORATE SOURCE:	The National Hospital for Neurology and Neurosurgery,						

Institute of Neurology, Sobell Department of Motor Neuroscience and Movement Disorders, The Graham Watts Laboratory, University College London, London, WC1N 3BG, UK

SOURCE: Nature Medicine (New York, NY, United States) (2004), 10(4), 402-405

CODEN: NAMEFT; ISSN: 1078-8956

PUBLISHER: Nature Publishing Group

DOCUMENT TYPE: Journal

LANGUAGE: English

AB Amyotrophic lateral sclerosis (ALS) is a fatal neurodegenerative condition in which motoneurons of the spinal cord and motor cortex die, resulting in progressive paralysis. This condition has no cure and results in eventual death, usually within 1-5 yr of diagnosis. Although the specific etiol. of ALS is unknown, 20% of familial cases of the disease carry mutations in the gene encoding Cu/Zn superoxide dismutase-1 (SOD1). Transgenic mice overexpressing human mutant SOD1 have a phenotype and pathol. that are very similar to that seen in human ALS patients. Here we show that treatment with arimoclomol, a coinducer of heat shock proteins (HSPs), significantly delays disease progression in mice expressing a SOD1 mutant in which glycine is substituted with alanine at position 93 (SOD1G93A). Arimoclomol-treated SOD1G93A mice show marked improvement in hind limb muscle function and motoneuron survival in the later stages of the disease, resulting in a 22% increase in lifespan. Pharmacol. activation of the heat shock response may therefore be a successful therapeutic approach to treating ALS, and possibly other neurodegenerative diseases.

OS.CITING REF COUNT: 149 THERE ARE 149 CAPLUS RECORDS THAT CITE THIS RECORD (149 CITINGS)

REFERENCE COUNT: 20 THERE ARE 20 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L2 ANSWER 19 OF 20 CAPLUS COPYRIGHT 2010 ACS on STN

ACCESSION NUMBER: 2001:780856 CAPLUS

DOCUMENT NUMBER: 135:318423

TITLE: Preparation of N-[2-hydroxy-3-(1-piperidinyl)propoxy]pyridine-1-oxide-3-carboxamidine, N-[2-hydroxy-3-(1-piperidinyl)propoxy]pyridine-1-oxide-3-carboximidoyl chloride, and enantiomers thereof.

INVENTOR(S): Ueroegdi, Laszlo; Jeges Csakai, Zita; Gruber, Lajos; Oetvoes, Laszlo; Toth, Jozsef; Toemeskezi, Istvan; Szakacs Schmidt, Aniko; Reider, Ferencne; Schneidern Barlay, Maria

PATENT ASSIGNEE(S): Biorex Kutato es Fejleszt, Hung.

SOURCE: PCI Int. Appl., 29 pp.

CODEN: PIXXD2

DOCUMENT TYPE: Patent

LANGUAGE: English

FAMILY ACC. NUM. COUNT: 1

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2001079174	A1	20011025	WO 2001-HU46	20010417
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW				
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF,				

BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG			
HU 2000001583	A2	20021128	HU 2000-1583 20000418
CA 2406266	A1	20011025	CA 2001-2406266 20010417
EP 1274685	A1	20030115	EP 2001-928133 20010417
EP 1274685	B1	20060712	
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT,			
IE, SI, LT, LV, FI, RO, MK, CY, AL, TR			
BR 2001010184	A	20030617	BR 2001-10184 20010417
JP 2004501080	T	20040115	JP 2001-576775 20010417
EE 200200591	A	20040415	EE 2002-591 20010417
EE 5085	B1	20081015	
NZ 522017	A	20040625	NZ 2001-522017 20010417
CN 1216868	C	20050831	CN 2001-810831 20010417
RU 2281282	C2	20060810	RU 2002-130710 20010417
AT 332894	T	20060815	AT 2001-928133 20010417
PT 1274685	E	20060929	PT 2001-928133 20010417
AU 2001254997	B2	20061123	AU 2001-254997 20010417
ES 2267758	T3	20070316	ES 2001-928133 20010417
IL 152337	A	20071031	IL 2001-152337 20010417
CZ 301576	B6	20100421	CZ 2002-3445 20010417
BG 107199	A	20030731	BG 2002-107199 20021016
HR 2002000825	A2	20041231	HR 2002-825 20021016
NO 2002005015	A	20021216	NO 2002-5015 20021018
NO 323535	B1	20070604	
ZA 2002008460	A	20031020	ZA 2002-8460 20021018
MX 2002010320	A	20040906	MX 2002-10320 20021018
IN 2002KN01301	A	20050311	IN 2002-KN1301 20021018
IN 206723	A1	20070511	
KR 742482	B1	20070725	KR 2002-714047 20021018
US 20040006232	A1	20040108	US 2003-257755 20030128
US 7126002	B2	20061024	
HK 1055741	A1	20060407	HK 2003-108135 20031110
PRIORITY APPLN. INFO.:			HU 2000-1583 A 20000418
			WO 2001-HU46 W 20010417
ASSIGNMENT HISTORY FOR US PATENT AVAILABLE IN LSUS DISPLAY FORMAT			
OTHER SOURCE(S): CASREACT 135:318423			
AB Title compds. were prepared Thus, 2-hydroxy-4-azoniaspiro[3.5]nonane chloride was stirred in aqueous NaOH for 40 min. at 5-10°; EtOH and 3-pyridinamidoxime 1-oxide (preparation given) was added and the mixture was refluxed 2 h to give 62% N-[2-hydroxy-3-(1-piperidinyl)propoxy]pyridine-1-oxide-3-carboxamidine. The latter in aqueous HCl at -5° was treated with aqueous NaNO2 followed by stirring for 1.5 h to give 85% N-[2-hydroxy-3-(1-piperidinyl)propoxy]pyridine-1-oxide-3-carboximidoyl chloride.			
OS.CITING REF COUNT:	3	THERE ARE 3 CAPLUS RECORDS THAT CITE THIS RECORD (4 CITINGS)	
REFERENCE COUNT:	4	THERE ARE 4 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT	
L2 ANSWER 20 OF 20 CAPLUS COPYRIGHT 2010 ACS on STN			
ACCESSION NUMBER:	2000:608728 CAPLUS		
DOCUMENT NUMBER:	133:207815		
TITLE:	Preparation of N-[2-hydroxy-3-(1-piperidinyl)propoxy]pyridine-1-oxide-3-carboximidoyl chloride and its use in the treatment of insulin resistance		
INVENTOR(S):	Kurthy, Maria; Biro, Katalin; Nagy, Karoly; Urogdi, Laszlo; Csakai, Zita; Szilbereky, Jenő; Mogyorosi, Tamas; Torok, Magdolna; Komaromi, Andras; Marvanyos, Ede; Barabas, Mihaly; Kardos, Mihalyne; Nagy, Zoltan; Koranyi, Laszlo; Nagy, Melinda		
PATENT ASSIGNEE(S):	Biorex Kutato Es Fejlesztő Rt., Hung.		

SOURCE: PCT Int. Appl., 36 pp.
 DOCUMENT TYPE: CODEN: PIXXD2
 LANGUAGE: Patent
 FAMILY ACC. NUM. COUNT: English
 PATENT INFORMATION: 1

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2000050403	A1	20000831	WO 2000-HU15	20000224
W: AU, BG, BR, CA, CZ, EE, HR, IL, IN, JP, KR, LT, LV, NO, PL, RO, RU, SI, SK, UA, US, YU, ZA				
RW: AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE				
CA 2360451	A1	20000831	CA 2000-2360451	20000224
BR 2000008969	A	20011127	BR 2000-8969	20000224
EP 1163224	A1	20011219	EP 2000-909542	20000224
EP 1163224	B1	20030416		
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO				
JP 2002537384	T	20021105	JP 2000-600986	20000224
EE 200100447	A	20021216	EE 2001-447	20000224
EE 4961	B1	20080215		
AT 237590	T	20030515	AT 2000-909542	20000224
PT 1163224	E	20030731	PT 2000-909542	20000224
ES 2193055	T3	20031101	ES 2000-909542	20000224
AU 779096	B2	20050106	AU 2000-31824	20000224
RU 2250901	C2	20050427	RU 2001-126126	20000224
CZ 297386	B6	20061115	CZ 2001-3053	20000224
IL 144866	A	20070704	IL 2000-144866	20000224
PL 197692	B1	20080430	PL 2000-350915	20000224
SK 287063	B6	20091007	SK 2001-1158	20000224
IN 2001KN00785	A	20050311	IN 2001-KN785	20010731
ZA 2001006488	A	20020807	ZA 2001-6488	20010807
HR 2001000584	A2	20020831	HR 2001-584	20010807
BG 105837	A	20020329	BG 2001-105837	20010822
BG 65178	B1	20070531		
NO 2001004103	A	20011022	NO 2001-4103	20010823
NO 319793	B1	20050912		
US 6649628	B1	20031118	US 2001-913263	20011218
PRIORITY APPLN. INFO.:				
HU 1999-475 A 19990226				
WO 2000-HU15 W 20000224				

ASSIGNMENT HISTORY FOR US PATENT AVAILABLE IN LSUS DISPLAY FORMAT

AB N-[2-hydroxy-3-(1-piperidinyl)propoxy]pyridine-1-oxide-3-carboximidoyl chloride, its stereoisomers, and their acid addition salts, useful in treatment of pathol. insulin resistance, and for the treatment of pathol. insulin resistance, were prepared

OS.CITING REF COUNT: 5 THERE ARE 5 CAPLUS RECORDS THAT CITE THIS RECORD (6 CITINGS)

REFERENCE COUNT: 4 THERE ARE 4 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

=> logoff

ALL L# QUERIES AND ANSWER SETS ARE DELETED AT LOGOFF

LOGOFF? (Y)/N/HOLD:y

COST IN U.S. DOLLARS

SINCE FILE TOTAL

ENTRY SESSION

FULL ESTIMATED COST

62.50 70.81

DISCOUNT AMOUNTS (FOR QUALIFYING ACCOUNTS)

SINCE FILE TOTAL

CA SUBSCRIBER PRICE

ENTRY	SESSION
-17.00	-17.00

STN INTERNATIONAL LOGOFF AT 10:19:09 ON 04 MAY 2010